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A B S T R A C T
Background
Herpes zoster, also known as ’shingles’, is a neurocutaneous disease characterised by the reactivation of the latent varicella zoster virus
(VZV), the virus that causes chickenpox when immunity to VZV declines. It is an extremely painful condition that can last many
weeks or months and it can significantly compromise the quality of life of affected individuals. The natural process of aging is associated
with a reduction in cellular immunity and this predisposes older people to herpes zoster. Vaccination with an attenuated form of VZV
activates specific T cell production avoiding viral reactivation. The Food and Drug Administration has approved a herpes zoster vaccine
with an attenuated active virus for clinical use among older adults, which has been tested in large populations. A new adjuvanted
recombinant VZV subunit zoster vaccine has also been tested. It consists of recombinant VZV glycoprotein E and a liposome-based
AS01B adjuvant system. This new vaccine is not yet available for clinical use.
Objectives
To evaluate the effectiveness and safety of vaccination for preventing herpes zoster in older adults.
Search methods
For this 2015 update, we searched the Cochrane Central Register of Controlled Trials (CENTRAL 2015, Issue 9), MEDLINE (1948
to the 3rd week of October 2015), EMBASE (2010 to October 2015), CINAHL (1981 to October 2015) and LILACS (1982 to
October 2015).
Selection criteria
Randomised controlled trials (RCTs) or quasi-RCTs comparing zoster vaccine with placebo or no vaccine, to prevent herpes zoster in
older adults (mean age > 60 years).
Data collection and analysis
Two review authors independently collected and analysed data using a data extraction form. They also performed ’Risk of bias’
assessment.
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Main results
We identified 13 studies involving 69,916 participants. The largest study included 38,546 participants. All studies were conducted in
high-income countries and included only healthy Caucasian individuals ≥ 60 years of age without immunosuppressive comorbidities.
Ten studies used live attenuated varicella zoster virus (VZV) vaccines. Three studies tested a new type of vaccine not yet available for
clinical use. We judged five of the included studies to be at low risk of bias.
The incidence of herpes zoster, at up to three years of follow-up, was lower in participants who received the vaccine than in those who
received a placebo: risk ratio (RR) 0.49; 95% confidence interval (CI) 0.43 to 0.56, risk difference (RD) 2%, number needed to treat to
benefit (NNTB) 50; GRADE: moderate quality evidence. The vaccinated group had a higher incidence of mild to moderate intensity
adverse events. These date came from one large study that included 38,546 people aged 60 years or older.
A study including 8122 participants compared the new vaccine (not yet available) to the placebo; the group that received the new
vaccine had a lower incidence of herpes zoster at 3.2 years of follow-up: RR 0.04, 95% CI 0.02 to 0.10, RD 3%, NNTB 33; GRADE:
moderate quality evidence. The vaccinated group had a higher incidence of adverse events but most them were of mild to moderate
intensity.
All studies received funding from the pharmaceutical industry.
Authors’ conclusions
Herpes zoster vaccine is effective in preventing herpes zoster disease and this protection can last three years. In general, zoster vaccine
is well tolerated; it produces few systemic adverse events and injection site adverse events of mild to moderate intensity.
There are studies of a new vaccine (with a VZV glycoproteic fraction plus adjuvant), which is currently not yet available for clinical use.
P L A I N L A N G U A G E S U M M A R Y
Vaccines for preventing herpes zoster (shingles) in older adults
Review question
There is a vaccine to prevent shingles. Our objective was to evaluate the effectiveness and safety of the vaccine to prevent shingles in
healthy older people.
Background
The varicella zoster virus causes chickenpox and can remain dormant inside nerve cells. After many years, it can reactivate, travel
through the nerve to the skin and produce blisters along the nerve path. This is called herpes zoster or shingles. It affects people with
low immunity such as older people. Before the blisters, the person may feel itching, numbness, tingling or local pain. Herpes zoster
causes inflammation of the nerves and severe pain, which can affect quality of life. There are about 5.22 episodes of herpes zoster for
every 1000 older people. This is increasing, in part because people are living longer.
Study characteristics
Our evidence is current to 26 October 2015. We found 13 randomised controlled trials including 69,917 healthy older adults. Only
five of the 13 trials were of high quality and had a low risk of bias. Pharmaceutical companies that produce the vaccines funded all of
the included studies.
Key results and quality of the evidence
All included studies were conducted in high-income countries and included only healthy elderly Caucasians (> 60 years) without any
immunosuppressive problems.
One big study included 38,546 persons 60 years of age or older. It compared the vaccine with a placebo (fake vaccine). It was a high
quality study, which showed that the vaccine is effective in preventing shingles at three years (moderate quality evidence). Adverse
effects caused by the vaccine were mostly mild to moderate symptoms at the injection site. Refrigerated vaccines caused fewer injection
site adverse effects than frozen vaccines. The injection of the vaccine into the muscle caused fewer adverse effects when it was injected
under the skin (subcutaneously). The herpes zoster vaccine caused fewer adverse effects than the ’pneumo 23’ vaccine.
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A new vaccine, not yet available for clinical use, is being tested. This vaccine contains a small part of varicella zoster virus plus substances
that boost the immune response of the body. A study including 8122 participants who were randomised to receive either the new
vaccine or a placebo vaccine showed that those in the new vaccine group had fewer episodes of herpes zoster and more mild to moderate
adverse events than those in the placebo group (moderate quality evidence).
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Available live attenuated VZV zoster vaccine versus placebo for preventing herpes zoster in older adults
Patient or population: healthy older adults
Settings: outpat ients
Intervention: available live attenuated VZV zoster vaccine
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo Available live attenu-
ated VZV zoster vac-
cine
Incidence of herpes
zoster
Clinical and laboratory
criteria
Follow-up: median 3.1
years
Study population RR 0.49
(0.43 to 0.56)
38,546
(1 study)
⊕⊕⊕©
moderate1
Absolute risk for avail-
able live attenuated
VZV zoster vaccine = 1.
6%
Absolute risk for
placebo group = 3.3%
33 per 1000 16 per 1000
(14 to 19)
Participants with AEs:
≥ 1 serious AE regard-
less of type of storage
of the vaccine
Clinical and laboratory
criteria
Follow-up: median 3.1
years
Study population RR 1.08
(0.96 to 1.2)
50,896
(4 studies)
⊕⊕⊕©
moderate1
Absolute risk for avail-
able live attenuated
VZV zoster vaccine = 2.
3%
Absolute risk for
placebo group = 2.2%
22 per 1000 23 per 1000
(21 to 26)
Participants with AEs:
hospitalised
Number of part icipants
hospitalised
Study population RR 1.00
(0.93 to 1.07)
6616
(1 study)
⊕⊕⊕©
moderate1
Absolute risk for avail-
able live attenuated
VZV zoster vaccine =
34.1%
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Follow-up: median 3.1
years
Absolute risk for
placebo group = 34.1%
341 per 1000 341 per 1000
(317 to 365)
Participants with AEs:
injection site AEs
Clinical and laboratory
criteria
Follow-up: median 3.1
years
Study population RR 2.99 (2.75 to 3.26) 6986
(3 studies)
⊕⊕⊕©
moderate1
Absolute risk for avail-
able live attenuated
VZV zoster vaccine =
47.9%
Absolute risk for
placebo group = 16.0%
160 per 1000 479 per 1000
(440 to 521)
Drop-outs: death
Number of deaths
Follow-up: median 3.1
years
Study population RR 1.01
(0.92 to 1.11)
50,687
(3 studies)
⊕⊕⊕©
moderate1
Absolute risk for avail-
able live attenuated
VZV zoster vaccine = 3.
3%
Absolute risk for
placebo group = 3.2%
32 per 1000 33 per 1000
(30 to 36)
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
AE: adverse event; CI: conf idence interval; RR: risk rat io
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1Did not describe random sequence generat ion.
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B A C K G R O U N D
Description of the condition
Herpes zoster, or shingles, is a neurocutaneous disease that can
be extremely painful. Frequently, the symptoms can last for many
weeks or months after complete healing of the lesions (Gilden
2000). It is caused by the reactivation of the varicella zoster virus
(VZV) when immunity to VZV declines.
The geographical distribution of VZV indicates that it is a com-
mon human pathogen with a worldwide occurrence (Cohen
2007). Although varicella occurs worldwide, the epidemiology of
the disease is markedly different in tropical and temperate coun-
tries. In temperate countries such as the United Kingdom (UK)
and the United States (US), most people have seroconverted to
VZV by adolescence (this means that they have had prior contact
with the virus and developed antibodies against it). Serological
studies of resident tropical populations and of immigrants from
tropical countries indicate that seroconversion generally occurs in
late adolescence and adulthood (Lee 1998).
The VZV is a highly contagious agent and in the first contact with
the virus, usually in childhood, the individual develops chicken-
pox (varicella). After this, the VZV can remain dormant for years
in the dorsal sensory ganglia of the spinal cord. The latency of
the virus is maintained by cellular immunity, which inhibits viral
replication. Years later, during periods of decreased cell-mediated
immunity or simply because of aging, the virus can replicate in the
dorsal sensory ganglia of the spinal cord andmigrate along sensory
nerves. Prodromal symptoms of viral reactivation include itching,
numbness, tingling or severe localised pain, which precede the ap-
pearance of skin lesions by one to five days. The typical cutaneous
manifestations of an acute herpes zoster episode include clusters
of vesicles that spread in a linear pattern along the path of nerves
and do not cross the midline of the body (Cohen 2007; Moffat
2007).Within three to five days, these lesions progress to pustules,
ulcerations and crusting and go on to heal spontaneously within
two to four weeks (Gnann 2002). This disease causes substan-
tial morbidity and has a significant impact on the quality of life
of patients (Gnann 2002; Partridge 2009; Sampathkumar 2009).
Schmader 2007 conducted a prospective, observational study of
165 outpatients with acute herpes zoster who were enrolled within
14 days of onset of rash. The pain was moderate to severe and
discomfort was common during the acute rash phase. Acute her-
petic neuralgia was associated with sleep disruption and impaired
general activities and enjoyment of life, especially after the onset
of the rash, and had a significant impact on the quality of life of
the patients.
Older adults (aged > 60 years old) have an increased risk of de-
veloping herpes zoster disease (Arvin 1996; Cho 2007; Heymann
2008; Jih 2009; Thomas 2004). Although familial history of her-
pes zoster suggests possible genetic predisposition to the disease
(Cho 2007; Haanpaa 2002), results from available case-control
studies are conflicting (Gatti 2010; Hicks 2008). Due to length-
ening lifespans, there are increasing concerns about quality of life
for older adults, a growing segment of the population, especially in
high-income countries. In the United States, the annual incidence
of herpes zoster increased from 3.10 episodes per 1000 in older
adults in 2000 to 5.22 in 2007 (Rimland 2010).
Description of the intervention
Vaccination with an attenuated form of VZV activates specific
T cell production, therefore avoiding viral reactivation. A herpes
zoster vaccine with an active virus has been approved for clinical
use among older adults by the Food and Drug Administration
(FDA) and has been tested in large populations (Oxman 2005).
A new adjuvanted recombinant VZV subunit zoster vaccine, not
yet available for clinical use, has also been tested. It is composed of
recombinant VZV glycoprotein E plus a liposome-based AS01B
adjuvant system (Lal 2015).
1. Available live attenuated VZV zoster vaccine: this vaccine
contains the same live attenuated virus used in the chickenpox
vaccine but it has over 14-fold more plaque-forming units
(PFUs) of the attenuated virus per dose. Therefore the two
vaccines are not interchangeable (Oxman 2005).
2. Adjuvanted recombinant subunit zoster vaccine (not yet
clinically available): this other type of vaccine has recently been
tested (Leroux-Roels 2012). It does not contain the live
attenuated virus but a small fraction of the virus, which cannot
replicate but can boost immunogenicity. This vaccine contains
antigen gE (glycoprotein E), which is the most abundant antigen
in VZV-infected cells and the main target for VZV-specific CD4
+ T-cell response (Arvin 1986). This vaccine also includes
adjuvant AS01, which is a liposome-based adjuvant system
containing immunoenhancers 3-O-desacyl-4′-monophosphoryl
lipid A (MPL) plus saponin QS-21 (Quillaja saponaria Molina,
fraction 21) (Baldridge 2004; Kensil 1991). It has not yet been
approved for clinical use.
How the intervention might work
Primary infection with VZV induces the production of specific
memory T cells in sufficient numbers to keep the virus in its
latent form. Host factors such as aging, or other conditions that
affect cellular immunity, may reduce T cells to levels that can no
longer inhibit viral replication therefore increasing the likelihood
of clinical manifestations of the disease.
1. Available live attenuated VZV zoster vaccine: this vaccine,
which consists of live attenuated VZV, activates specific T cell
production, thus increasing existing immunity and avoiding
reactivation of viral replication (Arvin 2005). Several randomised
controlled trials (RCTs) have evaluated the efficacy and safety of
live attenuated virus vaccine in preventing herpes zoster
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(Gilderman 2008; Mills 2010; Murray 2011; Oxman 2005;
Vermeulen 2012).
2. Adjuvanted recombinant VZV subunit zoster vaccine (not
yet available): this new vaccine contains antigen gE (glycoprotein
E), which is the most abundant antigen in VZV-infected cells
and the main target for VZV-specific immunity CD4 + T-cell
response (Arvin 1986). This vaccine also includes adjuvant
AS01, which is a liposome-based adjuvant system containing
immunoenhancers 3-O-desacyl-4′-monophosphoryl lipid A
(MPL) plus saponin QS-21 (Quillaja saponaria Molina, fraction
21) (Baldridge 2004; Kensil 1991). The adjuvant component is
important because it helps to elicit an early, high and long-lasting
immune response with less antigen (Rajesh 1995); consequently
this leads to additional stimulation of the immune system when
it is given with the gE antigen. The new adjuvanted recombinant
zoster vaccine improves immune stimulation against VZV and
its efficacy and safety have been tested in several RCTs (Chlibek
2013; Chlibek 2014; Lal 2015; Leroux-Roels 2012).
Why it is important to do this review
Although the incidence of herpes zoster increases with age, preva-
lence rates differ worldwide (Choi 2010; Hope-Simpson 1965; Jih
2009; Rimland 2010; Schmader 2008). Every year more than one
million new cases are diagnosed in the US (Weaver 2007). The
acute episode of herpes zoster can significantly affect the quality
of life of affected individuals due to pain, increased risk of depres-
sion, anxiety and significantly lower emotional well-being (Katz
2004).
Herpes zoster also has a significant impact on the health sys-
tem, particularly among older adults. In addition, the effective-
ness of some treatments for herpes zoster is relatively uncertain
(Hornberger 2006). Several randomised controlled trials (RCTs)
have evaluated the efficacy and safety of vaccines in preventing
herpes zoster (Gilderman 2008; Oxman 2005). Recent trials have
tested a newadjuvanted recombinantVZVvaccine (Chlibek 2013;
Chlibek 2014; Leroux-Roels 2012). If it is proved that this vaccine
is safe and effective, it could be given to immunocompromised
people who frequently have herpes zoster (Dolin 1978). There-
fore, it is necessary to conduct a systematic review of these trials
to critically appraise and synthesise the best available evidence.
This is an update of a Cochrane review first published in 2012
(Gagliardi 2012).
O B J E C T I V E S
To evaluate the effectiveness and safety of vaccination for prevent-
ing herpes zoster in older adults.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included RCTs and quasi-RCTs, regardless of publication date
or language.
Types of participants
We included studies involving older adults (mean age≥ 60 years).
We excluded trials involving participants with immunosuppressive
disorders.
Types of interventions
We included clinical trials that compared herpes zoster vaccine, of
any dose andpotency,with at least one of the following comparison
groups.
1. Any other type of intervention (for example, varicella
vaccine, antiviral medication).
2. Placebo.
3. Nothing (no vaccine).
Types of outcome measures
Primary outcomes
1. Incidence of herpes zoster, diagnosed according to the
criteria (clinical and/or laboratory) established by the primary
studies.
Secondary outcomes
1. Adverse events: local or systemic reactions (for example,
pain, pruritus, swelling, headache) occurring at any time after
vaccination.
2. Drop-outs.
Search methods for identification of studies
Electronic searches
In this 2015 update we searched the Cochrane Central Register of
Controlled Trials (CENTRAL 2015, Issue 9), MEDLINE (1948
to October week 3 2015), EMBASE (2010 to October 2015),
CINAHL (1981 toOctober 2015) and LILACS (1982 toOctober
2015).
We used the search strategy in Appendix 1 to search MEDLINE
and CENTRAL. We combined the MEDLINE search with the
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Cochrane Highly Sensitive Search Strategy for identifying ran-
domised trials in MEDLINE: sensitivity- and precision-maximis-
ing version (2008 revision); Ovid format (Lefebvre 2011). We
adapted the search strategy to search EMBASE (Appendix 2),
LILACS (Appendix 3) and CINAHL (Appendix 4). We imposed
no language or publication restrictions.
Searching other resources
We searched two trial registries, the World Health Organization
(WHO) International Clinical Trials Registry Platform (ICTRP)
and ClinicalTrials.gov, for completed and ongoing studies (latest
search 26 October 2015).
We checked the reference lists of relevant studies. We contacted
trial authors for additional information and unpublished studies.
We checked conference proceedings and thesis banks for unpub-
lished studies. We also contacted vaccine manufacturers for un-
published data.
Data collection and analysis
Selection of studies
Two review authors (AG, BNGS) independently assessed titles
and abstracts of all retrieved citations according to our inclusion
criteria. We used the Kappa coefficient to test concordance among
review authors (Latour 1997). We resolved discrepancies through
consensus and consulted a third review author (MRT) in case of
disagreements.
Data extraction and management
We created a specific data extraction form for this review to collect
relevant information such as study methods, participants, inter-
vention group, control group and outcomes.
Assessment of risk of bias in included studies
We evaluated themethodological quality of each included study in
accordance with the criteria established by the Cochrane tool for
assessing risk of bias (Higgins 2011). We evaluated the following
domains.
1. Random sequence generation (selection bias)
2. Allocation concealment (selection bias)
3. Blinding of participants and personnel (performance bias)
4. Blinding of outcome assessment (detection bias)
5. Incomplete outcome data (attrition bias)
6. Selective reporting (reporting bias)
7. Other bias
We classified each of these domains as ’low risk of bias’, ’uncertain
risk of bias’ or ’high risk of bias’.
Measures of treatment effect
Dichotomous data
For binary data, we calculated the results for each study using the
risk ratio (RR) with 95% confidence interval (CI) and number
needed to treat for an additional beneficial outcome (NNTB) for
efficacy and number needed to treat for an additional harmful
outcome (NNTH) for adverse events, where therewere statistically
significant differences. We entered the data into the Cochrane
Review Manager software (RevMan 2014), and conducted meta-
analyses using a random-effects model.
Continuous data
For outcomes presented in other forms (for example, reported as
medians, quartiles, etc.) or without consistent statistical informa-
tion (despite requests to the trial authors) (for example, standard
deviations (SDs), number of patients, etc.), we inserted these data
into an additional table.
Unit of analysis issues
The patient was the unit of analysis, including patients undergoing
more than one intervention in a cross-over trial.
Dealing with missing data
For dichotomous data, we performed intention-to-treat (ITT)
analyses to include all participants randomised to the intervention
groups.We contacted trial authors to supply anymissing data from
the included studies. In studies that did not explain the reasons
for withdrawal, we analysed data assuming the worst possible out-
come, since imputation of data is a matter of personal judgement
(Higgins 2011).
Assessment of heterogeneity
We assessed the consistency of results through visual inspection of
the forest plots and by calculating the I2 statistic (Higgins 2003),
which estimates the proportion of variation in point estimates that
is due to heterogeneity rather than sampling error. We assumed
substantial (significant) heterogeneity when the I2 statistic was >
50%. We analysed data using a fixed-effect model, but if there was
significant heterogeneity between studies, we used the random-
effects model.
Assessment of reporting biases
It was not necessary to prepare a funnel plot since we included
fewer than 10 studies in the meta-analysis.
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Data synthesis
For dichotomous variables we calculated the RR and for continu-
ous variables we calculated the mean difference (MD), when stud-
ies reported their results in the same units of measurement. When
continuous data were reported in different units, we pooled the
data through standardised mean differences (SMDs). For all sta-
tistical methods used to pool data, we used 95% CIs.
GRADE and ’Summary of findings’ table
We created a ’Summary of findings’ table using the following out-
comes: incidence of herpes zoster, adverse events and drop-outs.
We used the five GRADE considerations (study limitations, con-
sistency of effect, imprecision, indirectness and publication bias)
(Atkins 2004), in order to assess the quality of the body of evidence
as it relates to the studies that contribute data to the meta-analyses
for the prespecified outcomes (Guyatt 2006a; Guyatt 2006b). We
used the methods and recommendations described in Section 8.5
and Chapter 12 of theCochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011).We usedGRADEproGDT software
(GRADEproGDT 2015).We justified all decisions to downgrade
or upgrade the quality of studies using footnotes, and we made
comments to aid the reader’s understanding of the review where
necessary.
Factors that can reduce the quality of the evidence (downgrade)
include:
1. limitations in study design or execution (risk of bias): lower
by one or two levels;
2. inconsistency of results: lower by one or two levels;
3. indirectness of evidence: lower by one or two levels;
4. imprecision: lower by one or two levels;
5. publication bias: lower by one or two levels.
Factors that can increase the quality of the evidence (upgrade)
include:
1. large magnitude of effect: upgrade by one or two levels;
2. all plausible confounding that would reduce the
demonstrated effect or increase the effect if no effect was
observed: upgrade by one level;
3. dose-response gradient: upgrade by one level.
Based on those factors, for each outcome, the quality of evidence is
classified as: ’high quality evidence’, ’ moderate quality evidence’,
’low quality evidence’ or ’very low quality evidence’ (Schünemann
2011):
1. high quality evidence: RCTs or double-upgraded
observational studies;
2. moderate quality evidence: downgraded RCTs or upgraded
observational studies;
3. low quality evidence: double-downgraded RCTs or
observational studies;
4. very low quality evidence: triple-downgraded RCTs or
downgraded observational studies; or case series/case reports.
Subgroup analysis and investigation of heterogeneity
We grouped results from studies according to methodological and
clinical aspects, such as vaccine dosage (plaque-forming units (pfu)
per dose), vaccine conservation method (refrigerated or frozen),
participant age, previous episode of herpes zoster and simultaneous
administration of other vaccines.
Sensitivity analysis
Where possible, we performed sensitivity analyses. We investi-
gated the impact of quasi-RCTs, studies with lower methodolog-
ical quality and unpublished data on the results of the review.
R E S U L T S
Description of studies
In this 2015 review update, we included 13 RCTs published
in 20 papers (Berger 1998; Chlibek 2013; Chlibek 2014; Diez-
Domingo 2015; Gilderman 2008; Lal 2015; Levin 2000; Mills
2010;Murray 2011;Oxman 2005;Tyring 2007;Vermeulen2012;
Vesikari 2013). Only Mills 2010 used a cross-over design and re-
ported data separately for patients 50 to 59 years and 60 or older;
we only included data pertaining to the older participants of this
study. The Lal 2015 study presented efficacy data by age and in
theory we would be able to use these data for participants aged
60 or over. However, the authors replied that safety data per age
were not yet available and we therefore used the data provided for
participants 50 years of age or more.
Results of the search
In the first publication of this review, we searched five databases
(CENTRAL, MEDLINE, EMBASE, CINAHL and LILACS)
and identified 467 citations, which reduced to 328 after excluding
duplicates (Gagliardi 2012). Of these, we selected 19 citations for
full-text reading, which reported on 14 RCTs. We excluded six of
these trials and included eight in the review (corresponding to 13
published references). In the clinical trials registry platforms, we
identified three ongoing studies as of 25 June 2012.
In this 2015 update we searched the same five databases: CEN-
TRAL (2015, Issue 3); MEDLINE (1948 to October week 3
2015), EMBASE (2010 to October 2015), CINAHL (1981 to
October 2015) and LILACS (1982 toOctober 2015) andwe iden-
tified a total of 101 references. After excluding the references exam-
ined in the initial search and duplicated references, we identified
72 newly published records. After analysis of titles and abstracts,
we excluded 65 records and selected seven for full-text reading: we
included six of these and excluded one because it did not involve
older people (Leroux-Roels 2012). One of the newly included
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studies had two publications (European Geriatric Medicine 2013;4
(Suppl):81-141 and Vaccine 2015;33(6):789-95) (Diez-Domingo
2015). Since we considered both publications as being one study, a
total of five new studies are included in this update (Chlibek 2013;
Chlibek 2014; Diez-Domingo 2015; Lal 2015; Vesikari 2013).
Figure 1 depicts the complete process of study identification and
selection of all studies (including those included in the first pub-
lication of this review).
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Figure 1. Study flow diagram 2015 update
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We identified 11 ongoing studies in the trial registry platforms
(ClinicalTrials.gov site and the International Clinical Trials Reg-
istry Platform (ICTRP)) on15November 2015.The detailed steps
of the whole process of selection of studies are shown in Figure 1.
Included studies
The 13 included trials enrolled a total of 69,916 participants.
Available live attenuated VZV zoster vaccine
We included 10 trials (53,381 participants) reporting on the live
attenuated VZV zoster vaccine. All of them assessed the safety of
the vaccine and only Oxman 2005 also evaluated its efficacy. Four
studies compared the vaccine with placebo (Mills 2010; Murray
2011; Oxman 2005; Vermeulen 2012), one study compared it
with pneumo 23 vaccine (Berger 1998), and another study com-
pared different routes of administration (intramuscular versus sub-
cutaneous; Diez-Domingo 2015). One study assessed different
forms of vaccine conservation (refrigerated and frozen; Gilderman
2008); another study compared live versus inactivated virus (Levin
2000). One trial tested different amounts of the virus (higher-po-
tency zoster vaccine to lower-potency zoster vaccine; Tyring 2007),
and another compared two doses of a zoster vaccine versus a sin-
gle dose and also two doses given at different intervals (Vesikari
2013). The most important study was Oxman 2005, which in-
cluded 38,546 participants and evaluated the efficacy and safety
of zoster vaccine versus placebo and performed a more detailed sa-
fety investigation, with voluntary (not randomised) participation
of patients. This study followed participants for an average of five
years.
Investigators reported adverse events at various time intervals after
inoculation of the zoster vaccine: 28 days (Gilderman 2008; Mills
2010; Vesikari 2013), 35 days (Diez-Domingo 2015), 42 days
(Berger 1998; Oxman 2005; Tyring 2007; Vermeulen 2012), and
serious side effects until 182 days after the vaccination (Murray
2011). Vermeulen 2012 reported adverse events within sixmonths
after the second vaccination.
Adjuvanted recombinant VZV subunit zoster vaccine (not
yet available)
We included three studies on a new zoster vaccine that it not
yet available for clinical use. These studies involved a total of
16,535 participants (Chlibek 2013; Chlibek 2014; Lal 2015).
Both Chlibek 2013 and Chlibek 2014 evaluated adverse effects.
The first study compared four groups that received either lower
or higher volumes of adjuvants plus gE subunit VZV or unadju-
vanted gE or saline injections. The second trial compared adverse
events in three groups of VZV plus gE in three different quan-
tities, one group that received unadjuvanted gE and one group
that received only saline. The third study assessed the efficacy and
safety of the new vaccine versus placebo (Lal 2015).
The adverse effects were monitored for approximately one year
after last vaccination (Chlibek 2013), and 36 months after last
dose (Chlibek 2014). Lal 2015 is a ongoing study.
Excluded studies
We excluded the following seven studies.
• Hayward 1994, Hayward 1996 and Patterson-Bartlett
2007: RCTs evaluating zoster vaccine focused on
immunogenicity, without any clinical outcomes.
• Irwin 2007: a RCT that tested another intervention (Tai
Chi) and not the zoster vaccine.
• Kerzner 2007: a RCT evaluating zoster vaccine
administered concomitantly with influenza vaccine.
• Leroux-Roels 2012: a RCT evaluating zoster vaccine, but
including participants outside the age range of interest (55 to 57
years).
• Macaladad 2007: a RCT evaluating zoster vaccine, but
including participants outside the age range of interest (adults
less than 60 years).
Risk of bias in included studies
Details of the ’Risk of bias’ assessment for each trial are shown in
the Characteristics of included studies section. The overall risk of
bias is presented graphically in Figure 2 and summarised in Figure
3. We categorised Chlibek 2013, Diez-Domingo 2015, Lal 2015,
Oxman 2005, Vermeulen 2012 and Vesikari 2013 as having a
low risk of bias. All of these studies had at least five of the eight
domains categorised as ’low risk of bias’, thus fulfilling the criteria
recommended by Cochrane for establishing that a study is at low
risk of bias.
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Figure 2. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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See Table 1 for the complete evaluation of the risk of bias of
included studies.
Allocation
Randomisation criteria
We graded five studies as having a low risk of bias for random
sequence generation (selection bias) because they described how
the randomisationwas done (Chlibek 2013;Diez-Domingo 2015;
Lal 2015; Vermeulen 2012; Vesikari 2013). See Table 1 for more
details.
Allocation criteria
We classified Chlibek 2013, Diez-Domingo 2015, Lal 2015,
Oxman 2005, Vermeulen 2012 and Vesikari 2013 as having a low
risk of bias because of adequate allocation concealment described
by the trial authors. See Table 1 for more details.
Blinding
Seven trials were double-blind and we considered them at low risk
for this domain (Berger 1998; Chlibek 2013; Gilderman 2008;
Murray 2011; Oxman 2005; Tyring 2007; Vermeulen 2012). See
Table 1 for more details.
Incomplete outcome data
We classified Chlibek 2013, Chlibek 2014, Diez-Domingo 2015,
Gilderman 2008, Murray 2011, Oxman 2005, Tyring 2007,
Vesikari 2013 and Vermeulen 2012 as ’low risk’ in this domain
because the flow of patients was clear. Mills 2010 had no data on
the first arm of the cross-over study and we therefore classified it as
’high risk’. We classified Berger 1998 and Levin 2000 as ’unclear
risk’ as they did not provide any information for this domain.
Selective reporting
We classified the following studies as ’low risk’ in this domain:
Berger 1998; Chlibek 2013; Chlibek 2014; Diez-Domingo 2015;
Gilderman 2008; Lal 2015; Mills 2010; Murray 2011; Oxman
2005; Tyring 2007; Vermeulen 2012; Vesikari 2013. See Table 1
for more details. We classified Levin 2000 as having an ’unclear’
risk of bias for this domain because it was basically a study that
analysed immune response.
Other potential sources of bias
We did not identify any significant aspects pertaining to this do-
main.
Quality of evidence
In the comparison between available live attenuated zoster vaccine
versus placebo (Oxman 2005), the overall quality of the evidence
for the main effectiveness outcome (’incidence of herpes zoster’ up
to three years of follow-up) (Types of outcomemeasures) wasmod-
erate. The reason for downgrading the evidence was due to the risk
of bias of this study, because it did not describe random sequence
generation (Summary of findings for the main comparison).
We classified the quality of the evidence for safety outcomes up
to three years of follow-up (hospital admissions or participants
with injection site adverse effects) as moderate. We downgraded
by one point because of risk of bias due to the lack of description of
random sequence generation (Summary of findings for the main
comparison).
Effects of interventions
See: Summary of findings for the main comparison Available
live attenuated VZV zoster vaccine versus placebo for preventing
herpes zoster in older adults; Summary of findings 2 Adjuvanted
recombinant VZV subunit zoster vaccine (not yet available) versus
placebo for preventing herpes zoster in older adults
Primary outcome
1. Incidence of herpes zoster
Available live attenuated varicella zoster virus (VZV) vaccine
versus placebo
Oxman 2005 evaluated the effectiveness of zoster vaccine versus
placebo in reducing the incidence of herpes zoster with a me-
dian surveillance of 3.1 years and reported a significant reduction
for this outcome in the vaccinated group: risk ratio (RR) 0.49,
95% confidence interval (CI) 0.43 to 0.56 (Analysis 1.1.1). Al-
though this was a significant difference in favour of the interven-
tion, the magnitude of this effect was a risk difference (RD) of
2% and the number needed to treat for an additional beneficial
outcome (NNTB) was 50. The quality of the evidence was mod-
erate due to one downgrade because of risk of bias (no description
of the randomisation process) (Summary of findings for the main
comparison).
The vaccinated group had a reduced incidence of herpes zoster
as early as 30 days post-vaccination: RR 0.33, 95% CI 0.13 to
0.84 (Analysis 1.1.2). These cases were excluded from the final
intention-to-treat (ITT) analysis. At 42 days post-vaccination, the
benefits of vaccination are clear, with a RR of 0.29 (95% CI 0.13
to 0.68) (Analysis 1.1.3).
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The continuation of the Oxman 2005 study was published in
2012 (Schmader KE, Oxman MN, Levin MJ, Johnson G, Zhang
JH, Betts R et al. Clinical Infectious Diseases 2012;55(10): 1320-
8) and evaluated the effectiveness of the vaccine five years after
the individuals had been vaccinated. However, the published data
report different dates for the collection of outcomes in the inter-
vention and the placebo groups. The data from the zoster vaccine
group are from December 2004 to March 2006 (16 months). In
the placebo group, data were reported from December 2004 to
September 2005 (10 months), since in October 2005 the zoster
vaccine was also offered to participants in the placebo group, as
stated by the authors: “Beginning in October 2005, open-label
zoster vaccine was offered without charge to Shingles Prevention
Study placebo recipients.” We contacted the authors of this study
asking for the data corresponding to the period from December
2004 to September 2005 (10 months) for both groups (vaccine
and placebo). They replied to our request but did not provide this
information and suggested instead that we should assume a uni-
form rate of events and calculate the estimated number of cases
from that. According to their suggestion, we calculated that the
inferred rate of incidence of herpes zoster (fromDecember 2004 to
September 2005) would be 53 in the vaccine group at 10 months
(total number of herpes zoster cases in the vaccine group 84 in 16
months, therefore 53 in 10 months) and the incidence of herpes
zoster would be 95 cases in 10 months in the placebo group. The
resulting RR was 0.53, 95% CI 0.38 to 0.74, RD -0.01, 95% CI
-0.01 to -0.00 and NNTB 100, in favour of the vaccinated group
(Analysis 1.1.4). By the same reasoning, when considering the fol-
low-up period of five years, there was a significant decrease in the
incidence of herpes zoster in the vaccine group compared to the
placebo group: RR 0.50, 95%CI 0.44 to 0.56; RD -0.02, 95%CI
-0.02 to -0.02 and NNTB 50 (Analysis 1.1.5).We did not include
these data in Summary of findings for the main comparison since
they are inferred data.
The interference of herpes zoster in activities of daily life (ADL)
was measured by the zoster brief pain inventory (ZBPI ADL), in
which scores greater than or equal to 300 indicate significant pain-
related interference in daily life and quality of life (Coplan 2004).
There were no significant differences between the vaccinated and
placebo groups for this outcome in the study byOxman 2005 (RR
0.63, 95% CI 0.34 to 1.16) (Analysis 1.2).
Higher-potency versus lower-potency zoster vaccine
Tyring 2007 compared higher-potency zoster vaccine with lower-
potency zoster vaccine and reported a higher incidence of herpes
zoster (the polymerase chain reaction was positive for wild type of
VZV in two cases) in the first group but this difference was not
significant (RR 2.55, 95% CI 0.12 to 52.99) (Analysis 2.1).
Live versus inactivated zoster vaccine
One study, Levin 2000, compared live zoster vaccine with an inac-
tivated zoster vaccine and reported no differences in the incidence
of herpes zoster (RR 0.96, 95% CI 0.06 to 15.17) (Analysis 4.1).
Adjuvanted recombinant VZV subunit zoster vaccine (not yet
available)
The efficacy of the new recombinant adjuvanted VZV subunit
vaccine was tested by Lal 2015. During the follow-up of 3.2 years,
there was a decrease in the incidence of herpes zoster in vaccinated
participants compared to those who received a placebo: RR 0.04,
95% CI 0.02 to 0.10 (Analysis 10.1), RD 3% and NNTB 33.
We classified the evidence as being of moderate quality because
we downgraded the score due to lack of information on allocation
concealment and because the flow of the participants was not clear
(Summary of findings 2).
Secondary outcomes
1. Adverse events
Available live attenuated VZV zoster vaccine versus placebo
Four studies compared herpes zoster vaccine to placebo and pre-
sented safety data that could be pooled into a meta-analysis (Mills
2010; Murray 2011; Oxman 2005; Vermeulen 2012). Oxman
2005 presented more detailed assessment of safety only in a sub-
group of patients (zoster vaccine N = 3345; placebo N = 3271).
Murray 2011 assessed only serious adverse events.
The main findings for adverse events are:
Participants receiving the active agent had a higher risk of adverse
events than those receiving placebo. When we pooled data from
studies reporting the number of participants with one or more
adverse events (Mills 2010; Oxman 2005; Vermeulen 2012), we
observed an increased risk in the vaccine group: RR 1.70, 95% CI
1.61 to 1.80, RD 0.24, 95% CI 0.22 to 0.26 and number needed
to treat to harm (NNTH) 4.1, 95%CI 3.8 to 4.5 (Analysis 1.3.1).
As expected, vaccine-related adverse events were more frequent in
the vaccinated group than in the placebo group (RR 4.63, 95%
CI 2.64 to 8.12; RD 0.41, 95% CI 0.30 to 0.53 and NNTH 2.4,
95% CI 1.9 to 3.3) (Analysis 1.3.2) (Vermeulen 2012).
Vaccine-related systemic adverse events were more frequent in the
vaccinated group than in the placebo group: pooled data RR 1.29,
95% CI 1.06 to 1.57, RD 0.01, 95% CI -0.01 to 0.02 (Mills
2010; Oxman 2005) (Analysis 1.3.5).
There were no significant differences between the groups receiv-
ing zoster vaccine or placebo for: one or more serious adverse
event (including death) (Mills 2010; Murray 2011; Oxman 2005;
Vermeulen 2012); vaccine-related serious adverse events (Mills
2010; Murray 2011; Oxman 2005); discontinuation due to a vac-
cine-related adverse event (Mills 2010; Vermeulen 2012).
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The vaccinated group had a higher risk of injection site adverse
events than the placebo group, with a pooled RR of 2.99 (95% CI
2.75 to 3.26), a RD of 0.32 (95% CI 0.30 to 0.34) and a NNTH
of 3.1 (95% CI 2.9 to 3.3) (Analysis 1.3.14) (Mills 2010; Oxman
2005; Vermeulen 2012).
Specific injection site adverse events were more frequent in the
vaccinated group but mild to moderate in intensity.
In Summary of findings for the main comparison we present the
most important adverse events: serious adverse events, hospitali-
sation, injection site adverse events and death. Although the vac-
cinated groups had a higher rate of injection site adverse events,
this was not detected for serious adverse events, hospitalisation or
deaths.
See Table 2 for details of adverse events.
Adjuvanted recombinant VZV subunit zoster vaccine (not
yet available)
Lower or higher volumes of adjuvants plus gE subunit VZV
or unadjuvanted gE or saline
Chlibek 2013 compared adverse events in the four groups that
received two doses two months apart: two groups with different
amounts of adjuvants with the same amount of antigen (50 gE/
AS01B and 50 gE/AS01E), one group receiving 50 µg gE plus
saline and one group receiving only saline (placebo).
General and local reactions to vaccinationweremore frequent with
both adjuvanted candidate herpes zoster vaccines and were most
frequent with the groups that received higher amounts of adju-
vant (gE/AS01B ). The participants who received gE/AS01B had
a significantly higher incidence of adverse events: any symptom,
general reaction (fatigue, headache) and local reaction (any symp-
tom, pain and redness). However, all adverse events were generally
mild to moderate and transient. No vaccine-related severe adverse
events were reported.
Three groups of VZV subunit gE in three different quantities
versus unadjuvanted gE or saline
Chlibek 2014 compared adverse events in five groups that received
two doses two months apart: three groups received vaccines, each
one with different amounts of antigen (25 µg gE, 50 µg gE and
100 µg gE) but the same amount of adjuvant AS01B; one group
received one dose of saline + one dose 100 µg gE twomonths later;
and one group received100 µg gE/saline (unadjuvanted gE).
All adverse events were common in the three different formula-
tions of gE/AS01B andmore frequent than with the unadjuvanted
gE/saline. In the comparison between the three different amounts
of gE antigen, there were no differences in the incidence of adverse
events except for any myalgia in which there was a slightly higher
incidence in the group receiving 100 µg compared with 50 µg: RR
1.26, 95% CI 1.01 to 1.59, RD 0.11 95% CI 0.00 to 0.22 and
NNTH 9.0 95% CI 0 to 4.5 (Analysis 9.3.7). Thre was no dif-
ference between groups for more important myalgia that prevents
normal everyday activities.
Adjuvanted recombinant VZV subunit zoster vaccine (not yet
available) versus placebo
We did the analysis of adverse events in patients aged 50 years or
more because the data for adverse events by specific age groups
were not available. We performed intention-to-treat (ITT) anal-
yses for adverse events that did not include all randomised par-
ticipants. In other words, we considered the worst case scenario
for the intervention group (we assumed that the participants with
missing information had adverse events) and the best case scenario
for the placebo group (we assumed that the participants with miss-
ing information did not have adverse events). In this analysis, we
detected no differences between the groups. Therefore, we decided
to present the results for adverse events as they were published.
In the comparison between the new adjuvanted recombinantVZV
subunit zoster vaccine versus placebo, the vaccinated group had a
higher incidence of the following adverse events: systemic symp-
toms (myalgia, fatigue, headache, shivering, fever and gastroin-
testinal symptoms) and injection site adverse events (pain, redness
and swelling) but most symptoms were of mild to moderate in-
tensity. The most important difference between the adverse events
was injection site events with an absolute risk of 81.5% in com-
parison to placebo, which was 11.9% (Summary of findings 2).
There was no significant difference between groups for serious
adverse events, potential immune-mediated disease and deaths (
Summary of findings 2).
See Table 3 for details of adverse events for these comparisons
between the new adjuvanted recombinant VZV subunit zoster
vaccine versus placebo.
2. Drop-outs
There were no important differences in the reasons for drop-outs
in the two main studies that assessed the incidence of herpes zoster
between vaccinated and placebo groups, regardless of the type of
vaccine (live attenuated VZV zoster vaccine or adjuvanted recom-
binant VZV subunit zoster vaccine).
Lal 2015 described three reasons for drop-out: not receiving vac-
cine according to protocol, receiving the wrong vaccine and a di-
agnosis of herpes zoster less than 30 days after dose 2. This last
outcome had a RR of 0.29, 95% CI 0.09 to 0.87 but no RD. We
considered it as a drop-out and did not put it in the incidence
outcome since it was reported for participants aged 50 years or
more and not specifically for participants 60 years or more, who
were our group of interest.
See Table 4 for details on all the comparisons of drop-outs in all
of the included studies.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Adjuvanted recombinant VZV subunit zoster vaccine (not yet available) versus placebo for preventing herpes zoster in older adults
Patient or population: healthy older adults
Settings: outpat ients
Intervention: adjuvanted recombinant VZV subunit zoster vaccine (not yet available)
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo Adjuvanted recombi-
nant VZV subunit
zoster vaccine (not
yet available) versus
placebo
Incidence of herpes
zoster 3.2 years fol-
low-up (≥ 60 yo)
Clinical and laboratory
criteria
Follow-up: mean 3.2
years
Study population RR 0.04 (0.02 to 0.1) 8122
(1 study)
⊕⊕⊕©
moderate1
Absolute risk for ad-
juvanted recombinant
VZV subunit zoster vac-
cine (not yet available)
= 0.2%
Absolute risk for
placebo group = 3.4%
34 per 1000 2 per 1000
(1 to 3)
Participants with AEs:
any local symptom
Clinical criteria
Follow-up: mean 3.2
years
Study population RR 6.83 (6.30 to 7.42) 8759
(1 study)
⊕⊕⊕©
moderate1
Absolute risk for ad-
juvanted recombinant
VZV subunit zoster vac-
cine (not yet available)
= 81.5%
Absolute risk for
placebo group = 11.9%
119 per 1000 815 per 1000
(751 to 885)
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Participants with AEs:
serious AEs
Clinical and laboratory
criteria
Follow-up: mean 3.2
years
Study population RR 1.01 (0.91 to 1.1) 15,411
(1 study)
⊕⊕⊕©
moderate1
Absolute risk for ad-
juvanted recombinant
VZV subunit zoster vac-
cine (not yet available)
= 9.0%
Absolute risk for
placebo group = 8.9%
89 per 1000 90 per 1000
(81 to 99)
Participants with AEs:
potential immune-me-
diated disease
Clinical and laboratory
criteria
Follow-up: mean 3.2
years
Study population RR 0.81 (0.06 to 1.08) 15,411
(1 study)
⊕⊕⊕©
moderate1
Absolute risk for ad-
juvanted recombinant
VZV subunit zoster vac-
cine (not yet available)
= 1.0%
Absolute risk for
placebo group = 1.3%
13 per 1000 10 per 1000
(1 to 14)
Participants with AEs:
deaths
Number of deaths
Follow-up: mean 3.2
years
Study population RR 0.96 (0.78 to 1.19) 15,411
(1 study)
⊕⊕⊕©
moderate1
Absolute risk for ad-
juvanted recombinant
VZV subunit zoster vac-
cine (not yet available)
= 2.2%
Absolute risk for
placebo group = 2.3%
23 per 1000 22 per 1000
(18 to 27)
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
AE: adverse event; CI: conf idence interval; RR: risk rat io
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1Did not describe allocat ion concealment and part icipant f low not clear.
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D I S C U S S I O N
Summary of main results
Available live attenuated varicella zoster virus (VZV)
vaccine
For this vaccine we included a total of 10 clinical trials that had
clinical outcomes (herpes zoster cases, adverse events and drop-
outs) (Berger 1998; Diez-Domingo 2015; Gilderman 2008; Levin
2000; Mills 2010; Murray 2011; Oxman 2005; Tyring 2007;
Vermeulen 2012; Vesikari 2013). We excluded a total of six tri-
als: three with only immunological outcomes (Hayward 1994;
Hayward 1996; Patterson-Bartlett 2007), one RCT that tested an-
other intervention (Irwin 2007), one RCT evaluating zoster vac-
cine administered concomitantly with another vaccine (Kerzner
2007), and one trial that did not fulfil our age criteria (Macaladad
2007).
We considered four of these 10 studies to be at low risk of bias
(Diez-Domingo 2015; Oxman 2005; Vermeulen 2012; Vesikari
2013). Data from a major randomised controlled trial (RCT), the
Shingles Prevention Study (Oxman 2005), which included 38,546
participants, confirm its effectivenesswhen compared toplacebo in
the elderly population, for at least for 3.1 years. The continuation
of this study was the study with the longest duration of follow-
up, reporting an average five years of herpes zoster surveillance
in individuals aged 60 or older. The available data suggest that
the vaccine works for an average of five years to prevent herpes
zoster in individuals over 60 years of age. However, these long-
term effect estimates for the outcome incidence of herpes zoster
should be interpreted with caution since they were derived from
inferred data.
A previous review on zoster vaccine highlighted that individuals in
the Shingles Prevention Studywho developed herpes zoster despite
vaccination had a lower duration and severity of symptoms than
those in the placebo group (Sanford 2010).
The impact of zoster episodes on daily life activities was assessed.
Despite the lower incidence of cases in the vaccinated population,
there were no significant differences for this outcome when com-
pared to the placebo group.
According to a few observational studies acute herpes zoster pain
can have an important negative impact on the lives of a signifi-
cant proportion of affected individuals (Katz 2004; Lydick 1995;
Schmader 2007). However, one randomised study did not detect
significant differences in the health-related quality of life of her-
pes zoster patients treated with placebo compared to analgesics
(Dworkin 2009). Only one of the studies included in our review
addressed this issue and did not detect significant differences be-
tween the zoster vaccine versus the placebo groups (Oxman 2005).
The advantage of the vaccine is that it reduces the risk of develop-
ing herpes zoster, a disease that can potentially affect the quality
of life of patients. In our review, 13 participants in the vaccine
group and 42 in the placebo group had severe impairment in their
quality of life due to acute herpes zoster pain.
Data from other studies included in this review failed to detect
any significant differences in relevant outcomes for higher- versus
lower-potency zoster vaccines and live versus inactivated zoster
vaccines. It should be noted that there were no cases of herpes
zoster caused by attenuated live zoster vaccines.
The vaccine proved to be safe and well tolerated with a low inci-
dence of systemic adverse events. Although systemic adverse events
were more frequent in the vaccinated group than in the placebo
group, the number needed to treat for an additional harmful out-
come (NNTH) for any systemic adverse event is 100. Serious ad-
verse events and vaccine-related serious adverse events had similar
frequencies in both groups.
Although the rate of adverse events was higher in the group receiv-
ing the zoster vaccine, the rates of drop-outs were similar in the
vaccine and placebo group, suggesting that these adverse events
did not have important repercussions.
Diez-Domingo 2015 compared rates of adverse events with the
intramuscular versus the subcutaneous route using zoster vac-
cines. These authors reported a higher incidence of adverse events,
mainly injection site reactions (erythema, pain and swelling), in
the group vaccinated by the subcutaneous route. For every four
patients receiving the vaccine by the subcutaneous route, there
was one additional individual who had an adverse event when
compared to participants who received the vaccine by the intra-
muscular route. However, there were no differences in the rate of
severe injection site, systemic and vaccine-related systemic adverse
events.
In the Vesikari 2013 study we used only data for the single dose.
Injection site adverse events were less frequent in participants in-
oculated with refrigerated herpes zoster vaccine than in those re-
ceiving the frozen vaccine.
Even with this unfavourable safety profile, it is of note that the
majority of the adverse events were of mild to moderate intensity.
This is clearly reported in the adverse event sub-study of Oxman
2005.
A previously published review pooled data from two studies to
evaluate the safety of zoster vaccines and concluded that tolerability
was good and that safety was not a major concern (Sutradhar
2009). Berger 1998 compared different dosages of zoster vaccines
and pneumo 23 and also reported that zoster vaccine produced
fewer injection site adverse events than the pneumo 23 vaccine.
The Food and Drug Administration (FDA) approved zoster vac-
cine for older adults (60 years and over) in May 2006 (http://
www.fda.gov/ForConsumers/ConsumerUpdates/
ucm132873.htm).
Adjuvanted recombinant VZV subunit zoster vaccine
(not yet available)
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We included three trials that tested this new vaccine on clinical
outcomes (efficacy, adverse events and drop-out) and we consid-
ered two of them as having a low risk of bias (Chlibek 2013; Lal
2015). The main study, Lal 2015, evaluated the incidence of her-
pes zoster in a vaccinated group versus a placebo group during an
average of 3.2 years of follow-up and observed a significant de-
crease in this outcome in the vaccinated group. This new vaccine
also proved to be safe since there was no difference in serious ad-
verse events between the vaccinated and placebo groups. Although
systemic and injection sites adverse events were more frequent in
the vaccinated group, these were transient.
All studies received funding from the pharmaceutical industry.
Overall completeness and applicability of
evidence
All included studies except one enrolled healthy elderly partici-
pants with previous VZV contact but without a history of her-
pes zoster. Only Mills 2010 enrolled participants with a history
of herpes zoster. Most (> 68%) of the participants in the primary
studies were Caucasian and their mean/median age was 60 to 70
years. One study included individuals aged ≥ 70 years (Vesikari
2013).
All studies were conducted in high-income countries. Three stud-
ies were conducted in the United States (Gilderman 2008; Mills
2010; Oxman 2005), and one in Switzerland (Berger 1998). The
others were multi-country studies: Chlibek 2013 recruited par-
ticipants in the Czech Republic, Spain and the United States,
Chlibek 2014 enrolled participants in the Czech Republic, Ger-
many, The Netherlands and Sweden, Diez-Domingo 2015 re-
cruited participants in Germany and Spain, Murray 2011 enrolled
patients in Canada, Germany, Spain, theUnited Kingdom and the
United States, Tyring 2007 recruited participants in the United
States, Canada, the United Kingdom, Germany and Belgium, and
Vermeulen 2012 enrolled participants in the United States and
the Netherlands.
Despite the wide geographic diversity of the primary studies, we
consider the external validity to be low due to the homogeneous
characteristics of the participants enrolled in the primary studies.
Quality of the evidence
We classified Chlibek 2013 as having a low risk of bias in six do-
mains of the Cochrane ’Risk of bias’ tool: random sequence gener-
ation, allocation concealment, blinding (performance bias and de-
tection bias), blinding of participants and personnel (performance
bias), blinding of outcome assessment (detection bias), incomplete
outcome data and freedom from selective reporting. We judged it
to have an unclear risk of bias for the ’other bias’ domain because
it lacked details for this domain.
We classified Diez-Domingo 2015 and Vesikari 2013 as being at
low risk of bias for the domains random sequence generation (se-
lection bias), allocation concealment (selection bias), blinding of
participants and personnel (performance bias), incomplete out-
come data (attrition bias) and selective reporting (reporting bias).
We classified Oxman 2005 and Vermeulen 2012 as having a low
risk of bias in four of the domains of the Cochrane ’Risk of bias’
tool: allocation concealment, blinding, incomplete outcome data
and freedom from selective reporting. We classified Murray 2011
as having a low risk of bias in the following four domains: blinding,
blinding of outcome assessment, incomplete outcome data and
freedom from selective reporting.
Chlibek 2014 had a low risk of bias in three domains (blinding
of participants and personnel (performance bias), incomplete out-
come data and freedom from selective reporting).
Only Levin 2000 had an unclear risk of bias for selective reporting,
while we classified all other studies as having a low risk of bias for
this domain (Berger 1998; Chlibek 2013; Chlibek 2014; Diez-
Domingo 2015; Gilderman 2008; Mills 2010; Murray 2011;
Oxman 2005; Tyring 2007; Vermeulen 2012; Vesikari 2013).
Berger 1998, Chlibek 2013, Gilderman 2008, Murray 2011,
Oxman 2005, Tyring 2007 and Vermeulen 2012 had a low risk
of bias for blinding.
Nine studies were at low risk of attrition bias (Chlibek 2013;
Chlibek 2014; Diez-Domingo 2015; Gilderman 2008; Murray
2011; Oxman 2005; Tyring 2007; Vermeulen 2012; Vesikari
2013). We classified Berger 1998 and Levin 2000 as having an
unclear risk of bias for this domain and we considered Mills 2010
to have a high risk of bias for this domain.
Potential biases in the review process
Due to the existence of ongoing but unfinished studies, the
results currently described in this review may be underes-
timated (NCT00886613; NCT01165177; NCT01165229;
NCT01385566; NCT01505647; NCT01751165;
NCT01777321; NCT02075515; NCT02114333;
NCT02180295; NCT02526745).
Agreements and disagreements with other
studies or reviews
A cohort study followed 766,330 individuals of 65 years of age
or more (a 5% random sample of Medicare patients) who had
received and not received zoster vaccines between 1 January 2007
and31December 2009.Overall, the incidence rate of herpes zoster
in the vaccinated participants was 5.4 (95% confidence interval
(CI) 4.6 to 6.4) per 1000 person-years compared to 10.0 (95% CI
9.8 to 0.2) per 1000 person-years in those not vaccinated (Langan
2013).
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Although the primary studies did not assess adverse events associ-
ated with autoimmune diseases, a matched case-control study that
collected data fromMay 2006 to November 2014 was conducted
by the Vaccine Adverse Event Reporting System (a national vac-
cine safety surveillance database maintained jointly by the United
States Centers for Disease Control and Prevention (CDC) and the
Food and Drug Administration (FDA)) to clarify severe autoim-
mune adverse events post live attenuated herpes zoster vaccine.
The adverse events assessedwere arthritis, vasculitis, systemic lupus
erythematosus, thrombocytopenia, alopecia, Guillain-Barre syn-
drome, optic neuritis and multiple sclerosis. That study reported a
higher incidence of arthritis and alopecia, after vaccination. Com-
pared to the unexposed, patients with zoster vaccination had 2.2
and 2.7 times the odds of developing arthritis and alopecia, re-
spectively (P value < 0.001 and P value = 0.015, respectively) (Lay
2015).
Our main findings are in concordance with the previous review
by Sanford 2010 regarding both the effectiveness and tolerability
of herpes zoster vaccines and we have completed their data with
additional studies.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is a clear benefit in vaccinating elderly peoplewith the herpes
zoster vaccine, with no major safety/tolerability concerns. Herpes
zoster is more frequent among elderly individuals than in other
adults and its main clinical feature is pain; therefore prevention of
this disease is desirable. Moderate quality evidence suggests that in
persons of 60 years of age ormore the zoster vaccine can reduce the
incidence of herpes zoster for at least three years post-vaccination.
There are studies of a new vaccine (with a VZV glycoproteic frac-
tion plus adjuvant), which is currently not yet available for clinical
use.
Implications for research
The effectiveness of vaccines with lower concentrations (< 18,700
plaque-forming units/dose - the minimum dose used in Oxman
2005) of VZV should be tested to optimise the amount of virus
used in each dose and therefore reduce costs, thus making more
vaccine available to everyone who can benefit from it.
According to www.clinicaltrials.gov, https:/
/eudract.ema.europa.eu/ and http://www.who.int/ictrp/en/ there
are several ongoing studies:
1. V212/heat-treated VZV vaccine or with live zoster vaccine
or placebo in healthy volunteers 60 years of age or older
(NCT00886613).
2. Different routes of administration: a randomised controlled
trial (RCT) on the immunogenicity and safety of intradermal
administration of Zostavax™ (available live attenuated VZV
vaccine) (NCT01385566).
3. Different formulations of Zostavax™ (AMP): Zostavax™
manufactured with an alternative process compared with
Zostavax™ manufactured with the current process
(NCT01505647).
There are also several ongoing studies of the as yet unavailable vac-
cine candidate with adjuvanted recombinant subunit glycoproteic
gE:
1. In one the participants will receive intramuscular herpes
zoster vaccine GSK1437173A versus an intramuscular placebo
(NCT01165177).
2. In another, adults aged > 70 years will receive intramuscular
herpes zoster vaccine GSK1437173A versus an intramuscular
placebo (NCT01165229).
3. A study will evaluate the safety and immunogenicity of
GlaxoSmithKline (GSK) Biologicals’ herpes zoster vaccine
GSK1437173A in adults aged ≥ 50 years, given as two doses in
three different schedules: 0 and 2 months schedule; 0 and 6
months schedule and 0 and 12 months schedule
(NCT01751165).
4. A study is comparing herpes zoster subunit (HZ/su) vaccine
given subcutaneously at 0 and 2 months versus the same vaccine
given by the intramuscular route at 0 and 2 months
(NCT01777321).
5. A study is comparing herpes zoster vaccine GSK1437173A
in two different lots (Lot A and Lot B), with two doses given
intramuscularly (NCT02075515).
6. A study is assessing the immunogenicity and safety of
available live attenuated VZV zoster vaccine and adjuvanted
recombinant VZV subunit zoster vaccine, which is not yet
available (NCT02114333).
One study has been withdrawn prior to enrolment (
NCT02180295).
The study NCT02526745 is testing different amounts of VZV in
Chinese individuals of 50 years of age or more.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Berger 1998
Methods RCT, double-blind
Duration: 42 days post-vaccination
Participants 200 older adult participants
Age range 55 to 88 years
~59% male
~66 yo
Previous history of varicella confirmed by positive serology to VZV and a competent
immune system (no signs of immunodeficiency)
Interventions 1. A live attenuated VZV/Oka vaccine 3200 pfu/dose SC (frozen); N = 49
2. A live attenuated VZV/Oka vaccine 8500 pfu/dose SC (frozen); N = 51
3. A live attenuated VZV/Oka vaccine 41,650 pfu/dose SC (frozen); N = 49
4. Pneumococcal polysaccharide vaccine (pneumo 23) SC (refrigerated); N = 49
Outcomes Local adverse reaction during 42 days (6weeks): none,≥ 1 reaction, induration (diameter
≥ 2 cm), pain (all), pain (probably vaccine-related), redness (diameter≥ 2 cm), pruritus
and vesicles
Purpose of the Study “To evaluate the cell-mediated and humoral immunogenicity and the safety of 1 of 3
doses of a live attenuated varicella-zoster virus vaccine/OKA compared with a control
vaccine”
Funding sources Pasteur Mérrieux Connaught, Lyon, France
Notes No participants had fever during the 72 hours following vaccination
1 participant in the 8500 pfu VZV group presented with a mild vesicular rash after
vaccination, which lasted 7 days
Analysis of the vesicular fluid was negative for VZV (polymerase chain reaction (PCR)
analysis)
No intention-to-treat analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk “Three groups of different concentrations
of a live attenuated VZV/Oka vaccine un-
der double-blind conditions. 1 group of
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Berger 1998 (Continued)
pneumococcal polysaccharide vaccine un-
der single-blind conditions and used as a
control for a reactogenicity and immune
response”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not described
Selective reporting (reporting bias) Low risk The adverse events originally defined by the
authors were presented for all groups
Other bias Unclear risk Not described
Chlibek 2013
Methods RCT phase II, parallel-group, placebo-controlled, double-blind
12 centres (1 centre in the Czech Republic, 4 in Spain and 7 in the United States)
Duration: 1 year after the last vaccination (14 months)
Participants N = 410 participants aged > 50 years
Participants were excluded if they were using any investigational or non-registered drug
or vaccine within 30 days preceding the first dose of study vaccine or any non-replicating
vaccines within 2 weeks of enrolment, were receiving chronic (> 14 consecutive days)
immunosuppressants or other immune-modifying drugs within 3 months prior to en-
rolment (for corticosteroids,≥0.5mg/kg/day prednisone or equivalent), were previously
vaccinated against HZ or varicella, had a history of HZ, allergic disease or reactions
likely to be exacerbated by any component of the vaccine, had a confirmed or suspected
immunosuppressive or immunodeficient condition, were administered immunoglobu-
lins or any blood products within the 3 months preceding the first injection of study
vaccine or planned to receive them during the study period, or had an acute disease at
enrolment. In addition, women could not be pregnant or had to be using birth control
or be of non-childbearing potential
Mean age ~65 years
Just over half of the participants were women
The population was predominantly Caucasian
Interventions 1. 2 doses 2months apart 50µg purified gE/AS01B (1 mg dioleoyl phosphatidylcholine,
250 µg cholesterol, 50 µg MPL and 50 µg QS-21) 0.5 mL IM N = 150
2. 2 doses 2 months apart 50 µg purified gE/AS01E (500 µg dioleoyl phosphatidyl-
choline, 125 µg cholesterol, 25 µg MPL and 25 µg QS-21) 0.5 mL IM N = 149
3. 2 doses 2 months apart 50 µg purified gE/saline (unadjuvanted gE) 0.5 mL IM N =
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73
4. 2 doses 2 months apart saline 0.5 mL IM N = 38
Outcomes 1. Participants with solicited general solicited symptoms (fatigue, fever (recorded as
temperature), headache, gastrointestinal symptoms, and myalgia) between days 0 and 6
2. Participants with solicited local reactions (pain, redness and swelling at the injection
site) between days 0 and 6
3. Participants with unsolicited symptoms between days 0 and 29 after each dose
4. Participants with temperature was scored grade 3 (> 39.0°C)
5. Participants with other symptoms were scored grade 3 for prevents normal activity
6. Participants with redness and swelling at the injection site were scored grade 3 (> 100
mm)
7. Severe adverse events (SAEs) were collected for 1 year after the last vaccination and
were defined as events that resulted in death, were life-threatening, required hospitalisa-
tion or prolongation of existing hospitalisation, resulted in disability/incapacity, caused
a congenital anomaly/birth defect in the child of a study participant, or could have jeop-
ardised the participant or required medical or surgical intervention
Purpose of the Study Immunogenicity and reactogenicity of recombinant gE in a representative older adult
population
Funding sources GlaxoSmithKline Biologicals SA, Belgium
Notes “Of the 410 subjects, 395 completed the study. Of the 15 participants who discontinued
the study early, 2 withdrew due to treatment related AEs (1 participants each in the
gE/AS01E and gE/AS01B groups) and 2 withdrew for SAEs not considered treatment
related (digestive tract haemorrhage in the gE/AS01E group and myocardial infarction
in the gE/AS01B group), 2 vaccine-related adverse events led to withdrawal from the
study: 1 subject treated with gE/AS01B withdrew due to malaise beginning on the day
of vaccination, and 1 participants treated with gE/AS01E withdrew due to injection site
redness that lasted > 2 weeks. 2 lost to follow-up (gE/AS01B ), 8 consent withdrawal
(4 in the gE/AS01B , 2 in the gE/AS01E , 1 in the gE/saline and 1 after second dose of
vaccine in the group gE/AS01B ). 1 protocol violation (gE/AS01E)”
The only unsolicited symptom reported by > 3% of participants in any group was chills,
which was reported by 5% (8/150) of participants treated with gE/AS01B and 2% (3/
149) of those treated with gE/AS01E ; it was not reported in participants treated with
gE/ saline or saline alone
No vaccine-related SAEs and no cases of HZ were reported through month 14 of the
study
We had asked to authors about the AEs by age or by vaccination but they have answered
us only the published data
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The randomisation was made using an al-
gorithm that stratified by country, mini-
mized for age, and included a block size of
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11”
Allocation concealment (selection bias) Low risk “Treatments were allocated at each site us-
ing a central randomisation system on the
Internet”
Blinding (performance bias and detection
bias)
All outcomes
Low risk “The person in charge of the vaccination
accessed the randomisation system on In-
ternet using the subject number and age”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Both vaccine recipients and observers re-
sponsible for evaluations were blinded to
which formulation was administered”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Both vaccine recipients and observers re-
sponsible for evaluations were blinded to
which formulation was administered”
Incomplete outcome data (attrition bias)
All outcomes
Low risk The patient flow is clear
Selective reporting (reporting bias) Low risk The adverse events originally defined by the
authors were presented for all groups
Other bias Unclear risk We found no more details on this topic
Chlibek 2014
Methods RCT phase II, randomised, controlled, single-blind (participants)
11 centres in the Czech Republic, Germany, The Netherlands and Sweden
Duration: 36 months after first vaccination
Participants 714 healthy participants aged ≥ 60 years
Participants were excluded if they had a history of HZ; were previously vaccinated against
HZ or with any vaccine containing 3-O-desacyl- 4-monophosphoryl lipid A(MPL)
or Quillaja saponaria Molina, fraction 21 (QS21), were allergic to any of the vaccine
components, had received a vaccine (except influenza) within 2 weeks, an investigational
or non-registered product, chronic immunosuppressants, corticosteroids within 30 days,
or immunoglobulins or a blood product within 3 months before the first study vaccine
dose, or had a history of drug or alcohol abuse
The mean age was ~69.9 years
~60% female
Predominantly Caucasian (99.3%)
Interventions 1. 2 doses 2 months apart 25 µg gE/AS01B 0.5 mL IM N = 164
2. 2 doses 2 months apart 50 µg gE/AS01B 0.5 mL IM N = 166
3. 2 doses 2 months apart 100 µg gE/AS01B 0.5 mL IM N = 165
4. 1 dose saline + 1 dose 100 µg gE 2 months later 0.5 mL IM N = 165
5. 2 doses 2 months apart 100 µg gE/saline (unadjuvanted gE) 0.5 mL IM N = 54
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Outcomes 1. Participants with solicited general reactions (fatigue, fever, headache and myalgia):
recorded by participants on diary cards for 7 days after each vaccination
2. Participants with solicited local reactions (pain, redness and swelling at the injection
site)
3. Participants with unsolicited adverse events (AEs): recorded for 30 days after each
vaccination
4. Participants with serious adverse events (SAEs): recorded over the entire study period
(36 months)
Intensity of the solicited reactions was scored on a scale from 0 (absent) to 3 (severe). All
solicited local reactions were considered vaccination-related and causality of the solicited
general reactions, unsolicited AEs and SAEs was assessed by the investigators
Purpose of the Study “The aim of the current study is to evaluate the safety and immunogenicity of different
schedules and formulations of gE/AS01B in adults ≥ 60 years of age”
Funding sources GlaxoSmithKline Biologicals SA, Belgium
Notes 715 participants were enrolled but 714 vaccinated
701 completed the study through month 3
Most solicited reactions were transient (1.1 to 3.5 days on average) and were of mild to
moderate intensity (grade 1 or 2), with ≤ 4.8% of participants in each group reporting
grade 3 reactions
A total of 349 SAEs were reported in 205 participants during the study. 14 participants
died due to a SAE, most of which were due to cancer or heart failure. No SAEs were
considered related to the study vaccines by the investigators
47 participants (6.6%) were excluded from the according-to-protocol immunogenicity
cohort. The most common reasons for exclusion were non-compliance with the blood
sampling schedule (N = 27) and the absence of essential serological data (N = 9)
Of the 714 vaccinated participants, 685 (95.9%) were followed through month 12, 665
(93.1%) through month 24, and 646 (90.5%) through month 36
8 were withdrawn from 25 µg gE/AS01B group (3 not eligible, 2 lost to follow-up, 2
consent withdrawal and 1 death); 7 were withdrawn from the 50 µg gE/AS01B group
(1 not eligible, 2 consent withdrawal and 4 deaths); 6 were withdrawn from the 100 µg
gE/AS01B group (2 not eligible, 2 consent withdrawal and 2 deaths); 4 were withdrawn
from the saline + 100 µg gE/AS01B group (1 lost to follow-up, 1 consent withdrawal
and 2 deaths) and 4 were withdrawn from the 100 µg gE/saline group (2 lost to follow-
up and 2 deaths)
“The proportion of subjects with solicited reactions was higher for groups receiving two
doses of gE/AS01B but the proportion did not increase between the first and the second
vaccination (data not shown)”
We had asked the authors for information about the AEs by age or vaccination but they
have only provided the published data
Risk of bias
Bias Authors’ judgement Support for judgement
32Vaccines for preventing herpes zoster in older adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Chlibek 2014 (Continued)
Random sequence generation (selection
bias)
Unclear risk “Subjects were stratified by age (60-69years
and ≥70 years in a 1:4 ratio) and ran-
domised”; the method of randomisation is
not described
Allocation concealment (selection bias) Unclear risk No information was found about this do-
main
Blinding (performance bias and detection
bias)
All outcomes
High risk There was no mention of whether the pre-
pared injections were indistinguishable in
all aspects of their outward appearance
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Single-blind (only for participants) but the
participants themselves completed their di-
ary cards as described “solicited local reac-
tions (pain, redness and swelling) and gen-
eral reactions (fatigue, fever, headache and
myalgia) were recorded by subjects on diary
cards for seven days after each vaccination”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Although the participants themselves com-
pleted their diary cards the other AEs were
not blinded for the evaluator
Incomplete outcome data (attrition bias)
All outcomes
Low risk The patient flow is clear
Selective reporting (reporting bias) Low risk The adverse events originally defined by the
authors were presented
Other bias Unclear risk We found no more details on this topic
Diez-Domingo 2015
Methods Phase 3, open-label, randomised, comparative, 2-arm, multicentre study
10 centres in Germany and Spain
Duration: participants were followed up for a maximum of 35 days post-vaccination
Participants 353 participants of either gender aged≥ 50 years on day of vaccination, varicella history-
positive or residence for > 30 years in a country with endemic VZV infection
Mean age of the 354 participants was 62.6 years
~55% were female
Interventions 1. Intramuscular (IM) route: zoster vaccine (refrigerated) 0.65 mL containing not less
than 19,400 plaque-forming units (pfu) of VZV per dose by IM route; N = 176
2. Subcutaneous (SC) route: zoster vaccine (refrigerated): 0.65 mL containing not less
than 19,400 pfu of VZV per dose by SC route; N = 177
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Outcomes 1. Injection site adverse reactions (ISRs): injection site erythema, injection site swelling
and injection site pain were collected from day 0 to day 4 post-vaccination
ISRs were mainly mild (< 5 cm in size or defined as awareness of sign or symptom but
easily tolerated) or moderate (5 cm to < 10 cm in size or defined as discomfort enough
to cause interference with usual activity) in intensity. Few participants reported severe
ISRs (> 10 cm or defined as incapacitating with inability to work or do usual activity)
2. Fever - temperature > 38.3°C (day 0 to day 28 post-vaccination)
3. Unsolicited injection site adverse reactions and systemic adverse events and rashes of
interest (i.e. varicella, varicella-like rashes, herpes zoster or shingles and herpes zoster-
like rashes) were collected from day 0 to day 28 post-vaccination
4. Serious adverse events were collected any time during the study (day 0 to day 35 post-
vaccination)
Purpose of the Study “To evaluate the immunogenicity as measured by VZV antibody titres (gpELISA) at 4
weeks following ZOSTAVAX® administered by IM or SC route”
“To evaluate the immune response as measured by a second assay, the VZV Interferon-
gamma (IFN-)-ELISPOT at 4 weeks following ZOSTAVAX® administered by IM or
SC route”
“To describe the safety profile of ZOSTAVAX® administered by IM or SC route”
Funding sources Sanofi Pasteur MSD
Notes This was basically an immunogenicity study and we only used the safety data
More detailed unpublished data were kindly provided by Sanofi Pasteur MSD SNC
Data by age were not available
One participant reported in Group 1 (IM route) a zoster-like rash (right thoracic der-
matome) of mild intensity that occurred on day 12 after vaccine administration and
lasted 6 days. No specimen was obtained for PCR testing. No participant was withdrawn
due to an AE at any time after vaccine administration. No deaths were reported. 3 par-
ticipants reported a SAE: 1 participant (hernia obstructive) in Group 1 (IM route) and 2
participants (humerus fracture and deep vein thrombosis) in Group 2 (SC route). None
were assessed as vaccine-related by the investigator
No participant was withdrawn due to an AE at any time after vaccine administration
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The subjects were randomised using an
electronic case repot form (e-CRF)”
Allocation concealment (selection bias) Low risk “Allocation schedules were generated using
a 1:1 ratio with permuted blocks of 4-6”
Blinding (performance bias and detection
bias)
All outcomes
High risk Open-label study
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Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Between visit 1 and 2, the participants
were given a diary card to record their tem-
perature if they were febrile (oral temper-
ature ≥38.3 C), occurrence of any so-
licited injection site (erythema, swelling
and pain) adverse reactions (Days 0-4) and
any unsolicited injection site adverse re-
actions, varicella, varicella-like rashes, HZ
and zoster-like rashes and other systemic
adverse events (AEs) (Days 0-28). They
were also asked to report any serious AEs
(SAEs) that occurred at any time during the
study”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk The participants did not put any serious
AEs (SAEs) in their diary cards themselves,
therefore this was not blinded for the staff.
“They were also asked to report any serious
AEs (SAEs) that occurred at any time dur-
ing the study”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Clear patient flow
Selective reporting (reporting bias) Low risk All data on adverse events that the authors
proposed in their methodology were de-
scribed in the results for both groups
Other bias Unclear risk We found no more details on this topic
Gilderman 2008
Methods RCT, double-blind, multicentre, USA
Duration: 28 days post-vaccination
Participants 368 participants (367 analysed)
~55% female
~63 yo
68.1% white participants
Immunocompetent with a history of varicella or residence in a country where VZV
infection is endemic
Interventions 1. Zoster vaccine refrigerated SC; N = 182
2. Zoster vaccine frozen SC; N = 185
Outcomes Participants with follow-up, participants with 1 or more adverse events (AEs), partici-
pants with serious AEs, vaccine-related serious AEs, death, participants who discontin-
ued due to any AE, participants who discontinued due to a vaccine-related AE
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Purpose of the Study “To support the development of a refrigerator-stable formulation of Zostavax with a
confirmatory clinical trial with varicella-zoster virus antibody-seropositive adults ≥50
years of age”
Funding sources Merck & Co., Inc
Notes 1 patient withdrew consent prior to intervention
No intention-to-treat analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind, with in-house blinding
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The formulations were visually indistinct,
supplied in identical glass vials
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Clear patient flow
Selective reporting (reporting bias) Low risk The adverse events that the investigators se-
lected were reported in the results section,
for both refrigerated and frozen zoster vac-
cines
Other bias Unclear risk Not described
Lal 2015
Methods Randomised, placebo-controlled study conducted in 18 countries in Europe, North
America, Latin America, Asia and Australia
Mean follow-up of 3.2 years and ongoing (it is expected to be approximately 60 months)
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Participants 15,411 participants, 50 years of age or older, with no history of herpes zoster, not previ-
ously vaccinated against varicella or herpes zoster, and no immunosuppressive condition
Mean age ~62.4 years
~61.2% were female
~71.5% of white race
The majority from Europe: 51.2%
Interventions 1. Recombinant zoster vaccine (2 doses: first dose month 0 and second dose month 2);
N = 7698
2. Placebo (2 doses: first dose month 0 and second dose month 2); N = 7713
Outcomes Cases of herpes zoster
A reactogenicity subgroup - 7 days after each vaccination: systemic reactions (fatigue,
fever, gastrointestinal symptoms, headache,myalgia and shivering) and solicited injection
site reactions (pain, redness and swelling)
Serious adverse events were recorded in all participants for up to 12 months after the
second dose
Death
Potentially immune-mediated diseases
Purpose of the Study “The primary objective of the study was to evaluate overall vaccine efficacy in reducing
the risk of herpes zoster, as compared with placebo. Secondary objectives included deter-
mining the vaccine efficacy in reducing the incidence of herpes zoster in each age group
(50 to 59 years, 60 to 69 years, and ≥70 years) and HZ/su safety and reactogenicity
profiles.”
Funding sources Supported by GlaxoSmithKline Biologicals
Notes We used the available data for efficacy by age ≥ 60 y (a total of 8122 participants) and
we contacted the authors asking for AEs by age but the data were not provided; therefore
we used the AEs published for ≥ 50 y
A total of 16,160 participants were enrolled. Of these participants, 749 were excluded
from the efficacy analyses, mostly owing to deviations from Good Clinical Practice
standards at 2 study centres (involving 726 patients)
The remaining 15,411 participants constituted the total vaccinated cohort for analysis;
of these participants, 14,759 (95.8%) were included in the modified vaccinated cohort
but we did not consider this last cohort since we used ITT analysis
Most participants received two doses of the study vaccines (95.6% of HZ/su recipients
and 96.4% of placebo recipients)
“A reactogenicity subgroup of participants. This subgroup included all participants who
were 70 years of age or older and randomly selected participants in the two other age
groups (50 to 59 years and 60 to 69 years). The participants rated the intensity of the
solicited reactions on a scale from 0 (absent) to 3 (preventing normal everyday activities)
. Unsolicited adverse events were recorded for 30 days after each dose. Serious adverse
events were recorded in all participants for up to 12 months after the second dose. Such
events that were considered to be related to the study vaccine or study participation, any
events resulting in death, and potentially immune-mediated diseases were evaluated in
all participants over the entire study period. (A full list of potentially immune-mediated
37Vaccines for preventing herpes zoster in older adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Lal 2015 (Continued)
diseases is provided in the Supplementary Appendix.)”
We contacted the authors of this study asking for details about the reason why the
participants did not receive dose 2. They replied to our email but could not provide this
information because “the ZOE-50 study, which was the subject of the NEJM report, is
still ongoing and consequently blinded at the subject level. Therefore, information on
the specific reasons for non-receipt of the second vaccine or placebo dose is not presently
available.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “We randomly assigned participants in a 1:
1 ratio to receive either vaccine or placebo
using an online centralized randomization
system”
Allocation concealment (selection bias) Unclear risk Despite the sequence and random number
generationbeing appropriate, therewere no
details about allocation
Blinding (performance bias and detection
bias)
All outcomes
Low risk “Because the appearance of the reconsti-
tuted HZ/su vaccine differed from the
placebo solution, injections were prepared
and administered by study staff who did
not participate in any study assessment”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Because the appearance of the reconsti-
tuted HZ/su vaccine differed from the
placebo solution, injections were prepared
and administered by study staff who did
not participate in any study assessment”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “The investigators, participants, and those
who were responsible for the evaluation
of any study end point were unaware of
whether vaccine or placebo had been ad-
ministered”
Incomplete outcome data (attrition bias)
All outcomes
High risk No clear participant flow; the number of
patients randomised to each group is not
described for all outcomes
Selective reporting (reporting bias) Low risk All data that the authors proposed in their
methodology were described in the results
Other bias Unclear risk Not described
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Methods RCT, non-blinded
USA
Duration: 36 months post-vaccination
Participants 167 participants
~55% female
~65 yo (age range 55 to 89 years)
Healthy people free from immunosuppressive illness or medication, with a history of
varicella but not HZ
Interventions 1. Live zoster vaccine SC (not specified if frozen); N = 85
2. Inactivated zoster vaccine (live vaccine heated at 56 ºC for 7 days) SC; N = 82
Outcomes Confirmed HZ
Purpose of the Study “To compare a live attenuated varicella vaccine versus heat-inactivated varicella vaccine
in relation the confirmed cases of HZ and immunogenicity in individuals aged 55-89
years”
Funding sources Merck Research Laboratories, West Point, PA, USA
Notes Author answered our e-mail and provided data for 1 clinical outcome. Most outcomes
evaluated were immunologic
There is a misspelling of an author name on the paper, where Dr Levin was referenced
as Dr. Levine
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
High risk Open study
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not described
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Selective reporting (reporting bias) Unclear risk Not described
Other bias Unclear risk Not described
Mills 2010
Methods RCT, cross-over, multicentre (9 centres in USA)
Participants N = 101 healthy participants with physician-documented history of HZ
~60% female
Mean age in the intervention group was 68.3 years and in the placebo group 67.4 years
Data collected for 28 days after each injection
Interventions 1. Lyophilised (frozen) zoster vaccine SC; N = 51
2. Placebo SC; N = 50
Outcomes In participants ≥ 60 yo
1. Adverse events (AEs): 1 or more AE, injection site AEs, systemic and vaccine-related
systemic AEs
2. Drop-outs
Purpose of the Study “To determine the safety profile and immunogenicity of zoster vaccine in individuals
who experienced a prior episode of herpes zoster”
Funding sources Merck & Co., Inc
Notes We only used the data for participants 60 years or older
Data were analysed with pooled data from cross-over arms
Author contacted and answered our message. There was no separate analysis for the first
arm, prior to cross-over
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Double-blind but not explained how
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not described
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
High risk Nodata from the first arm of this cross-over
study were reported
Selective reporting (reporting bias) Low risk All of the adverse events listed in the meth-
ods section were described in the results
Other bias Unclear risk Not described
Murray 2011
Methods Randomised, double-blind, placebo-controlled, age-stratified study
Multicentre at 46 sites in Canada, Germany, Spain, the UK and the US
Duration: 182 days post-vaccination
Participants 11,980 afebrile participants ≥ 60 years of age; no prior receipt of any varicella or zoster
vaccine; no intercurrent illness that might interfere with the interpretation of the study
or prevent the participant from completion of the study; no immune dysfunction caused
by a medical condition; no use of immunosuppressive therapy; no concomitant use of
systemic antiviral therapy with activity against herpes viruses
Median age in both group was 69 years
Female ~58.7%
~96.2% white participants
Interventions 1. Zoster vaccine (refrigerated) SC; N = 5983
2. Placebo SC; N = 5997
Outcomes 1 or more serious side effect(s) occurring 26 weeks (182 days) after the vaccination;
vaccine-related serious side effects, death, injection site adverse events, systemic adverse
events; rashes and temperature were only reported if they were considered serious
Purpose of the Study “To evaluate the general safety of zoster vaccine in adults ≥ 60 years old”
Funding sources Merck Sharp Dohme Corp.
Notes Non-serious adverse events were not reported
The study reported 1 or more serious side effect(s) occurring 6 weeks (42 days) and 26
weeks (182 days) after vaccination. In our analyses, we included only the data reported
for the second monitoring period, i.e. serious adverse event(s) detected at 182 days after
vaccination
36participants discontinuedbecause of adverse events, 27participantswithdrew consent,
75 participants were lost to follow-up, 7 participants discontinued because of protocol
deviation and 2 participants were discontinued following physician’s decision (both were
in the placebo group)
ITT analysis
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“For all analyses, cross-treated (i.e. randomised to ZV and received placebo, or ran-
domised to placebo and received ZV) participants were considered according to the vac-
cine received and not the vaccine assigned”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “The ZV and placebo were reconstituted
with sterile diluent immediately prior to
administration, and were indistinguishable
from each other in appearance. Placebowas
the vaccine stabiliser of ZV with no live
virus.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “An independent data monitoring com-
mittee was established for continuous sa-
fety oversight during the study”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Clear patient flow
Selective reporting (reporting bias) Low risk The serious adverse events that were de-
fined in themethods sectionwere presented
in the results
Other bias Unclear risk Not described
Oxman 2005
Methods Randomised, placebo-controlled, double-blind study at 22 sites in the US
Time of follow-up: at least 7 years of surveillance for HZ
Participants N = 38,546 participants
60 years of age or older, with history of varicella or had resided in the continental United
States for at least 30 years
Median age in both groups was 69 years
~59% male
95.4% white race
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Interventions 1. Zoster vaccine (frozen) (18,700 to 60,000 plaque-forming units per dose (pfu/dose)
and more than 90% of vaccinated participants received 32,300 pfu or less) SC; N = 19,
270
2. Placebo SC; N = 19,276
Outcomes Confirmed cases of HZ, cases of HZ within 30 days of vaccination, confirmed HZ cases
and all adverse events occurring within 42 days after vaccination and during the whole
study
Participants with follow-up, participants with 1 or more AEs (systemic or injection site)
, participants with serious AEs, vaccine-related AEs (systemic or injection site), death,
varicella-like rash at injection site and not at injection site, herpes zoster-like rash, rash
unrelated to HZ, participants hospitalised, hospitalisation related to HZ
Purpose of the Study “To determine whether vaccination with a live attenuated varicella-zoster virus vaccine
would decrease the incidence, severity, or both of HZ and postherpetic neuralgia in
adults 60 years of age or older”
Funding sources “Supported by the Cooperative Studies Program, Department of Veterans Affairs, Office
of Research and Development; by a grant from Merck (to the Cooperative Studies
Program); and by a grant from the James R. and Jesse V. Scott Fund for Shingles Research
(to Dr. Oxman). The vaccine and placebo used for the study were supplied by Merck;
famciclovir was supplied by SmithKline Beecham and Novartis Pharmaceuticals”
Notes “Zoster vaccine and placebo were lyophilised, held frozen at -15°C until reconstituted
with sterile water, and administered within 30 minutes”
132 participants withdrew from the study and 113 were lost to follow-up
1588 participants died during the study, but it was not described whether these were
related to the protocol or not
Only a subgroup of patients had a safety assessment (zoster vaccine N = 3345; placebo
N = 3271), being the adverse event sub-study
This study performed 2 ITT analyses, with all individuals developing HZ and only with
those who developed after 30 days from the vaccine injection (modified ITT). For the
meta-analysis we considered the modified ITT
There was a break in surveillance for cases of HZ of approximately 15 months between
the completion of the Shingles Prevention Study surveillance in September 2003 and
resumption of follow-up in the Short-Term Persistence Substudy in December 2004.
Beginning in October 2005, open-label zoster vaccine was offered without charge to
Shingles Prevention Study placebo recipients. Placebo recipients enrolled in the Short-
Term Persistence Substudy completed the study upon receiving zoster vaccine, since
they could then no longer serve as unvaccinated controls. The Short-Term Persistence
Substudy participantswhowere zoster vaccine recipients in the Shingles Prevention Study
continued to be followed until the initiation of the Long-Term Persistence Substudy in
March 2006
The 2012 publication evaluated the effectiveness of the vaccine for up to 7 years after the
participants had been vaccinated. However, the data available in this publication report
different dates for the collection of outcomes in the intervention and in the placebo
groups. The data from the zoster vaccine group are from December 2004 to March
2006 (16 months). In the placebo group, data are reported only from December 2004
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to September 2005 (10 months), because in October 2005 the zoster vaccine was also
offered to participants in the placebo group, as stated by the authors reported above
We contacted the authors of this study asking for the data corresponding to the period
from December 2004 to September 2005 (10 months) for both groups (vaccine and
placebo). They replied to our email but did not provide this information and suggested
instead that we should “assume a uniform rate of events and calculate the estimated
number of cases from that”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Low risk “Each study site received randomly ordered
vials of zoster vaccine and placebo in sepa-
rate boxes for each age stratum”
Blinding (performance bias and detection
bias)
All outcomes
Low risk “All other study personnel were blinded to
study treatment assignments”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Since the reconstituted zoster vaccine had
a different appearance from the placebo, re-
constitution and administration were per-
formed by technicians who did not oth-
erwise interact with participants, evaluate
outcomes or adverse events, answer the tele-
phone or enter study data.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Clear patient flow
Selective reporting (reporting bias) Low risk All data on effectiveness and adverse events
that the authors proposed in their method-
ology were described in the results for both
groups
Other bias Unclear risk Not described
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Methods Randomised clinical trial, blinded to participant, investigator and sponsor
18 sites in the United States, Canada, United Kingdom, Germany and Belgium
Duration: 42 days post-vaccination
Participants 698 healthy participants, varicella history-positive (or resident for more 30 years in a
country with endemic VZV infection), HZ history-negative, men and women 50 or
more years of age
Median age in zoster vaccine higher-potency group was 64 years andmedian age of zoster
vaccine lower-potency group was 65 years
~59.25% female (61.2% in the higher-potency group and 57.3% in the lower-potency
group)
92.6% white participants
Interventions 1. Higher-potency zoster vaccine (frozen) SC (~207,000 pfu/0.65 mL dose); N = 459
2. Lower-potency zoster vaccine (frozen) SC (~58,000 pfu/0.65 mL dose); N = 233
Outcomes Herpes zoster or HZ-like rash, varicella or varicella-like rash, local and systemic clinical
adverse events and tolerability of both
Purpose of the Study “To compare the safety and tolerability profile of a higher potency zoster vaccine (~207,
000 plaque forming units (PFU)/0.65-mL dose) with that of a lower potency vaccine
(~58,000 PFU/0,65-mL dose)”
Funding sources Merck Research Laboratories
Notes Lower-potency zoster vaccine in this study was similar to vaccine potencies studied in
Oxman 2005
Randomised 2:1 ratio to receive 1 injection of each
3 participants were discontinued from the study. 2 participants lost to follow-up in the
higher-potency zoster vaccine group and 1 participant belonging to the lower-potency
zoster vaccine group withdrew consent prior to completion of the follow-up period, but
was included in the safety analyses
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk Blinded participants, investigator and
sponsor
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The 2 potency formulations were indistin-
guishable in appearance. All participants
received a single 0.65 mL subcutaneous in-
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jection of either the higher-potency zoster
vaccine or the lower-potency zoster vaccine
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Clear patient flow
Selective reporting (reporting bias) Low risk The adverse events defined in the methods
section were reported in the results for both
higher-potency and lower-potency zoster
vaccines
Other bias Unclear risk Not described
Vermeulen 2012
Methods Randomised, double-blind, placebo-controlled,multicentre study:United States (5 sites)
and the Netherlands (1 site)
Duration: 6 months after the second vaccination
Participants N = 209 healthy participants
≥ 60 years with a history of varicella and no prior HZ
The mean age at enrolment was 68.7 years for the ZV group and 70.7 years for the
placebo group, ~48% ≥ 70 years old and 8% ≥ 80 years old
> 60% women
Almost all white participants (97.1% in both groups)
Interventions 1. Lyophilised zoster vaccine (frozen) SC (23,000 pfu); N = 104
2. Placebo SC; N = 105
Outcomes Adverse events (AEs), both injection site and/or systemic. Swelling, redness, pain or
tenderness or rash at the injection site, or varicella(-like) rash or HZ(-like) rash, any
serious AEs (SAEs)
Purpose of the Study “To examine the safety, tolerability and immunogenicity after 1 and 2 doses of zoster
vaccine in adults 60 years of age and older”
Funding sources Merck Sharp Dohme Corp
Notes The first and second doses were administered 42 days apart (post-vaccination 1 and post-
vaccination 2)
1 participant withdrew consent before vaccination in the vaccine group
Discontinued after first vaccination vaccine group: clinical AE = 3, withdrew consent =
1, no participants lost follow-up or due to protocol deviation, other = 2
Discontinued after first vaccination placebo group: 1 participant due to clinical AE,
no participants lost to follow-up, 1 withdrew consent, 1 participant due to protocol
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deviation and 1 for other reason
Discontinued after second vaccination vaccine group: only 1 participant due to clinical
AE
Discontinued after second vaccination placebo group: 1 to lost follow-up and 2 for other
reasons
No ITT analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Subjects were randomised in a 1:1 ratio
to receive 2 doses of either ZV or placebo,
according to a computer-generated, study-
centre specific allocation schedule”
Allocation concealment (selection bias) Low risk “Allocation numbers were assigned sequen-
tially by the study site personnel to subjects
who met the study eligibility criteria, be-
ginning with the lowest number available
at the study centre, after informed consent
and medical history had been obtained.
The allocation schedule was generated by
a sponsor statistician not otherwise associ-
ated with the ZV program”
Blinding (performance bias and detection
bias)
All outcomes
Low risk “The subject, investigator, clinical study
site personnel, and sponsor personnel di-
rectly involved in the study were blinded to
whether the subject received zoster vaccine
or placebo. They remained blinded until all
subjects completed the study”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “The clinical materials were prepared by
an unblinded vaccine coordinator at each
clinical site, because of differences in the
turbidity of the study vaccine and placebo.
Each vial of vaccine or placebo was labelled
with a subject-specific allocation number.
The unblended vaccine coordinator re-
constituted the study vaccine/placebo and
wrapped the syringe in anopaque label con-
taining subject allocation number and time
of reconstitution. The unblinded vaccine
coordinator did not have any contact with
the subject and did not disclose the con-
tents of the syringe to the person adminis-
tering the study vaccine/placebo”
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Vermeulen 2012 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Clear patient flow
Selective reporting (reporting bias) Low risk All adverse events listed by the authors were
described in their results for both vaccina-
tions
Other bias Unclear risk Not described
Vesikari 2013
Methods Phase 3, open-label, randomised, 24 centres: Finland (6 centres), Germany (13 centres)
, Italy (2 centres), Spain (2 centres) and The Netherlands (1 centre)
Time of follow-up: 12 months after the last dose
Participants 759 individuals randomised aged ≥ 70 y with either a history of varicella or > 30 y
residency in a country with endemic VZV infection were enrolled
Individuals were excluded if they had: a history of HZ, previous varicella or HZ vaccina-
tion, exposure to varicella or HZ during the preceding 4 weeks, fever (oral temperature
38.3°C) during the preceding 72 hours, live virus vaccination during the preceding 4
weeks and inactivated vaccination during the preceding 2 weeks
509 (67.2%) were aged 70 to 79 years and 248 (32.8%) were aged > 80 years (total =
757)
~56% female
Interventions 1. Refrigerated live attenuated HZ vaccine single dose SC; N = 749
2. Refrigerated live attenuated HZ vaccine 2 doses 1 month apart schedule: 1 month
after first dose SC; N = 242
3. Refrigerated live attenuated HZ vaccine 2 doses 3 months apart schedule: 3 months
after first dose SC; N = 246
Outcomes AEs, immediate and not immediate, both at injection site and/or systemic:
1. Erythema, swelling and pain within 4 days of vaccination and other injection site
reactions were recorded by participants in a diary card
2. Other injection site reaction and systemic AEs were recorded in the diary card for up
to 28 days following each vaccination
3. Vaccine-related serious AEs, deaths and occurrences of HZ, varicella, or zoster-like
and varicella-like rashes were recorded by the investigators until the study was stopped
(1 year)
4. Varicella(-like) rash or HZ(-like) rash, any SAEs, vaccine-related AEs
Purpose of the Study “The primary objective of the studywas to demonstrate that a second dose ofHZ vaccine,
administered 1 mo or 3 mo after the first dose, elicits superior VZV antibody titres 4
weeks after vaccination compared with the first dose”
“Secondary objectives of the study were to compare VZV antibody titres 12 mo after
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completion of each two-dose schedule with those 12 mo after a single dose, and to
describe the safety profile of all three HZ vaccination schedules”
Funding sources Sanofi Pasteur MSD
Notes This was an immunogenicity study. For safety analyses, 1 patient randomised to the 1
mo between doses was analysed as receiving the 3 mo schedule
More detailed unpublished data were kindly provided by Sanofi Pasteur MSD SNC
For the period of first vaccination, the data for the 3 groups were pooled
Randomised 1:1:1 ratio to receive: 1 injection only; 2 injections with 1 month between
the doses (day 28 to 35) and 2 injections with 3 months between the doses (day 81 to
97)
For safety analyses, 1 patient randomised to the 1 month between doses was analysed as
receiving the 3 months schedule
“Seventeen participants withdrew from study due to adverse events, of whom ten with-
drew within 28 d after vaccination”
The injection site reactions were generally mild to moderate in intensity and resolved in
3 to 7 d
19 participants reported serious AEs between screening and 12 mo after the last vaccine
dose
2 serious AEs were reported by 1 participant
None of the serious AEs was considered by the investigator to be vaccine-related
Serious AEs occurred within 28 d of the first vaccine dose in 1.2% of participants (n =
9), and within 28 d of the second dose in 0.9% of participants (n = 4)
In 7 participants serious AEs occurred between 28 d and 12 mo after the last dose
Until the study was stopped, 12 participants died, 7 within 12 mo of the last vaccination
and 5 > 12 mo after the last vaccination
No intention-to-treat analysis
We asked the authors for the outcomes by age but they kindly answered that there was
no analysis of safety by age group
We used only the data for single doses since the authors state in their conclusion “The
results of this study demonstrate that there is no apparent advantage to administering a
second dose of Zostavax on a one month or three month schedule among individuals
aged ≥ 70 years.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Used “blocks of randomisation”
Allocation concealment (selection bias) Low risk “The allocation schedule was generated us-
ing balanced permuted blocks of randomi-
sation”
Blinding (performance bias and detection
bias)
All outcomes
High risk Open-label study
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Vesikari 2013 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Solicited injection-site reactions (ery-
thema, swelling, and pain) occurring
within 4 d of vaccination were recorded by
participants in a diary card. Other injec-
tion-site reactions and systemic AEs were
recorded in the diary card for up to 28 d
following each vaccination”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Although participants completed their di-
ary cards themselves the other AEswere not
blinded for the evaluator
Incomplete outcome data (attrition bias)
All outcomes
Low risk Clear patient flow
Selective reporting (reporting bias) Low risk All data that the authors proposed in their
methodology were described in the results
Other bias Unclear risk We found no more details on this topic
AE: adverse event
AS01: liposome-based adjuvant system containing the immunoenhancers 3-O-desacyl-4′-monophosphoryl lipid A (MPL) and the
saponin QS-21 (Quillaja saponaria Molina, fraction 21)
Adjuvanted gE/AS01B : 50 µg purified gE with adjuvant B (1 mg dioleoyl phosphatidylcholine, 250 µg cholesterol 50 µg MPL and
50 µg QS-21)
Adjuvanted gE/AS01E : 50 µg purified gE with adjuvant E (500 µg dioleoyl phosphatidylcholine, 125 µg cholesterol, 25 µg MPL
and 25 µg QS-21)
AS01B : adjuvant B composed of 1 mg dioleoyl phosphatidylcholine, 250 µg cholesterol 50 µg MPL and 50 µg QS-21
AS01E : adjuvant E composed of 500 µg dioleoyl phosphatidylcholine, 125 µg cholesterol, 25 µg MPL and 25 µg QS-21
d: days
Elderly or older adults: aged ≥ 60 years old
Frozen: -15 °C or colder
gE: recombinant subunit VZV composed of glycoprotein E
gE/saline: unadjuvanted gE
HZ: herpes zoster
ID: identification
IM: intramuscular
ITT: intention-to-treat
mo: month
MPL: immunoenhancer 3-O-desacyl-4′-monophosphoryl lipid A
µg: micrograms
N: number
NNTB: number needed to treat for an additional beneficial outcome
NNTH: number needed to treat for an additional harmful outcome
pfu: plaque-forming units
QS-21: immunoenhancer saponin quillaja saponaria Molina, fraction 21
Refrigerated: 2 °C to 8 °C
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Recombinant vaccine: the HZ/su vaccine contains 50 µg of recombinant VZV glycoprotein E and the liposome-based AS01B adjuvant
system contains 50 µg of 3-O-desacyl-4′-monophosphoryl lipid A (MPL) and 50 µg of Quillaja saponaria Molina, fraction 21 (QS21,
Antigenics, a wholly owned subsidiary of Agenus)
SAEs: serious adverse events
SC: subcutaneously
UK: United Kingdom
US: United States
VZV: varicella zoster virus
y: year
yo: years old
ZV: zoster vaccine
Zoster vaccine 1-mo schedule: ZV 2 doses given 1 month apart
Zoster vaccine 3-mo schedule: ZV 2 doses given 3 months apart
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Hayward 1994 RCT, evaluating zoster vaccine, with no clinical outcome: focus on immunogenicity
Hayward 1996 RCT, evaluating zoster vaccine, with no clinical outcome: focus on immunogenicity
Irwin 2007 RCT: intervention tested was Tai Chi, not the zoster vaccine
Kerzner 2007 RCT, evaluating zoster vaccine when administered concomitantly with influenza vaccine
Leroux-Roels 2012 RCT, evaluating zoster vaccine but the mean of age was outside our inclusion criteria (means ranged from
55 to 57 years)
Macaladad 2007 RCT, evaluating zoster vaccine but the age was outside the range of interest: adults≥ 30 years of age (adults
less than 60 years of age)
Patterson-Bartlett 2007 RCT, evaluating zoster vaccine, with no clinical outcome: focus on immunogenicity
RCT: randomised controlled trial
Characteristics of ongoing studies [ordered by study ID]
NCT00886613
Trial name or title ’A double-blind, randomised, placebo-controlled, parallel group study to evaluate biomarkers of immunity
to varicella zoster virus following immunisation with V212/heat-treated varicella-zoster virus (VZV) vaccine
or with ZOSTAVAX in healthy volunteers’
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Methods Allocation: randomised
Endpoint classification: efficacy study
Intervention model: parallel assignment
Masking: double-blind (participant, investigator)
Primary purpose: prevention
Participants 120 healthy participants, 60 years and older, both genders
Interventions 1. V212 (heat-treated VZV vaccine)
2. Live zoster vaccine
3. Placebo
Outcomes Immunogenicity (skin tests) and safety (adverse events)
Starting date March 2009
Contact information Please refer to this study by its ClinicalTrials.gov identifier: NCT00886613
Notes This study has been completed. No publications provided
NCT01165177
Trial name or title ’Efficacy, safety, and immunogenicity study of GSKBiologicals’ herpes zoster vaccine GSK1437173A in adults
aged ≥ 50 years’
Methods Allocation: randomised
Endpoint classification: efficacy Study
Intervention model: parallel assignment
Masking: double-blind (participant, investigator, outcomes assessor)
Primary purpose: prevention
Participants 16,256 healthy volunteers, 50 years and older, both genders
Interventions 1. Participants will receive herpes zoster vaccine GSK1437173A according to a 0, 2-month schedule, intra-
muscular injection
2. Participants will receive NaCl solution placebo according to a 0, 2-month schedule, intramuscular injection
Outcomes Confirmed HZ cases, incidence of PHN, duration of severe ’worst’ HZ-associated pain, incidence of overall
and HZ-related mortality, incidence of HZ complications in participants with confirmed HZ, incidence of
overall and HZ-related hospitalisations, duration of pain medication administered for HZ in participants
with confirmedHZ, occurrence of solicited local and general symptoms in a subset of participants, occurrence
of unsolicited adverse events (AEs), occurrence of serious adverse events (SAEs), occurrence of SAEs related
to study participation or to a concurrent GSK medication/vaccine in all participants, occurrence of fatal
SAEs, occurrence and relationship to vaccination of any potential immune-mediated diseases (pIMDs) in all
participants, occurrence and relationship to vaccination of any potential immune-mediated diseases (pIMDs)
in all participants
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Starting date August 2010
Contact information Please refer to this study by its ClinicalTrials.gov identifier: NCT01165177
Notes It has been published but remains ongoing
NCT01165229
Trial name or title ’Efficacy, safety and immunogenicity of GSK Biologicals’ herpes zoster vaccine GSK1437173A in adults aged
>= 70 years’
Methods Allocation: randomised
Endpoint classification: efficacy study
Intervention model: parallel assignment
Masking: double-blind (participant, investigator, outcomes assessor)
Primary purpose: prevention
Participants 14,512 healthy participants, 70 years and older, both genders
Interventions 1. Herpes zoster vaccine intramuscular injection
2. Placebo intramuscular injection
Outcomes Confirmed HZ cases, occurrence of overall postherpetic neuralgia, safety: occurrence of adverse events (AEs)
Starting date August 2010
Contact information Please refer to this study by its ClinicalTrials.gov identifier: NCT01165229
Notes This study is ongoing, but not recruiting participants. No publications provided
Secondary ID: EudraCT number 2009-015791-94
NCT01385566
Trial name or title ’A partially blinded randomised clinical trial to study the immunogenicity and safety of intradermal admin-
istration of ZOSTAVAX™ (V211)’
Methods Allocation: randomised
Endpoint classification: safety/efficacy study
Intervention model: parallel assignment
Masking: single-Blind (participant)
Primary purpose: prevention
Participants 223 healthy volunteers, 50 years and older, both genders
Interventions 1. Active comparator: full dose subcutaneous. Participants will receive a full dose of Zostavax™ administered
subcutaneously onDay 1 of the study. 9 participants in this group will also receive saline placebo intradermally
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in the alternate limb on Day 1
2. Experimental: 1/3 dose subcutaneous. Participants will receive a 1/3 dose of Zostavax™ administered
subcutaneously onDay 1 of the study. 6 participants in this group will also receive saline placebo intradermally
in the alternate limb on Day 1. Participants will have the option to receive a full subcutaneous dose of
Zostavax™ after completion of the study
3. Experimental: full dose intradermal. Participants will receive a full dose of Zostavax™ administered intra-
dermally on Day 1 of the study. 6 participants in this group will also receive saline placebo intradermally in the
alternate limb on Day 1. Participants will have the option to receive a full subcutaneous dose of Zostavax™
after completion of the study
4. Experimental: 1/3 dose intradermal. Participants will receive a 1/3 dose of Zostavax™ administered
intradermally on Day 1 of the study. 6 participants in this group will also receive saline placebo intradermally
in the alternate limb on Day 1. Participants will have the option to receive a full subcutaneous dose of
Zostavax™ after completion of the study
5. Experimental: 1/10 dose intradermal. Participants will receive a 1/10 dose of Zostavax™ administered
intradermally on Day 1 of the study. 6 participants in this group will also receive saline placebo intradermally
in the alternate limb on Day 1. Participants will have the option to receive a full subcutaneous dose of
Zostavax™ after completion of the study
6. Experimental: 1/27 dose intradermal. Participants will receive a 1/27 dose of Zostavax™ administered
intradermally on Day 1 of the study. 6 participants in this group will also receive saline placebo intradermally
in the alternate limb on Day 1. Participants will have the option to receive a full subcutaneous dose of
Zostavax™ after completion of the study
Outcomes Geometric mean fold change from baseline in varicella zoster virus (VZV)-specific antibodies, number of
participants reporting an adverse experience (AE), number of participants reporting a serious adverse expe-
rience (SAE), number of participants reporting specific local injection site adverse experiences, number of
participants reporting a non-injection site rash
Starting date September 2011
Contact information Please refer to this study by its ClinicalTrials.gov identifier: NCT01385566
Notes This study has been completed. No publications provided
NCT01505647
Trial name or title ’A phase III double-blinded, randomised, multicenter, controlled study to evaluate the safety, tolerability, and
immunogenicity of ZOSTAVAX™made with an alternative manufacturing process (AMP)’
Methods Allocation: randomised
Endpoint classification: safety/efficacy study
Intervention model: parallel assignment
Masking: double-blind (participant, investigator)
Primary purpose: prevention
Participants 498 healthy volunteers, 50 years and older, both genders
Interventions 1. Experimental: Zostavax™ (AMP) Zostavax™ manufactured with an alternative process
2. Active comparator: Zostavax™ manufactured with the current process
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Outcomes Geometric mean titre (GMT) of varicella zoster virus (VZV) antibody, geometric mean fold rise (gmfr) in
VZV antibody titres, number of participants with 1 or more adverse experiences (AEs), number of participants
with 1 or more serious adverse experience (SAE) day 1 to 42 post-vaccination, number of participants with
1 or more serious adverse experience day 1 to 182 post-vaccination
Starting date April 2012
Contact information Please refer to this study by its ClinicalTrials.gov identifier: NCT01505647
Notes This study has been completed. No publications provided
NCT01751165
Trial name or title ’Open-label study to evaluate the safety and immunogenicity of GSK Biologicals’ herpes zoster vaccine
GSK1437173A in adults aged ≥ 50 years’
Methods Allocation: randomised
Endpoint classification: efficacy study
Intervention model: parallel assignment
Masking: open-label
Primary purpose: prevention
Participants 354 healthy volunteers, 50 years and older, both genders
Interventions 1. HZ/su-0,2 Group. Participants will receive HZ/su vaccine on a 0.2 month schedule
2. HZ/su-0,6 Group. Participants will receive HZ/su vaccine on a 0.6 month schedule
3. HZ/su-0,12 Group. Participants will receive HZ/su vaccine on a 0.12 month schedule
Outcomes Anti-gEhumoral immunogenicity in terms of antibody concentration, occurrence of solicited local and general
symptoms, occurrence of unsolicited symptoms, occurrence of serious adverse events (SAEs), occurrence of
AEs of specific interest
Starting date March 2013
Contact information Please refer to this study by its ClinicalTrials.gov identifier: NCT01751165
Notes This study is ongoing, but not recruiting participants. No publications provided
Secondary ID: EudraCT number 2012-004456-11 or Study ID: 116697
NCT01777321
Trial name or title ’Safety and immunogenicity study of GSK Biologicals’ herpes zoster subunit (HZ/su) vaccine GSK1437173A
when administered subcutaneously vs. intramuscularly in adults aged ≥ 50 years’
Methods Allocation: randomised
Endpoint classification: safety/efficacy study
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Intervention model: parallel assignment
Masking: open-label
Primary purpose: prevention
Participants 60 healthy volunteers, 50 years and older, both genders
Interventions 1. Experimental: subcutaneus HZ/su Group 0.2 month schedule
2. Active comparator: intramuscular HZ/su Group 0.2 month schedule
Outcomes Evaluation of gE-specific antibody concentrations, occurrence of solicited local and general symptoms, oc-
currence of unsolicited symptoms, occurrence of serious adverse events (SAEs), occurrence of adverse events
(AEs) of specific interest
Starting date June 2013
Contact information Please refer to this study by its ClinicalTrials.gov identifier: NCT01777321
Notes This study has been completed. No publications provided
NCT02075515
Trial name or title ’Consistency, immunogenicity and safety study of GSK Biologicals’ herpes zoster vaccine GSK1437173A in
adults ≥ 50 years of age’
Methods Allocation: randomised
Endpoint classification: efficacy study
Intervention model: parallel assignment
Masking: double-blind (participant, caregiver, investigator)
Primary purpose: prevention
Participants 651 healthy volunteers, 50 years and older, both genders
Interventions 1.HZ/su Lot A vaccine, 2 doses administered intramuscularly
2. HZ/su Lot B vaccine, 2 doses administered intramuscularly
3. HZ/su Lot C vaccine, 2 doses administered intramuscularly
Outcomes Anti-gE humoral immunogenicity, occurrence of solicited local and general symptoms, occurrence of unso-
licited symptoms, occurrence of serious adverse events (SAEs), occurrence of AEs of specific interest
Starting date August 2014
Contact information Please refer to this study by its ClinicalTrials.gov identifier: NCT02075515
Notes This study is ongoing, but not recruiting participants. No publications provided
Secondary ID: EudraCT number: 2013-000373-76 or Study ID: 117177
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NCT02114333
Trial name or title ’A comparison of the immunogenicity and descriptive safety of a live attenuated herpes zoster vaccine and the
GSK herpes zoster recombinant HZ/su candidate vaccine in 50 to 59 year old and 70 to 85 year old vaccine
recipients’
Methods Allocation: randomised
Endpoint classification: pharmacodynamics study
Intervention model: parallel assignment
Masking: single-blind (participant)
Primary purpose: basic science
Participants 160 healthy volunteers aged 50 years to 85 years, both genders
Interventions 1. No previous zoster vaccine: live zoster vaccine subcutaneous and second dose placebo, normal saline
subcutaneous
2. No previous zoster vaccine: recombinant vaccine HZ/su intramuscular and second dose recombinant
vaccine intramuscular
3. 1 previous dose of zoster vaccine at least 5 years previously: live zoster vaccine subcutaneous and second
dose placebo, normal saline subcutaneous
4. 1 previous dose of zoster vaccine at least 5 years previously: recombinant vaccine HZ/su intramuscular and
second dose recombinant vaccine intramuscular
Outcomes Unsolicited adverse events, interferon gamma/ Interleukin 2 (IFNg/IL2) dual colour fluorospot number,
glycoprotein-based enzyme-linked immunosorbent assay (gpELISA)
Starting date May 2014
Contact information Please refer to this study by its ClinicalTrials.gov identifier: NCT02114333
Notes This study is currently recruiting participants. No publications provided
NCT02180295
Trial name or title ’A phase III, double-blind, lot-to-lot consistency clinical trial to evaluate the safety, tolerability and immuno-
genicity of V212 in healthy adults’
Methods Allocation: randomised
Endpoint classification: safety study
Intervention model: parallel assignment
Masking: double-blind (participant, investigator, outcomes assessor)
Primary purpose: prevention
Participants 0 healthy volunteers, 50 years and older, both genders
Interventions 1. Biological: V212 Lot 1. Approximately7.5 units/0.5 mL subcutaneous injection administered in a 4-dose
regimen given approximately 30 days apart
2. Biological: V212 Lot 2. Approximately 7.5 units/0.5 mL subcutaneous injection administered in a 4-dose
regimen given approximately 30 days apart
3. Biological: V212 Lot 3. Approximately 7.5 units/0.5 mL subcutaneous injection administered in a 4-dose
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regimen given approximately 30 days apart
Outcomes Geometric mean titre of VZV glycoprotein enzyme-linked immunosorbent assay (gpELISA) antibody titres,
number or percentage of participants with a serious adverse experience (time frame: up to 28 days post dose
4)
Starting date July 2014
Contact information Please refer to this study by its ClinicalTrials.gov identifier: NCT02180295
Notes This study has been withdrawn prior to enrolment. No publications provided
NCT02526745
Trial name or title ’Safety and immunogenicity study of live attenuated vaccine against herpes zoster in Chinese adults aged 50
years and older’
Methods Allocation: randomised
Intervention model: parallel assignment
Masking: double-blind (participant, investigator)
Primary purpose: prevention
Participants 440 participants. Aged 50 to 80 years, both gender, accepts healthy volunteers
Interventions 1. Vaccine with low dose of virus content, between 4.7 to 5.0 lg PFU
2.Vaccine with high dose of virus content, between 4.3 to 5.0 lg PFU
3. Vaccine with middle dose of virus content, between 4.3 to 5.0 lg PFU
4. Vaccine with very low dose of virus content, between 4.3 to 5.0 lg PFU
5. Placebo
Outcomes Primary outcome measures:
• Evaluate the rate of adverse reactions of live attenuated herpes zoster vaccine in Chinese adults. Time
frame: 42 days
• Adverse reactions associated with vaccine will be observed in Chinese adults (50 years and older) after
vaccination. Solicited local adverse events include pain, redness, swelling, induration, rash, pruritus at
injection site. solicited general adverse events include fever, nausea, vomiting, diarrhoea, decreased appetite,
be agitated (irritability, abnormal crying), fatigue, allergy
Secondary outcome measures:
• Evaluate the seroconversion rate of anti-herpes zoster virus antibodies in serum of adults after
vaccination. Time frame: 6 months.
Starting date November 2015
Contact information Beijing Chaoyang District Centre for Disease Control and Prevention Please refer to this study by its Clini-
calTrials.gov identifier: NCT02526745
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Notes This study evaluates the safety and immunogenicity of live attenuated vaccine in adults aged 50 years and
older. Half of participants will receive high doses of the vaccine,while the other half will receive low doses of
the vaccine in phase I clinical trial. At the phase II clinical trial, participants will be distributed equally to four
groups (low, middle, high doses of the vaccine and placebo)
AE: adverse event
GSK: GlaxoSmithKline
HZ: herpes zoster
PFU: plaque-forming units
PHN: postherpetic neuralgia
pIMDs: potential immune-mediated diseases
SAE: serious adverse event
VZV: varicella zoster virus
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D A T A A N D A N A L Y S E S
Comparison 1. Available live attenuated VZV zoster vaccine versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incidence of herpes zoster 2 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 3.1 years follow-up 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 30 days of vaccination 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.3 42 days of vaccination 2 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.4 3.3 to 7.8 years after
vaccination substudy
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.5 Mean 5 years follow-up 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Incidence of herpes zoster
with ZBPI ADL. Severity of
interference scores of 300 or
greater (high score is worse)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3 Participants with AEs 4 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 One or more AEs 3 6986 Risk Ratio (M-H, Fixed, 95% CI) 1.70 [1.61, 1.80]
3.2 Vaccine-related AEs 1 209 Risk Ratio (M-H, Fixed, 95% CI) 4.63 [2.64, 8.12]
3.3 Systemic AEs 3 6986 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.98, 1.16]
3.4 Systemic pruritus 1 209 Risk Ratio (M-H, Fixed, 95% CI) 7.07 [0.37, 135.13]
3.5 Vaccine-related systemic
AEs
2 6777 Risk Ratio (M-H, Fixed, 95% CI) 1.29 [1.06, 1.57]
3.6 Varicella-like rash not
at injection site (day of
vaccination to day 42)
2 38755 Risk Ratio (M-H, Fixed, 95% CI) 1.12 [0.58, 2.18]
3.7 Herpes zoster-like rash
(day of vaccination to day 42)
1 38546 Risk Ratio (M-H, Fixed, 95% CI) 0.47 [0.27, 0.84]
3.8 Rash unrelated to herpes
zoster (day of vaccination to
day 42)
1 38546 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.86, 1.07]
3.9 ≥ 1 serious AEs regardless
of type of storage of the vaccine
4 50896 Risk Ratio (M-H, Fixed, 95% CI) 1.08 [0.96, 1.20]
3.10 Vaccine-related serious
AEs
3 50687 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.25, 4.00]
3.11 Discontinued due to
vaccine-related AEs
2 370 Risk Ratio (M-H, Fixed, 95% CI) 5.05 [0.25, 103.88]
3.12 Hospitalised 1 6616 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.93, 1.07]
3.13 Hospitalisation related to
herpes zoster
1 6616 Risk Ratio (M-H, Fixed, 95% CI) 0.81 [0.25, 2.67]
3.14 Injection site AEs 3 6986 Risk Ratio (M-H, Fixed, 95% CI) 2.99 [2.75, 3.26]
3.15 Erythema inoculation
site
2 6825 Risk Ratio (M-H, Fixed, 95% CI) 5.15 [4.51, 5.87]
3.16 Pain inoculation site 2 6825 Risk Ratio (M-H, Fixed, 95% CI) 4.14 [3.67, 4.68]
3.17 Pruritus inoculation site 2 6825 Risk Ratio (M-H, Fixed, 95% CI) 6.91 [4.87, 9.82]
3.18 Swelling inoculation site 2 6825 Risk Ratio (M-H, Fixed, 95% CI) 5.85 [4.96, 6.91]
3.19 Warmth inoculation site 2 6825 Risk Ratio (M-H, Fixed, 95% CI) 5.15 [2.75, 9.66]
3.20 Rash inoculation site 1 6616 Risk Ratio (M-H, Fixed, 95% CI) 3.26 [1.31, 8.11]
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3.21 Haematoma inoculation
site
1 6616 Risk Ratio (M-H, Fixed, 95% CI) 1.13 [0.76, 1.67]
3.22 Mass inoculation site 1 6616 Risk Ratio (M-H, Fixed, 95% CI) 14.67 [3.51, 61.33]
3.23 Varicella-like rash
at injection site (day of
vaccination to day 42)
1 38546 Risk Ratio (M-H, Fixed, 95% CI) 2.86 [1.21, 6.76]
4 Drop-outs 4 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 For any reason 3 38916 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.91, 1.08]
4.2 Death 3 50687 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.92, 1.11]
4.3 Withdrew consent 3 50735 Risk Ratio (M-H, Fixed, 95% CI) 0.87 [0.64, 1.19]
4.4 Lost to follow-up 3 50735 Risk Ratio (M-H, Fixed, 95% CI) 1.29 [0.97, 1.73]
4.5 Protocol deviation 2 12189 Risk Ratio (M-H, Fixed, 95% CI) 1.58 [0.41, 6.02]
4.6 Clinical adverse event 2 12189 Risk Ratio (M-H, Fixed, 95% CI) 1.36 [0.73, 2.54]
4.7 Physician decision 1 11980 Risk Ratio (M-H, Fixed, 95% CI) 0.20 [0.01, 4.17]
5 Participants with no follow-up 3 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
Comparison 2. Live attenuated VZV zoster vaccine higher-potency zoster vaccine versus lower-potency zoster
vaccine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incidence of herpes zoster 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2 Vaccine-related adverse effects 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3 Vaccine-related systemic adverse
effects
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
4 Vaccine-related serious adverse
effects
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
4.1 Death 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Injection site vaccine-related
adverse effects
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
5.1 Erythema 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.2 Pain 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.3 Swelling 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.4 Pruritus 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Participants with no follow-up 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
Comparison 3. Live attenuated VZV zoster vaccine zoster vaccine refrigerated versus zoster vaccine frozen
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Participants with adverse effects 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 One or more adverse
effects
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Vaccine-related adverse
effects
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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1.3 Systemic adverse effects 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.4 Systemic vaccine-related
adverse effects
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.5 Serious adverse effects 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.6 Vaccine-related serious
adverse effects
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.7 Death 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.8 Injection site adverse
effects
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.9 Injection site vaccine-
related adverse effects
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.10 Discontinued due to any
adverse effects
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.11 Discontinued due to a
vaccine-related adverse effect
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Participants with no follow-up 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
Comparison 4. Live attenuated VZV zoster vaccine versus inactivated zoster vaccine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incidence of herpes zoster 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
Comparison 5. Live attenuated VZV zoster vaccine versus pneumo 23 vaccine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 3200 pfu VZV/dose 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 ≥ 1 reaction injection site 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Induration (diameter ≥ 2
cm injection site)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.3 Pain injection site 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.4 Pain (injection site,
probably vaccine-related)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.5 Redness injection site
(diameter ≥ 2 cm)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.6 Pruritus injection site 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.7 Vesicles at injection site 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 8500 pfu VZV/dose 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2.1 ≥ 1 reaction injection site 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 Induration (diameter ≥ 2
cm injection site)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.3 Pain injection site 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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2.4 Pain (injection site,
probably vaccine-related)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.5 Redness injection site
(diameter ≥ 2 cm)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.6 Pruritus injection site 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.7 Vesicle injection site 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 41,650 pfu/dose 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3.1 ≥ 1 reaction injection site 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 Induration (diameter ≥ 2
cm injection site)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.3 Pain injection site 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.4 Pain (injection site,
probably vaccine-related)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.5 Redness injection site
(diameter ≥ 2 cm)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.6 Pruritus injection site 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.7 Vesicle injection site 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Duration in days of adverse
effects
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.1 Erythema 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 Swelling 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.3 Pain 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.4 Rash 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.5 Pruritus 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.6 Haematoma 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 6. Live attenuated VZV zoster vaccine IM route versus zoster vaccine SC route
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Participants with adverse events 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 At least one AE 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Vaccine-related AE 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.3 All systemic AE 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.4 Vaccine-related systemic
AE
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.5 Headache considered
as vaccine-related by the
investigator
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.6 Solicited injection site
reaction
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.7 Unsolicited injection site
reaction
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.8 Injection site erythema 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.9 Severe injection site
erythema (> 10 cm)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.10 Injection site pain 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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1.11 Severe injection site pain
(inability to work or usual
activity)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.12 Injection site swelling 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.13 Severe injection site
swelling (> 10 cm)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.14 Injection site pruritus 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.15 Withdrawal due to AE 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 7. Live attenuated VZV zoster vaccine 2 doses versus single dose and also 2 doses given at different
intervals
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Zoster vaccine 1 month schedule
versus zoster vaccine 3 month
schedule
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 Participants with AE 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Participants with vaccine-
related AE
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.3 Participants with serious
AE
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.4 Participants with vaccine-
related serious AE
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.5 Participants with
withdrawal due to AE
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.6 Participants with vaccine-
related withdrawal due to AE
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.7 Participants with non-
serious vaccine-related
withdrawal due to AE
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.8 Participants with systemic
AE
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.9 Participants with vaccine-
related systemic AE
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.10 Participants with rash
of interest non-injection site
rashes
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.11 Participants with
varicella/varicella-like rash
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.12 Participants with herpes
zoster/zoster-like rash
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.13 Participants with
injection site reaction
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.14 Participants with
solicited injection site reaction
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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1.15 Participants with
unsolicited injection site
reaction
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.16 Participants with
erythema injection site
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.17 Participants with pain
injection site
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.18 Participants with swelling
injection site
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Zoster vaccine 1 month schedule
versus zoster vaccine single dose
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2.1 Participants with adverse
events
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 Participants with vaccine-
related AE
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.3 Participants with serious
AE
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.4 Participants with vaccine-
related serious AE
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.5 Participants with
withdrawal due to AE
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.6 Participants with vaccine-
related withdrawal due to AE
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.7 Participants with non-
serious vaccine-related
withdrawal due to AE
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.8 Participants with systemic
AE
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.9 Participants with vaccine-
related systemic AE
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.10 Participants with rash
of interest non-injection site
rashes
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.11 Participants with
varicella/varicella-like rash
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.12 Participants with herpes
zoster/zoster-like rash
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.13 Participants with
injection site reaction
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.14 Participants with
solicited injection site reaction
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.15 Participants with
unsolicited injection site
reaction
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.16 Participants with
erythema injection site
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.17 Participants with pain
injection site
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.18 Participants with swelling
injection site
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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3 Zoster vaccine 3 month schedule
versus zoster vaccine single dose
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3.1 Participants with AE 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 Participants with vaccine-
related AE
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.3 Participants with serious
AE
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.4 Participants with vaccine-
related serious AE
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.5 Participants with
withdrawal due to AE
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.6 Participants with vaccine-
related withdrawal due to AE
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.7 Participants with non-
serious vaccine-related
withdrawal due to AE
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.8 Participants with systemic
AE
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.9 Participants with vaccine-
related systemic AE
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.10 Participants with rash
of interest non-injection site
rashes
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.11 Participants with
varicella/varicella-like rash
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.12 Participants with herpes
zoster/zoster-like rash
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.13 Participants with
injection site reaction
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.14 Participants with
solicited injection site reaction
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.15 Participants with
unsolicited injection site
reaction
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.16 Participants with
erythema injection site
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.17 Participants with pain
injection site
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.18 Participants with swelling
injection site
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Comparison 8. Adjuvanted recombinant VZV subunit zoster vaccine: lower or higher quantities of adjuvants plus
gE subunit VZV versus unadjuvanted gE or saline
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 50 µg gE/AS01E versus 50 µg
gE/AS01B
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 Participants with any
symptom
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Participants with any
grade 3 symptom
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.3 Participants with any
general symptom
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.4 Participants with any
grade 3 general symptom
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.5 Participants with fatigue 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.6 Participants with grade 3
fatigue
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.7 Participants with fever 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.8 Participants with grade 3
fever
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.9 Participants with
gastrointestinal symptom
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.10 Participants with grade 3
gastrointestinal symptom
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.11 Participants with
headache
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.12 Participants with grade 3
headache
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.13 Participants with myalgia 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.14 Participants with grade 3
myalgia
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.15 Participants with any
local symptom
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.16 Participants with any
grade 3 local symptom
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.17 Participants with local
pain
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.18 Participants with grade 3
local pain
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.19 Participants with local
redness
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.20 Participants with grade 3
local redness
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.21 Participants with local
swelling
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.22 Participants with grade 3
local swelling
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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1.23 Participants with consent
withdrawal
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.24 Participants with lost
follow-up
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.25 Participants with serious
AE
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 50 µg gE/AS01E versus 50 µg
gE/saline (unadjuvanted gE)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2.1 Participants with any
symptom
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 Participants with any
grade 3 symptom
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.3 Participants with any
general symptom
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.4 Participants with any
grade 3 general symptom
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.5 Participants with fatigue 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.6 Participants with grade 3
fatigue
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.7 Participants with fever 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.8 Participants with grade 3
fever
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.9 Participants with
gastrointestinal symptom
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.10 Participants with grade 3
gastrointestinal symptom
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.11 Participants with
headache
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.12 Participants with grade 3
headache
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.13 Participants with myalgia 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.14 Participants with grade 3
myalgia
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.15 Participants with any
local symptom
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.16 Participants with any
grade 3 local symptom
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.17 Participants with local
pain
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.18 Participants with grade 3
local pain
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.19 Participants with local
redness
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.20 Participants with grade 3
local redness
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.21 Participants with local
swelling
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.22 Participants with grade 3
local swelling
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.23 Participants with consent
withdrawal
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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2.24 Participants with lost
follow-up
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.25 Participants with serious
AE
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 50 µg gE/AS01B versus 50 µg
gE/saline (unadjuvanted gE)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3.1 Participants with any
symptom
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 Participants with any
grade 3 symptom
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.3 Participants with any
general symptom
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.4 Participants with any
grade 3 general symptom
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.5 Participants with fatigue 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.6 Participants with grade 3
fatigue
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.7 Participants with fever 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.8 Participants with grade 3
fever
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.9 Participants with
gastrointestinal symptom
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.10 Participants with grade 3
gastrointestinal symptom
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.11 Participants with
headache
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.12 Participants with grade 3
headache
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.13 Participants with myalgia 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.14 Participants with grade 3
myalgia
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.15 Participants with any
local symptom
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.16 Participants with any
grade 3 local symptom
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.17 Participants with local
pain
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.18 Participants with grade 3
local pain
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.19 Participants with local
redness
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.20 Participants with grade 3
local redness
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.21 Participants with local
swelling
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.22 Participants with grade 3
local swelling
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.23 Participants with consent
withdrawal
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.24 Participants with lost
follow-up
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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3.25 Participants with serious
AE
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 50 µg gE/AS01E versus saline 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
4.1 Participants with any
symptom
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 Participants with any
grade 3 symptom
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.3 Participants with any
general symptom
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.4 Participants with any
grade 3 general symptom
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.5 Participants with fatigue 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.6 Participants with grade 3
fatigue
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.7 Participants with fever 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.8 Participants with grade 3
fever
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.9 Participants with
gastrointestinal symptom
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.10 Participants with grade 3
gastrointestinal symptom
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.11 Participants with
headache
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.12 Participants with grade 3
headache
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.13 Participants with myalgia 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.14 Participants with grade 3
myalgia
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.15 Participants with any
local symptom
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.16 Participants with any
grade 3 local symptom
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.17 Participants with local
pain
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.18 Participants with grade 3
local pain
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.19 Participants with local
redness
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.20 Participants with grade 3
local redness
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.21 Participants with local
swelling
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.22 Participants with grade 3
local swelling
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.23 Participants with consent
withdrawal
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.24 Participants with lost
follow-up
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.25 Participants with serious
AE
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 50 µg gE/AS01B versus saline 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
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5.1 Participants with any
symptom
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.2 Participants with any
grade 3 symptom
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.3 Participants with any
general symptom
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.4 Participants with any
grade 3 general symptom
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.5 Participants with fatigue 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.6 Participants with grade 3
fatigue
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.7 Participants with fever 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.8 Participants with grade 3
fever
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.9 Participants with
gastrointestinal symptom
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.10 Participants with grade 3
gastrointestinal symptom
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.11 Participants with
headache
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.12 Participants with grade 3
headache
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.13 Participants with myalgia 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.14 Participants with grade 3
myalgia
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.15 Participants with any
local symptom
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.16 Participants with any
grade 3 local symptom
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.17 Participants with local
pain
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.18 Participants with grade 3
local pain
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.19 Participants with local
redness
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.20 Participants with grade 3
local redness
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.21 Participants with local
swelling
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.22 Participants with grade 3
local swelling
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.23 Participants with consent
withdrawal
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.24 Participants with lost
follow-up
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.25 Participants with serious
AE
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 50 µg gE/Saline (unadjuvanted)
versus saline
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
6.1 Participants with any
symptom
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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6.2 Participants with any
grade 3 symptom
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.3 Participants with any
general symptom
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.4 Participants with any
grade 3 general symptom
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.5 Participants with fatigue 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.6 Participants with grade 3
fatigue
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.7 Participants with fever 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.8 Participants with grade 3
fever
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.9 Participants with
gastrointestinal symptom
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.10 Participants with grade 3
gastrointestinal symptom
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.11 Participants with
headache
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.12 Participants with grade 3
headache
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.13 Participants with myalgia 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.14 Participants with grade 3
myalgia
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.15 Participants with any
local symptom
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.16 Participants with any
grade 3 local symptom
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.17 Participants with local
pain
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.18 Participants with grade 3
local pain
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.19 Participants with local
redness
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.20 Participants with grade 3
local redness
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.21 Participants with local
swelling
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.22 Participants with grade 3
local swelling
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.23 Participants with consent
withdrawal
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.24 Participants with lost
follow-up
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.25 Participants with serious
AE
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Comparison 9. Adjuvanted recombinant VZV subunit zoster vaccine: 3 groups of VZV subunit gE in 3 different
quantities versus unadjuvanted gE or saline
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 25 µg gE/AS01B versus 50 µg
gE/AS01B
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 Participants with any
fatigue
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Participants with grade 3
fatigue
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.3 Participants with any fever 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.4 Participants with grade 3
fever
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.5 Participants with any
headache
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.6 Participants with grade 3
headache
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.7 Participants with any
myalgia
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.8 Participants with grade 3
myalgia
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.9 Participants with local
pain
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.10 Participants with grade 3
local pain
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.11 Participants with local
redness
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.12 Participants with grade 3
local redness
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.13 Participants with local
swelling
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.14 Participants with grade 3
local swelling
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.15 Participants with consent
withdrawal
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.16 Participants with lost to
follow-up
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.17 Participants with death 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 25 µg gE/AS01B versus 100 µg
gE/AS01B
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2.1 Participants with any
fatigue
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 Participants with grade 3
fatigue
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.3 Participants with any fever 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.4 Participants with grade 3
fever
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
73Vaccines for preventing herpes zoster in older adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
2.5 Participants with any
headache
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.6 Participants with grade 3
headache
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.7 Participants with any
myalgia
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.8 Participants with grade 3
myalgia
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.9 Participants with local
pain
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.10 Participants with grade 3
local pain
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.11 Participants with local
redness
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.12 Participants with grade 3
local redness
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.13 Participants with local
swelling
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.14 Participants with grade 3
local swelling
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.15 Participants with consent
withdrawal
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.16 Participants with lost to
follow-up
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.17 Participants with death 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 50 µg gE/AS01B versus 100 µg
gE/AS01B
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3.1 Participants with any
fatigue
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 Participants with grade 3
fatigue
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.3 Participants with any fever 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.4 Participants with grade 3
fever
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.5 Participants with any
headache
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.6 Participants with grade 3
headache
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.7 Participants with any
myalgia
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.8 Participants with grade 3
myalgia
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.9 Participants with local
swelling
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.10 Participants with grade 3
local pain
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.11 Participants with local
redness
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.12 Participants with grade 3
local redness
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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3.13 Participants with local
pain
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.14 Participants with grade 3
local swelling
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.15 Participants with consent
withdrawal
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.16 Participants with lost to
follow-up
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.17 Participants with death 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 25 µg gE/AS01B versus 100 µg
gE/saline (unadjuvanted gE)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
4.1 Participants with any
fatigue
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 Participants with grade 3
fatigue
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.3 Participants with any fever 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.4 Participants with grade 3
fever
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.5 Participants with any
headache
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.6 Participants with grade 3
headache
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.7 Participants with any
myalgia
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.8 Participants with grade 3
myalgia
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.9 Participants with local
pain
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.10 Participants with grade 3
local pain
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.11 Participants with local
redness
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.12 Participants with grade 3
local redness
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.13 Participants with local
swelling
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.14 Participants with grade 3
local swelling
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.15 Participants with consent
withdrawal
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.16 Participants with lost to
follow-up
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.17 Participants with death 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 50 µg gE/AS01B a versus 100 µg
gE/saline (unadjuvanted gE)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
5.1 Participants with any
fatigue
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.2 Participants with grade 3
fatigue
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.3 Participants with any fever 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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5.4 Participants with grade 3
fever
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.5 Participants with any
headache
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.6 Participants with grade 3
headache
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.7 Participants with any
myalgia
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.8 Participants with grade 3
myalgia
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.9 Participants with local
pain
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.10 Participants with grade 3
local pain
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.11 Participants with local
redness
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.12 Participants with grade 3
local redness
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.13 Participants with local
swelling
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.14 Participants with grade 3
local swelling
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.15 Participants with consent
withdrawal
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.16 Participants with lost to
follow-up
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.17 Participants with death 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 100 µg gE/AS01B versus 100 µg
gE/saline (unadjuvanted gE)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
6.1 Participants with any
fatigue
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.2 Participants with grade 3
fatigue
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.3 Participants with any fever 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.4 Participants with grade 3
fever
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.5 Participants with any
headache
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.6 Participants with grade 3
headache
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.7 Participants with any
myalgia
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.8 Participants with grade 3
myalgia
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.9 Participants with local
pain
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.10 Participants with grade 3
local pain
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.11 Participants with local
redness
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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6.12 Participants with grade 3
local redness
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.13 Participants with local
swelling
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.14 Participants with grade 3
local swelling
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.15 Participants with consent
withdrawal
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.16 Participants with lost to
follow-up
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.17 Participants with death 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 25 µg gE/AS01B versus saline +
100 µg gE/AS01B
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
7.1 Participants with any
fatigue
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.2 Participants with grade 3
fatigue
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.3 Participants with any fever 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.4 Participants with grade 3
fever
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.5 Participants with any
headache
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.6 Participants with grade 3
headache
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.7 Participants with any
myalgia
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.8 Participants with grade 3
myalgia
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.9 Participants with local
pain
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.10 Participants with grade 3
local pain
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.11 Participants with local
redness
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.12 Participants with grade 3
local redness
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.13 Participants with local
swelling
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.14 Participants with grade 3
local swelling
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.15 Participants with consent
withdrawal
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.16 Participants with lost to
follow-up
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.17 Participants with death 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 50 µg gE/AS01B versus saline +
100 µg gE/AS01B
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
8.1 Participants with any
fatigue
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.2 Participants with grade 3
fatigue
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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8.3 Participants with any fever 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.4 Participants with grade 3
fever
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.5 Participants with any
headache
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.6 Participants with grade 3
headache
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.7 Participants with any
myalgia
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.8 Participants with grade 3
myalgia
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.9 Participants with local
pain
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.10 Participants with grade 3
local pain
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.11 Participants with local
redness
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.12 Participants with grade 3
local redness
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.13 Participants with local
swelling
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.14 Participants with grade 3
local swelling
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.15 Participants with consent
withdrawal
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.16 Participants with lost to
follow-up
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.17 Participants with death 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9 100 µg gE/AS01B versus saline
+ 100 µg gE/AS01B
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
9.1 Participants with any
fatigue
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.2 Participants with grade 3
fatigue
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.3 Participants with any fever 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.4 Participants with grade 3
fever
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.5 Participants with any
headache
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.6 Participants with grade 3
headache
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.7 Participants with any
myalgia
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.8 Participants with grade 3
myalgia
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.9 Participants with local
pain
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.10 Participants with grade 3
local pain
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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9.11 Participants with local
redness
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.12 Participants with grade 3
local redness
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.13 Participants with local
swelling
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.14 Participants with grade 3
local swelling
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.15 Participants with consent
withdrawal
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.16 Participants with lost to
follow-up
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.17 Participants with death 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
10 Saline + 100 µg gE/AS01B
versus 100 µg gE/saline
(unadjuvanted gE)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
10.1 Participants with any
fatigue
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.2 Participants with grade 3
fatigue
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.3 Participants with any
fever
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.4 Participants with grade 3
fever
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.5 Participants with any
headache
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.6 Participants with grade 3
headache
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.7 Participants with any
myalgia
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.8 Participants with grade 3
myalgia
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.9 Participants with local
pain
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.10 Participants with grade
3 local pain
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.11 Participants with local
redness
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.12 Participants with grade
3 local redness
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.13 Participants with local
swelling
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.14 Participants with grade
3 local swelling
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.15 Participants with
consent withdrawal
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.16 Participants with lost to
follow-up
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.17 Participants with death 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Comparison 10. Adjuvanted recombinant VZV subunit zoster vaccine (not yet available) versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incidence of herpes zoster 3.2
years follow-up (≥ 60 yo)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2 Participants with AEs 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2.1 Any symptom 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 Grade 3 any symptom 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.3 Grade 3 any symptom
related to vaccination
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.4 Any systemic symptom 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.5 Grade 3 any systemic AEs 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.6 Myalgia 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.7 Fatigue 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.8 Headache 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.9 Shivering 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.10 Fever 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.11 Gastrointestinal
symptom
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.12 Any local symptom 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.13 Grade 3 any local
symptom
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.14 Local pain 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.15 Local redness 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.16 Local swelling 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.17 Serious AEs 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.18 Serious AEs within 30
days after vaccination
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.19 Serious AEs within 30
days after vaccination related to
vaccination
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.20 Potential immune-
mediated disease
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.21 Deaths 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.22 Deaths within 30 days
after vaccination
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.23 Unsolicited report of AEs 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.24 Grade 3 unsolicited
report of AEs
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Drop-outs 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3.1 Did not receive vaccine
according to protocol
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 Received wrong vaccine 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.3 Had diagnosis of HZ < 30
days after dose 2
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Analysis 1.1. Comparison 1 Available live attenuated VZV zoster vaccine versus placebo, Outcome 1
Incidence of herpes zoster.
Review: Vaccines for preventing herpes zoster in older adults
Comparison: 1 Available live attenuated VZV zoster vaccine versus placebo
Outcome: 1 Incidence of herpes zoster
Study or subgroup Zoster vaccine Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 3.1 years follow-up
Oxman 2005 315/19270 642/19276 0.49 [ 0.43, 0.56 ]
2 30 days of vaccination
Oxman 2005 6/19270 18/19276 0.33 [ 0.13, 0.84 ]
3 42 days of vaccination
Oxman 2005 7/19270 24/19276 0.29 [ 0.13, 0.68 ]
Vermeulen 2012 0/104 0/105 Not estimable
4 3.3 to 7.8 years after vaccination substudy
Oxman 2005 53/7320 95/6950 0.53 [ 0.38, 0.74 ]
5 Mean 5 years follow-up
Oxman 2005 368/19254 737/19247 0.50 [ 0.44, 0.56 ]
0.1 0.2 0.5 1 2 5 10
Zoster vaccine Placebo
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Analysis 1.2. Comparison 1 Available live attenuated VZV zoster vaccine versus placebo, Outcome 2
Incidence of herpes zoster with ZBPI ADL. Severity of interference scores of 300 or greater (high score is
worse).
Review: Vaccines for preventing herpes zoster in older adults
Comparison: 1 Available live attenuated VZV zoster vaccine versus placebo
Outcome: 2 Incidence of herpes zoster with ZBPI ADL. Severity of interference scores of 300 or greater (high score is worse)
Study or subgroup Vaccine Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Oxman 2005 13/315 42/642 0.63 [ 0.34, 1.16 ]
0.2 0.5 1 2 5
Zoster vaccine Placebo
Analysis 1.3. Comparison 1 Available live attenuated VZV zoster vaccine versus placebo, Outcome 3
Participants with AEs.
Review: Vaccines for preventing herpes zoster in older adults
Comparison: 1 Available live attenuated VZV zoster vaccine versus placebo
Outcome: 3 Participants with AEs
Study or subgroup Zoster vaccine Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 One or more AEs
Mills 2010 42/80 12/81 1.0 % 3.54 [ 2.02, 6.22 ]
Oxman 2005 1929/3345 1117/3271 95.1 % 1.69 [ 1.60, 1.79 ]
Vermeulen 2012 74/104 46/105 3.9 % 1.62 [ 1.27, 2.08 ]
Subtotal (95% CI) 3529 3457 100.0 % 1.70 [ 1.61, 1.80 ]
Total events: 2045 (Zoster vaccine), 1175 (Placebo)
Heterogeneity: Chi2 = 6.76, df = 2 (P = 0.03); I2 =70%
Test for overall effect: Z = 19.28 (P < 0.00001)
2 Vaccine-related AEs
Vermeulen 2012 55/104 12/105 100.0 % 4.63 [ 2.64, 8.12 ]
Subtotal (95% CI) 104 105 100.0 % 4.63 [ 2.64, 8.12 ]
0.05 0.2 1 5 20
Zoster vaccine Placebo
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(. . . Continued)
Study or subgroup Zoster vaccine Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 55 (Zoster vaccine), 12 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 5.34 (P < 0.00001)
3 Systemic AEs
Mills 2010 14/80 9/81 1.1 % 1.58 [ 0.72, 3.43 ]
Oxman 2005 820/3345 768/3271 98.7 % 1.04 [ 0.96, 1.14 ]
Vermeulen 2012 13/104 1/105 0.1 % 13.13 [ 1.75, 98.53 ]
Subtotal (95% CI) 3529 3457 100.0 % 1.07 [ 0.98, 1.16 ]
Total events: 847 (Zoster vaccine), 778 (Placebo)
Heterogeneity: Chi2 = 7.14, df = 2 (P = 0.03); I2 =72%
Test for overall effect: Z = 1.46 (P = 0.14)
4 Systemic pruritus
Vermeulen 2012 3/104 0/105 100.0 % 7.07 [ 0.37, 135.13 ]
Subtotal (95% CI) 104 105 100.0 % 7.07 [ 0.37, 135.13 ]
Total events: 3 (Zoster vaccine), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.30 (P = 0.19)
5 Vaccine-related systemic AEs
Mills 2010 2/80 0/81 0.3 % 5.06 [ 0.25, 103.80 ]
Oxman 2005 209/3345 160/3271 99.7 % 1.28 [ 1.05, 1.56 ]
Subtotal (95% CI) 3425 3352 100.0 % 1.29 [ 1.06, 1.57 ]
Total events: 211 (Zoster vaccine), 160 (Placebo)
Heterogeneity: Chi2 = 0.80, df = 1 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 2.49 (P = 0.013)
6 Varicella-like rash not at injection site (day of vaccination to day 42)
Oxman 2005 18/19270 14/19276 84.9 % 1.29 [ 0.64, 2.59 ]
Vermeulen 2012 0/104 2/105 15.1 % 0.20 [ 0.01, 4.16 ]
Subtotal (95% CI) 19374 19381 100.0 % 1.12 [ 0.58, 2.18 ]
Total events: 18 (Zoster vaccine), 16 (Placebo)
Heterogeneity: Chi2 = 1.38, df = 1 (P = 0.24); I2 =28%
Test for overall effect: Z = 0.34 (P = 0.73)
7 Herpes zoster-like rash (day of vaccination to day 42)
Oxman 2005 17/19270 36/19276 100.0 % 0.47 [ 0.27, 0.84 ]
Subtotal (95% CI) 19270 19276 100.0 % 0.47 [ 0.27, 0.84 ]
Total events: 17 (Zoster vaccine), 36 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.55 (P = 0.011)
8 Rash unrelated to herpes zoster (day of vaccination to day 42)
Oxman 2005 595/19270 620/19276 100.0 % 0.96 [ 0.86, 1.07 ]
Subtotal (95% CI) 19270 19276 100.0 % 0.96 [ 0.86, 1.07 ]
Total events: 595 (Zoster vaccine), 620 (Placebo)
0.05 0.2 1 5 20
Zoster vaccine Placebo
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(. . . Continued)
Study or subgroup Zoster vaccine Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
9≥ 1 serious AEs regardless of type of storage of the vaccine
Mills 2010 0/80 0/81 Not estimable
Murray 2011 340/5983 300/5997 54.1 % 1.14 [ 0.98, 1.32 ]
Oxman 2005 255/19270 254/19276 45.9 % 1.00 [ 0.85, 1.19 ]
Vermeulen 2012 0/104 0/105 Not estimable
Subtotal (95% CI) 25437 25459 100.0 % 1.08 [ 0.96, 1.20 ]
Total events: 595 (Zoster vaccine), 554 (Placebo)
Heterogeneity: Chi2 = 1.11, df = 1 (P = 0.29); I2 =10%
Test for overall effect: Z = 1.26 (P = 0.21)
10 Vaccine-related serious AEs
Mills 2010 0/80 0/81 Not estimable
Murray 2011 2/5983 1/5997 25.0 % 2.00 [ 0.18, 22.10 ]
Oxman 2005 2/19270 3/19276 75.0 % 0.67 [ 0.11, 3.99 ]
Subtotal (95% CI) 25333 25354 100.0 % 1.00 [ 0.25, 4.00 ]
Total events: 4 (Zoster vaccine), 4 (Placebo)
Heterogeneity: Chi2 = 0.52, df = 1 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 0.00 (P = 1.0)
11 Discontinued due to vaccine-related AEs
Mills 2010 0/80 0/81 Not estimable
Vermeulen 2012 2/104 0/105 100.0 % 5.05 [ 0.25, 103.88 ]
Subtotal (95% CI) 184 186 100.0 % 5.05 [ 0.25, 103.88 ]
Total events: 2 (Zoster vaccine), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.05 (P = 0.29)
12 Hospitalised
Oxman 2005 1137/3345 1115/3271 100.0 % 1.00 [ 0.93, 1.07 ]
Subtotal (95% CI) 3345 3271 100.0 % 1.00 [ 0.93, 1.07 ]
Total events: 1137 (Zoster vaccine), 1115 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.08 (P = 0.93)
13 Hospitalisation related to herpes zoster
Oxman 2005 5/3345 6/3271 100.0 % 0.81 [ 0.25, 2.67 ]
Subtotal (95% CI) 3345 3271 100.0 % 0.81 [ 0.25, 2.67 ]
Total events: 5 (Zoster vaccine), 6 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.34 (P = 0.74)
0.05 0.2 1 5 20
Zoster vaccine Placebo
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(. . . Continued)
Study or subgroup Zoster vaccine Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
14 Injection site AEs
Mills 2010 36/80 3/81 0.5 % 12.15 [ 3.90, 37.86 ]
Oxman 2005 1604/3345 539/3271 97.5 % 2.91 [ 2.67, 3.17 ]
Vermeulen 2012 51/104 11/105 2.0 % 4.68 [ 2.59, 8.47 ]
Subtotal (95% CI) 3529 3457 100.0 % 2.99 [ 2.75, 3.26 ]
Total events: 1691 (Zoster vaccine), 553 (Placebo)
Heterogeneity: Chi2 = 8.45, df = 2 (P = 0.01); I2 =76%
Test for overall effect: Z = 25.67 (P < 0.00001)
15 Erythema inoculation site
Oxman 2005 1188/3345 227/3271 97.1 % 5.12 [ 4.48, 5.85 ]
Vermeulen 2012 42/104 7/105 2.9 % 6.06 [ 2.85, 12.86 ]
Subtotal (95% CI) 3449 3376 100.0 % 5.15 [ 4.51, 5.87 ]
Total events: 1230 (Zoster vaccine), 234 (Placebo)
Heterogeneity: Chi2 = 0.19, df = 1 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 24.42 (P < 0.00001)
16 Pain inoculation site
Oxman 2005 1147/3345 278/3271 99.3 % 4.03 [ 3.57, 4.56 ]
Vermeulen 2012 38/104 2/105 0.7 % 19.18 [ 4.75, 77.46 ]
Subtotal (95% CI) 3449 3376 100.0 % 4.14 [ 3.67, 4.68 ]
Total events: 1185 (Zoster vaccine), 280 (Placebo)
Heterogeneity: Chi2 = 4.81, df = 1 (P = 0.03); I2 =79%
Test for overall effect: Z = 22.97 (P < 0.00001)
17 Pruritus inoculation site
Oxman 2005 237/3345 33/3271 94.4 % 7.02 [ 4.90, 10.08 ]
Vermeulen 2012 10/104 2/105 5.6 % 5.05 [ 1.13, 22.48 ]
Subtotal (95% CI) 3449 3376 100.0 % 6.91 [ 4.87, 9.82 ]
Total events: 247 (Zoster vaccine), 35 (Placebo)
Heterogeneity: Chi2 = 0.18, df = 1 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 10.80 (P < 0.00001)
18 Swelling inoculation site
Oxman 2005 871/3345 147/3271 97.4 % 5.79 [ 4.90, 6.85 ]
Vermeulen 2012 32/104 4/105 2.6 % 8.08 [ 2.96, 22.03 ]
Subtotal (95% CI) 3449 3376 100.0 % 5.85 [ 4.96, 6.91 ]
Total events: 903 (Zoster vaccine), 151 (Placebo)
Heterogeneity: Chi2 = 0.41, df = 1 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 20.91 (P < 0.00001)
19 Warmth inoculation site
Oxman 2005 57/3345 11/3271 95.7 % 5.07 [ 2.66, 9.65 ]
0.05 0.2 1 5 20
Zoster vaccine Placebo
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Study or subgroup Zoster vaccine Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Vermeulen 2012 3/104 0/105 4.3 % 7.07 [ 0.37, 135.13 ]
Subtotal (95% CI) 3449 3376 100.0 % 5.15 [ 2.75, 9.66 ]
Total events: 60 (Zoster vaccine), 11 (Placebo)
Heterogeneity: Chi2 = 0.05, df = 1 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 5.11 (P < 0.00001)
20 Rash inoculation site
Oxman 2005 20/3345 6/3271 100.0 % 3.26 [ 1.31, 8.11 ]
Subtotal (95% CI) 3345 3271 100.0 % 3.26 [ 1.31, 8.11 ]
Total events: 20 (Zoster vaccine), 6 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.54 (P = 0.011)
21 Haematoma inoculation site
Oxman 2005 53/3345 46/3271 100.0 % 1.13 [ 0.76, 1.67 ]
Subtotal (95% CI) 3345 3271 100.0 % 1.13 [ 0.76, 1.67 ]
Total events: 53 (Zoster vaccine), 46 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.60 (P = 0.55)
22 Mass inoculation site
Oxman 2005 30/3345 2/3271 100.0 % 14.67 [ 3.51, 61.33 ]
Subtotal (95% CI) 3345 3271 100.0 % 14.67 [ 3.51, 61.33 ]
Total events: 30 (Zoster vaccine), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 3.68 (P = 0.00023)
23 Varicella-like rash at injection site (day of vaccination to day 42)
Oxman 2005 20/19270 7/19276 100.0 % 2.86 [ 1.21, 6.76 ]
Subtotal (95% CI) 19270 19276 100.0 % 2.86 [ 1.21, 6.76 ]
Total events: 20 (Zoster vaccine), 7 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.39 (P = 0.017)
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Analysis 1.4. Comparison 1 Available live attenuated VZV zoster vaccine versus placebo, Outcome 4 Drop-
outs.
Review: Vaccines for preventing herpes zoster in older adults
Comparison: 1 Available live attenuated VZV zoster vaccine versus placebo
Outcome: 4 Drop-outs
Study or subgroup Vaccine Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 For any reason
Vermeulen 2012 2/104 1/105 0.1 % 2.02 [ 0.19, 21.93 ]
Mills 2010 1/80 4/81 0.4 % 0.25 [ 0.03, 2.22 ]
Oxman 2005 911/19270 919/19276 99.5 % 0.99 [ 0.91, 1.08 ]
Subtotal (95% CI) 19454 19462 100.0 % 0.99 [ 0.91, 1.08 ]
Total events: 914 (Vaccine), 924 (Placebo)
Heterogeneity: Chi2 = 1.86, df = 2 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 0.23 (P = 0.82)
2 Death
Mills 2010 0/80 0/81 Not estimable
Murray 2011 24/5983 17/5997 2.1 % 1.42 [ 0.76, 2.63 ]
Oxman 2005 793/19270 792/19276 97.9 % 1.00 [ 0.91, 1.10 ]
Subtotal (95% CI) 25333 25354 100.0 % 1.01 [ 0.92, 1.11 ]
Total events: 817 (Vaccine), 809 (Placebo)
Heterogeneity: Chi2 = 1.16, df = 1 (P = 0.28); I2 =14%
Test for overall effect: Z = 0.21 (P = 0.83)
3 Withdrew consent
Vermeulen 2012 1/104 1/105 1.2 % 1.01 [ 0.06, 15.93 ]
Murray 2011 17/5983 10/5997 11.6 % 1.70 [ 0.78, 3.72 ]
Oxman 2005 57/19270 75/19276 87.2 % 0.76 [ 0.54, 1.07 ]
Subtotal (95% CI) 25357 25378 100.0 % 0.87 [ 0.64, 1.19 ]
Total events: 75 (Vaccine), 86 (Placebo)
Heterogeneity: Chi2 = 3.45, df = 2 (P = 0.18); I2 =42%
Test for overall effect: Z = 0.86 (P = 0.39)
4 Lost to follow-up
Vermeulen 2012 0/104 0/105 Not estimable
Murray 2011 45/5983 30/5997 36.6 % 1.50 [ 0.95, 2.38 ]
Oxman 2005 61/19270 52/19276 63.4 % 1.17 [ 0.81, 1.70 ]
Subtotal (95% CI) 25357 25378 100.0 % 1.29 [ 0.97, 1.73 ]
Total events: 106 (Vaccine), 82 (Placebo)
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Study or subgroup Vaccine Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heterogeneity: Chi2 = 0.68, df = 1 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 1.76 (P = 0.079)
5 Protocol deviation
Vermeulen 2012 0/104 1/105 42.8 % 0.34 [ 0.01, 8.17 ]
Murray 2011 5/5983 2/5997 57.2 % 2.51 [ 0.49, 12.91 ]
Subtotal (95% CI) 6087 6102 100.0 % 1.58 [ 0.41, 6.02 ]
Total events: 5 (Vaccine), 3 (Placebo)
Heterogeneity: Chi2 = 1.21, df = 1 (P = 0.27); I2 =17%
Test for overall effect: Z = 0.67 (P = 0.50)
6 Clinical adverse event
Vermeulen 2012 3/104 1/105 5.9 % 3.03 [ 0.32, 28.65 ]
Murray 2011 20/5983 16/5997 94.1 % 1.25 [ 0.65, 2.42 ]
Subtotal (95% CI) 6087 6102 100.0 % 1.36 [ 0.73, 2.54 ]
Total events: 23 (Vaccine), 17 (Placebo)
Heterogeneity: Chi2 = 0.55, df = 1 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 0.96 (P = 0.34)
7 Physician decision
Murray 2011 0/5983 2/5997 100.0 % 0.20 [ 0.01, 4.17 ]
Subtotal (95% CI) 5983 5997 100.0 % 0.20 [ 0.01, 4.17 ]
Total events: 0 (Vaccine), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.04 (P = 0.30)
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Analysis 1.5. Comparison 1 Available live attenuated VZV zoster vaccine versus placebo, Outcome 5
Participants with no follow-up.
Review: Vaccines for preventing herpes zoster in older adults
Comparison: 1 Available live attenuated VZV zoster vaccine versus placebo
Outcome: 5 Participants with no follow-up
Study or subgroup Vaccine Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Mills 2010 1/80 4/81 0.25 [ 0.03, 2.22 ]
Murray 2011 4/5983 7/5997 0.57 [ 0.17, 1.96 ]
Oxman 2005 61/19270 52/19276 1.17 [ 0.81, 1.70 ]
0.01 0.1 1 10 100
Zoster vaccine Placebo
Analysis 2.1. Comparison 2 Live attenuated VZV zoster vaccine higher-potency zoster vaccine versus
lower-potency zoster vaccine, Outcome 1 Incidence of herpes zoster.
Review: Vaccines for preventing herpes zoster in older adults
Comparison: 2 Live attenuated VZV zoster vaccine higher-potency zoster vaccine versus lower-potency zoster vaccine
Outcome: 1 Incidence of herpes zoster
Study or subgroup Higher potency Lower potency Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Tyring 2007 2/459 0/234 2.55 [ 0.12, 52.99 ]
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Analysis 2.2. Comparison 2 Live attenuated VZV zoster vaccine higher-potency zoster vaccine versus
lower-potency zoster vaccine, Outcome 2 Vaccine-related adverse effects.
Review: Vaccines for preventing herpes zoster in older adults
Comparison: 2 Live attenuated VZV zoster vaccine higher-potency zoster vaccine versus lower-potency zoster vaccine
Outcome: 2 Vaccine-related adverse effects
Study or subgroup Higher potency Lower potency Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Tyring 2007 300/459 145/234 1.05 [ 0.94, 1.19 ]
0.01 0.1 1 10 100
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Analysis 2.3. Comparison 2 Live attenuated VZV zoster vaccine higher-potency zoster vaccine versus
lower-potency zoster vaccine, Outcome 3 Vaccine-related systemic adverse effects.
Review: Vaccines for preventing herpes zoster in older adults
Comparison: 2 Live attenuated VZV zoster vaccine higher-potency zoster vaccine versus lower-potency zoster vaccine
Outcome: 3 Vaccine-related systemic adverse effects
Study or subgroup Higher potency Lower potency Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Tyring 2007 50/459 31/234 0.82 [ 0.54, 1.25 ]
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Analysis 2.4. Comparison 2 Live attenuated VZV zoster vaccine higher-potency zoster vaccine versus
lower-potency zoster vaccine, Outcome 4 Vaccine-related serious adverse effects.
Review: Vaccines for preventing herpes zoster in older adults
Comparison: 2 Live attenuated VZV zoster vaccine higher-potency zoster vaccine versus lower-potency zoster vaccine
Outcome: 4 Vaccine-related serious adverse effects
Study or subgroup Higher potency Lower potency Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Death
Tyring 2007 0/459 0/234 Not estimable
0.01 0.1 1 10 100
Higher potency Lower potency
Analysis 2.5. Comparison 2 Live attenuated VZV zoster vaccine higher-potency zoster vaccine versus
lower-potency zoster vaccine, Outcome 5 Injection site vaccine-related adverse effects.
Review: Vaccines for preventing herpes zoster in older adults
Comparison: 2 Live attenuated VZV zoster vaccine higher-potency zoster vaccine versus lower-potency zoster vaccine
Outcome: 5 Injection site vaccine-related adverse effects
Study or subgroup Higher potency Lower potency Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Erythema
Tyring 2007 225/459 111/234 1.03 [ 0.88, 1.22 ]
2 Pain
Tyring 2007 225/459 111/234 1.03 [ 0.88, 1.22 ]
3 Swelling
Tyring 2007 188/459 77/234 1.24 [ 1.01, 1.54 ]
4 Pruritus
Tyring 2007 57/459 19/234 1.53 [ 0.93, 2.51 ]
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Analysis 2.6. Comparison 2 Live attenuated VZV zoster vaccine higher-potency zoster vaccine versus
lower-potency zoster vaccine, Outcome 6 Participants with no follow-up.
Review: Vaccines for preventing herpes zoster in older adults
Comparison: 2 Live attenuated VZV zoster vaccine higher-potency zoster vaccine versus lower-potency zoster vaccine
Outcome: 6 Participants with no follow-up
Study or subgroup Higher potency Lower potency Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Tyring 2007 2/461 1/234 1.02 [ 0.09, 11.14 ]
0.02 0.1 1 10 50
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Analysis 3.1. Comparison 3 Live attenuated VZV zoster vaccine zoster vaccine refrigerated versus zoster
vaccine frozen, Outcome 1 Participants with adverse effects.
Review: Vaccines for preventing herpes zoster in older adults
Comparison: 3 Live attenuated VZV zoster vaccine zoster vaccine refrigerated versus zoster vaccine frozen
Outcome: 1 Participants with adverse effects
Study or subgroup Refrigerated Frozen Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 One or more adverse effects
Gilderman 2008 82/180 101/183 0.83 [ 0.67, 1.01 ]
2 Vaccine-related adverse effects
Gilderman 2008 68/180 87/183 0.79 [ 0.62, 1.01 ]
3 Systemic adverse effects
Gilderman 2008 34/180 39/183 0.89 [ 0.59, 1.34 ]
4 Systemic vaccine-related adverse effects
Gilderman 2008 10/180 11/183 0.92 [ 0.40, 2.12 ]
5 Serious adverse effects
Gilderman 2008 1/180 0/183 3.05 [ 0.13, 74.37 ]
6 Vaccine-related serious adverse effects
0.5 0.7 1 1.5 2
Zoster vac. refrigerated Zoster vaccine frozen
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Study or subgroup Refrigerated Frozen Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gilderman 2008 0/180 0/183 Not estimable
7 Death
Gilderman 2008 0/180 0/183 Not estimable
8 Injection site adverse effects
Gilderman 2008 64/180 85/183 0.77 [ 0.60, 0.98 ]
9 Injection site vaccine-related adverse effects
Gilderman 2008 64/180 85/183 0.77 [ 0.60, 0.98 ]
10 Discontinued due to any adverse effects
Gilderman 2008 0/180 0/183 Not estimable
11 Discontinued due to a vaccine-related adverse effect
Gilderman 2008 0/180 0/183 Not estimable
0.5 0.7 1 1.5 2
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Analysis 3.2. Comparison 3 Live attenuated VZV zoster vaccine zoster vaccine refrigerated versus zoster
vaccine frozen, Outcome 2 Participants with no follow-up.
Review: Vaccines for preventing herpes zoster in older adults
Comparison: 3 Live attenuated VZV zoster vaccine zoster vaccine refrigerated versus zoster vaccine frozen
Outcome: 2 Participants with no follow-up
Study or subgroup Refrigerated Frozen Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gilderman 2008 2/182 2/185 1.02 [ 0.14, 7.14 ]
0.01 0.1 1 10 100
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Analysis 4.1. Comparison 4 Live attenuated VZV zoster vaccine versus inactivated zoster vaccine,
Outcome 1 Incidence of herpes zoster.
Review: Vaccines for preventing herpes zoster in older adults
Comparison: 4 Live attenuated VZV zoster vaccine versus inactivated zoster vaccine
Outcome: 1 Incidence of herpes zoster
Study or subgroup Live Zoster Vaccine
Inactivated
Zoster
Vaccin Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Levin 2000 1/85 1/82 0.96 [ 0.06, 15.17 ]
0.02 0.1 1 10 50
Live zoster vaccine Inactivated zoster vaccine
Analysis 5.1. Comparison 5 Live attenuated VZV zoster vaccine versus pneumo 23 vaccine, Outcome 1
3200 pfu VZV/dose.
Review: Vaccines for preventing herpes zoster in older adults
Comparison: 5 Live attenuated VZV zoster vaccine versus pneumo 23 vaccine
Outcome: 1 3200 pfu VZV/dose
Study or subgroup Zoster vaccine Pneumo 23 Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1≥ 1 reaction injection site
Berger 1998 20/50 32/49 0.61 [ 0.41, 0.91 ]
2 Induration (diameter≥ 2 cm injection site)
Berger 1998 9/50 8/49 1.10 [ 0.46, 2.62 ]
3 Pain injection site
Berger 1998 14/50 28/49 0.49 [ 0.30, 0.81 ]
4 Pain (injection site, probably vaccine-related)
Berger 1998 7/50 14/49 0.49 [ 0.22, 1.11 ]
5 Redness injection site (diameter ≥ 2 cm)
Berger 1998 13/50 13/49 0.98 [ 0.51, 1.90 ]
0.05 0.2 1 5 20
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(Continued . . . )
94Vaccines for preventing herpes zoster in older adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup Zoster vaccine Pneumo 23 Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
6 Pruritus injection site
Berger 1998 5/50 3/49 1.63 [ 0.41, 6.47 ]
7 Vesicles at injection site
Berger 1998 0/50 0/49 Not estimable
0.05 0.2 1 5 20
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Analysis 5.2. Comparison 5 Live attenuated VZV zoster vaccine versus pneumo 23 vaccine, Outcome 2
8500 pfu VZV/dose.
Review: Vaccines for preventing herpes zoster in older adults
Comparison: 5 Live attenuated VZV zoster vaccine versus pneumo 23 vaccine
Outcome: 2 8500 pfu VZV/dose
Study or subgroup Zoster vaccine Pneumo 23 Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1≥ 1 reaction injection site
Berger 1998 21/51 32/49 0.63 [ 0.43, 0.93 ]
2 Induration (diameter≥ 2 cm injection site)
Berger 1998 11/51 8/49 1.32 [ 0.58, 3.01 ]
3 Pain injection site
Berger 1998 19/51 28/49 0.65 [ 0.42, 1.00 ]
4 Pain (injection site, probably vaccine-related)
Berger 1998 10/51 14/49 0.69 [ 0.34, 1.40 ]
5 Redness injection site (diameter ≥ 2 cm)
Berger 1998 9/51 13/49 0.67 [ 0.31, 1.41 ]
6 Pruritus injection site
Berger 1998 4/51 3/49 1.28 [ 0.30, 5.43 ]
7 Vesicle injection site
Berger 1998 1/51 0/49 2.88 [ 0.12, 69.16 ]
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Analysis 5.3. Comparison 5 Live attenuated VZV zoster vaccine versus pneumo 23 vaccine, Outcome 3
41,650 pfu/dose.
Review: Vaccines for preventing herpes zoster in older adults
Comparison: 5 Live attenuated VZV zoster vaccine versus pneumo 23 vaccine
Outcome: 3 41,650 pfu/dose
Study or subgroup Zoster vaccine Pneumo 23 Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1≥ 1 reaction injection site
Berger 1998 13/49 32/49 0.41 [ 0.24, 0.68 ]
2 Induration (diameter≥ 2 cm injection site)
Berger 1998 4/49 8/49 0.50 [ 0.16, 1.55 ]
3 Pain injection site
Berger 1998 12/49 28/49 0.43 [ 0.25, 0.74 ]
4 Pain (injection site, probably vaccine-related)
Berger 1998 6/49 14/49 0.43 [ 0.18, 1.02 ]
5 Redness injection site (diameter ≥ 2 cm)
Berger 1998 6/49 13/49 0.46 [ 0.19, 1.12 ]
6 Pruritus injection site
Berger 1998 4/49 3/49 1.33 [ 0.31, 5.65 ]
7 Vesicle injection site
Berger 1998 0/49 0/49 Not estimable
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Analysis 5.4. Comparison 5 Live attenuated VZV zoster vaccine versus pneumo 23 vaccine, Outcome 4
Duration in days of adverse effects.
Review: Vaccines for preventing herpes zoster in older adults
Comparison: 5 Live attenuated VZV zoster vaccine versus pneumo 23 vaccine
Outcome: 4 Duration in days of adverse effects
Study or subgroup Zoster vaccine Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Erythema
Oxman 2005 1191 5 (7) 221 2.6 (5.6) 2.40 [ 1.56, 3.24 ]
2 Swelling
Oxman 2005 887 3.8 (3.3) 144 1.9 (3.1) 1.90 [ 1.35, 2.45 ]
3 Pain
Oxman 2005 1157 3.7 (8) 279 2.7 (8.5) 1.00 [ -0.10, 2.10 ]
4 Rash
Oxman 2005 19 4.3 (4.4) 7 20.9 (22.9) -16.60 [ -33.68, 0.48 ]
5 Pruritus
Oxman 2005 239 4.3 (4.7) 32 1.9 (2.6) 2.40 [ 1.32, 3.48 ]
6 Haematoma
Oxman 2005 53 9.7 (8.9) 45 10.2 (15.1) -0.50 [ -5.52, 4.52 ]
-200 -100 0 100 200
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Analysis 6.1. Comparison 6 Live attenuated VZV zoster vaccine IM route versus zoster vaccine SC route,
Outcome 1 Participants with adverse events.
Review: Vaccines for preventing herpes zoster in older adults
Comparison: 6 Live attenuated VZV zoster vaccine IM route versus zoster vaccine SC route
Outcome: 1 Participants with adverse events
Study or subgroup IM route SC route Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 At least one AE
Diez-Domingo 2015 83/176 123/177 0.68 [ 0.56, 0.82 ]
2 Vaccine-related AE
Diez-Domingo 2015 68/176 118/177 0.58 [ 0.47, 0.72 ]
3 All systemic AE
Diez-Domingo 2015 41/176 40/177 1.03 [ 0.70, 1.51 ]
4 Vaccine-related systemic AE
Diez-Domingo 2015 12/176 13/177 0.93 [ 0.44, 1.98 ]
5 Headache considered as vaccine-related by the investigator
Diez-Domingo 2015 3/176 4/177 0.75 [ 0.17, 3.32 ]
6 Solicited injection site reaction
Diez-Domingo 2015 60/176 114/177 0.53 [ 0.42, 0.67 ]
7 Unsolicited injection site reaction
Diez-Domingo 2015 9/176 14/177 0.65 [ 0.29, 1.45 ]
8 Injection site erythema
Diez-Domingo 2015 28/176 93/177 0.30 [ 0.21, 0.44 ]
9 Severe injection site erythema (> 10 cm)
Diez-Domingo 2015 2/176 3/177 0.67 [ 0.11, 3.96 ]
10 Injection site pain
Diez-Domingo 2015 45/176 70/177 0.65 [ 0.47, 0.88 ]
11 Severe injection site pain (inability to work or usual activity)
Diez-Domingo 2015 2/176 2/177 1.01 [ 0.14, 7.06 ]
12 Injection site swelling
Diez-Domingo 2015 24/176 66/177 0.37 [ 0.24, 0.56 ]
13 Severe injection site swelling (> 10 cm)
Diez-Domingo 2015 1/176 4/177 0.25 [ 0.03, 2.23 ]
14 Injection site pruritus
Diez-Domingo 2015 3/176 11/177 0.27 [ 0.08, 0.97 ]
15 Withdrawal due to AE
Diez-Domingo 2015 0/176 0/177 Not estimable
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Analysis 7.1. Comparison 7 Live attenuated VZV zoster vaccine 2 doses versus single dose and also 2 doses
given at different intervals, Outcome 1 Zoster vaccine 1 month schedule versus zoster vaccine 3 month
schedule.
Review: Vaccines for preventing herpes zoster in older adults
Comparison: 7 Live attenuated VZV zoster vaccine 2 doses versus single dose and also 2 doses given at different intervals
Outcome: 1 Zoster vaccine 1 month schedule versus zoster vaccine 3 month schedule
Study or subgroup 1-mo schedule 3-mo schedule Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Participants with AE
Vesikari 2013 123/232 107/221 1.10 [ 0.91, 1.31 ]
2 Participants with vaccine-related AE
Vesikari 2013 100/232 95/221 1.00 [ 0.81, 1.24 ]
3 Participants with serious AE
Vesikari 2013 2/232 2/221 0.95 [ 0.14, 6.70 ]
4 Participants with vaccine-related serious AE
Vesikari 2013 0/232 0/221 Not estimable
5 Participants with withdrawal due to AE
Vesikari 2013 1/232 0/221 2.86 [ 0.12, 69.80 ]
6 Participants with vaccine-related withdrawal due to AE
Vesikari 2013 0/232 0/221 Not estimable
7 Participants with non-serious vaccine-related withdrawal due to AE
Vesikari 2013 0/232 0/221 Not estimable
8 Participants with systemic AE
Vesikari 2013 48/232 34/221 1.34 [ 0.90, 2.00 ]
9 Participants with vaccine-related systemic AE
Vesikari 2013 8/232 6/221 1.27 [ 0.45, 3.60 ]
10 Participants with rash of interest non-injection site rashes
Vesikari 2013 1/232 1/221 0.95 [ 0.06, 15.14 ]
11 Participants with varicella/varicella-like rash
Vesikari 2013 1/232 1/221 0.95 [ 0.06, 15.14 ]
12 Participants with herpes zoster/zoster-like rash
Vesikari 2013 0/232 0/221 Not estimable
13 Participants with injection site reaction
Vesikari 2013 98/232 94/221 0.99 [ 0.80, 1.23 ]
0.01 0.1 1 10 100
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Study or subgroup 1-mo schedule 3-mo schedule Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
14 Participants with solicited injection site reaction
Vesikari 2013 98/232 93/221 1.00 [ 0.81, 1.25 ]
15 Participants with unsolicited injection site reaction
Vesikari 2013 3/232 7/221 0.41 [ 0.11, 1.56 ]
16 Participants with erythema injection site
Vesikari 2013 90/232 85/221 1.01 [ 0.80, 1.27 ]
17 Participants with pain injection site
Vesikari 2013 39/232 44/221 0.84 [ 0.57, 1.25 ]
18 Participants with swelling injection site
Vesikari 2013 54/232 49/221 1.05 [ 0.75, 1.47 ]
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Analysis 7.2. Comparison 7 Live attenuated VZV zoster vaccine 2 doses versus single dose and also 2 doses
given at different intervals, Outcome 2 Zoster vaccine 1 month schedule versus zoster vaccine single dose.
Review: Vaccines for preventing herpes zoster in older adults
Comparison: 7 Live attenuated VZV zoster vaccine 2 doses versus single dose and also 2 doses given at different intervals
Outcome: 2 Zoster vaccine 1 month schedule versus zoster vaccine single dose
Study or subgroup 1 month schedule Single dose Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Participants with adverse events
Vesikari 2013 123/232 433/749 0.92 [ 0.80, 1.05 ]
2 Participants with vaccine-related AE
Vesikari 2013 100/232 353/749 0.91 [ 0.77, 1.08 ]
3 Participants with serious AE
Vesikari 2013 2/232 9/749 0.72 [ 0.16, 3.30 ]
4 Participants with vaccine-related serious AE
Vesikari 2013 0/232 0/749 Not estimable
5 Participants with withdrawal due to AE
Vesikari 2013 1/232 9/749 0.36 [ 0.05, 2.82 ]
6 Participants with vaccine-related withdrawal due to AE
Vesikari 2013 0/232 7/749 0.21 [ 0.01, 3.74 ]
7 Participants with non-serious vaccine-related withdrawal due to AE
Vesikari 2013 0/232 7/749 0.21 [ 0.01, 3.74 ]
8 Participants with systemic AE
Vesikari 2013 48/232 210/749 0.74 [ 0.56, 0.97 ]
9 Participants with vaccine-related systemic AE
Vesikari 2013 8/232 48/749 0.54 [ 0.26, 1.12 ]
10 Participants with rash of interest non-injection site rashes
Vesikari 2013 1/232 2/749 1.61 [ 0.15, 17.72 ]
11 Participants with varicella/varicella-like rash
Vesikari 2013 1/232 0/749 9.66 [ 0.39, 236.25 ]
12 Participants with herpes zoster/zoster-like rash
Vesikari 2013 0/232 2/749 0.64 [ 0.03, 13.36 ]
13 Participants with injection site reaction
Vesikari 2013 98/232 341/749 0.93 [ 0.78, 1.10 ]
14 Participants with solicited injection site reaction
Vesikari 2013 98/232 338/749 0.94 [ 0.79, 1.11 ]
15 Participants with unsolicited injection site reaction
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Study or subgroup 1 month schedule Single dose Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Vesikari 2013 3/232 28/749 0.35 [ 0.11, 1.13 ]
16 Participants with erythema injection site
Vesikari 2013 90/232 298/749 0.98 [ 0.81, 1.17 ]
17 Participants with pain injection site
Vesikari 2013 39/232 171/749 0.74 [ 0.54, 1.01 ]
18 Participants with swelling injection site
Vesikari 2013 54/232 162/749 1.08 [ 0.82, 1.41 ]
0.01 0.1 1 10 100
1 month schedule Single dose
Analysis 7.3. Comparison 7 Live attenuated VZV zoster vaccine 2 doses versus single dose and also 2 doses
given at different intervals, Outcome 3 Zoster vaccine 3 month schedule versus zoster vaccine single dose.
Review: Vaccines for preventing herpes zoster in older adults
Comparison: 7 Live attenuated VZV zoster vaccine 2 doses versus single dose and also 2 doses given at different intervals
Outcome: 3 Zoster vaccine 3 month schedule versus zoster vaccine single dose
Study or subgroup 3 month schedule Single dose Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Participants with AE
Vesikari 2013 107/221 433/749 0.84 [ 0.72, 0.97 ]
2 Participants with vaccine-related AE
Vesikari 2013 95/221 353/749 0.91 [ 0.77, 1.08 ]
3 Participants with serious AE
Vesikari 2013 2/221 9/749 0.75 [ 0.16, 3.46 ]
4 Participants with vaccine-related serious AE
Vesikari 2013 0/221 0/749 Not estimable
5 Participants with withdrawal due to AE
Vesikari 2013 0/221 9/749 0.18 [ 0.01, 3.04 ]
6 Participants with vaccine-related withdrawal due to AE
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Study or subgroup 3 month schedule Single dose Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Vesikari 2013 0/221 7/749 0.23 [ 0.01, 3.93 ]
7 Participants with non-serious vaccine-related withdrawal due to AE
Vesikari 2013 0/221 7/749 0.23 [ 0.01, 3.93 ]
8 Participants with systemic AE
Vesikari 2013 34/221 210/749 0.55 [ 0.39, 0.76 ]
9 Participants with vaccine-related systemic AE
Vesikari 2013 6/221 48/749 0.42 [ 0.18, 0.98 ]
10 Participants with rash of interest non-injection site rashes
Vesikari 2013 1/221 2/749 1.69 [ 0.15, 18.60 ]
11 Participants with varicella/varicella-like rash
Vesikari 2013 1/221 0/749 10.14 [ 0.41, 247.92 ]
12 Participants with herpes zoster/zoster-like rash
Vesikari 2013 0/221 2/749 0.68 [ 0.03, 14.02 ]
13 Participants with injection site reaction
Vesikari 2013 94/221 341/749 0.93 [ 0.79, 1.11 ]
14 Participants with solicited injection site reaction
Vesikari 2013 93/221 338/749 0.93 [ 0.78, 1.11 ]
15 Participants with unsolicited injection site reaction
Vesikari 2013 7/221 28/749 0.85 [ 0.38, 1.91 ]
16 Participants with erythema injection site
Vesikari 2013 85/221 298/749 0.97 [ 0.80, 1.17 ]
17 Participants with pain injection site
Vesikari 2013 44/221 171/749 0.87 [ 0.65, 1.17 ]
18 Participants with swelling injection site
Vesikari 2013 49/221 162/749 1.03 [ 0.77, 1.36 ]
0.01 0.1 1 10 100
3 month schedule Single dose
103Vaccines for preventing herpes zoster in older adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 8.1. Comparison 8 Adjuvanted recombinant VZV subunit zoster vaccine: lower or higher
quantities of adjuvants plus gE subunit VZV versus unadjuvanted gE or saline, Outcome 1 50 µg gE/AS01E
versus 50 µg gE/AS01B.
Review: Vaccines for preventing herpes zoster in older adults
Comparison: 8 Adjuvanted recombinant VZV subunit zoster vaccine: lower or higher quantities of adjuvants plus gE subunit VZV versus unadjuvanted gE or saline
Outcome: 1 50 g gE/AS01E versus 50 g gE/AS01B
Study or subgroup 50 gE/AS01E 50 gE/AS01B Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Participants with any symptom
Chlibek 2013 115/149 130/150 0.89 [ 0.80, 0.99 ]
2 Participants with any grade 3 symptom
Chlibek 2013 12/149 14/150 0.86 [ 0.41, 1.80 ]
3 Participants with any general symptom
Chlibek 2013 82/149 95/150 0.87 [ 0.72, 1.05 ]
4 Participants with any grade 3 general symptom
Chlibek 2013 7/149 13/150 0.54 [ 0.22, 1.32 ]
5 Participants with fatigue
Chlibek 2013 52/149 72/150 0.73 [ 0.55, 0.96 ]
6 Participants with grade 3 fatigue
Chlibek 2013 5/149 9/150 0.56 [ 0.19, 1.63 ]
7 Participants with fever
Chlibek 2013 18/149 25/150 0.72 [ 0.41, 1.27 ]
8 Participants with grade 3 fever
Chlibek 2013 0/149 0/150 Not estimable
9 Participants with gastrointestinal symptom
Chlibek 2013 18/149 17/150 1.07 [ 0.57, 1.99 ]
10 Participants with grade 3 gastrointestinal symptom
Chlibek 2013 2/149 0/150 5.03 [ 0.24, 103.96 ]
11 Participants with headache
Chlibek 2013 37/149 56/150 0.67 [ 0.47, 0.94 ]
12 Participants with grade 3 headache
Chlibek 2013 0/149 5/150 0.09 [ 0.01, 1.64 ]
13 Participants with myalgia
Chlibek 2013 49/149 62/150 0.80 [ 0.59, 1.07 ]
14 Participants with grade 3 myalgia
Chlibek 2013 2/149 7/150 0.29 [ 0.06, 1.36 ]
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Study or subgroup 50 gE/AS01E 50 gE/AS01B Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
15 Participants with any local symptom
Chlibek 2013 106/149 126/150 0.85 [ 0.75, 0.96 ]
16 Participants with any grade 3 local symptom
Chlibek 2013 5/149 8/150 0.63 [ 0.21, 1.88 ]
17 Participants with local pain
Chlibek 2013 104/149 125/150 0.84 [ 0.74, 0.95 ]
18 Participants with grade 3 local pain
Chlibek 2013 2/149 6/150 0.34 [ 0.07, 1.64 ]
19 Participants with local redness
Chlibek 2013 26/149 44/150 0.59 [ 0.39, 0.91 ]
20 Participants with grade 3 local redness
Chlibek 2013 3/149 2/150 1.51 [ 0.26, 8.91 ]
21 Participants with local swelling
Chlibek 2013 25/149 23/150 1.09 [ 0.65, 1.84 ]
22 Participants with grade 3 local swelling
Chlibek 2013 1/149 1/150 1.01 [ 0.06, 15.95 ]
23 Participants with consent withdrawal
Chlibek 2013 2/149 5/150 0.40 [ 0.08, 2.04 ]
24 Participants with lost follow-up
Chlibek 2013 1/149 1/150 1.01 [ 0.06, 15.95 ]
25 Participants with serious AE
Chlibek 2013 1/149 1/150 1.01 [ 0.06, 15.95 ]
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Analysis 8.2. Comparison 8 Adjuvanted recombinant VZV subunit zoster vaccine: lower or higher
quantities of adjuvants plus gE subunit VZV versus unadjuvanted gE or saline, Outcome 2 50 µg gE/AS01E
versus 50 µg gE/saline (unadjuvanted gE).
Review: Vaccines for preventing herpes zoster in older adults
Comparison: 8 Adjuvanted recombinant VZV subunit zoster vaccine: lower or higher quantities of adjuvants plus gE subunit VZV versus unadjuvanted gE or saline
Outcome: 2 50 g gE/AS01E versus 50 g gE/saline (unadjuvanted gE)
Study or subgroup 50 gE/AS01E 50 gE/saline Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Participants with any symptom
Chlibek 2013 115/149 32/73 1.76 [ 1.34, 2.32 ]
2 Participants with any grade 3 symptom
Chlibek 2013 12/149 2/73 2.94 [ 0.68, 12.79 ]
3 Participants with any general symptom
Chlibek 2013 82/149 24/73 1.67 [ 1.17, 2.40 ]
4 Participants with any grade 3 general symptom
Chlibek 2013 7/149 2/73 1.71 [ 0.37, 8.05 ]
5 Participants with fatigue
Chlibek 2013 52/149 16/73 1.59 [ 0.98, 2.59 ]
6 Participants with grade 3 fatigue
Chlibek 2013 5/149 2/73 1.22 [ 0.24, 6.16 ]
7 Participants with fever
Chlibek 2013 18/149 0/73 18.25 [ 1.12, 298.73 ]
8 Participants with grade 3 fever
Chlibek 2013 0/149 0/73 Not estimable
9 Participants with gastrointestinal symptom
Chlibek 2013 18/149 5/73 1.76 [ 0.68, 4.56 ]
10 Participants with grade 3 gastrointestinal symptom
Chlibek 2013 2/149 0/73 2.47 [ 0.12, 50.73 ]
11 Participants with headache
Chlibek 2013 37/149 10/73 1.81 [ 0.96, 3.44 ]
12 Participants with grade 3 headache
Chlibek 2013 0/149 0/73 Not estimable
13 Participants with myalgia
Chlibek 2013 49/149 12/73 2.00 [ 1.14, 3.52 ]
14 Participants with grade 3 myalgia
Chlibek 2013 2/149 0/73 2.47 [ 0.12, 50.73 ]
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Study or subgroup 50 gE/AS01E 50 gE/saline Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
15 Participants with any local symptom
Chlibek 2013 106/149 17/73 3.05 [ 1.99, 4.69 ]
16 Participants with any grade 3 local symptom
Chlibek 2013 5/149 0/73 5.43 [ 0.30, 96.83 ]
17 Participants with local pain
Chlibek 2013 104/149 14/73 3.64 [ 2.25, 5.90 ]
18 Participants with grade 3 local pain
Chlibek 2013 2/149 0/73 2.47 [ 0.12, 50.73 ]
19 Participants with local redness
Chlibek 2013 26/149 3/73 4.25 [ 1.33, 13.57 ]
20 Participants with grade 3 local redness
Chlibek 2013 3/149 0/73 3.45 [ 0.18, 65.98 ]
21 Participants with local swelling
Chlibek 2013 25/149 3/73 4.08 [ 1.27, 13.08 ]
22 Participants with grade 3 local swelling
Chlibek 2013 1/149 0/73 1.48 [ 0.06, 35.89 ]
23 Participants with consent withdrawal
Chlibek 2013 2/149 1/73 0.98 [ 0.09, 10.63 ]
24 Participants with lost follow-up
Chlibek 2013 1/149 0/73 1.48 [ 0.06, 35.89 ]
25 Participants with serious AE
Chlibek 2013 1/149 0/73 1.48 [ 0.06, 35.89 ]
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Analysis 8.3. Comparison 8 Adjuvanted recombinant VZV subunit zoster vaccine: lower or higher
quantities of adjuvants plus gE subunit VZV versus unadjuvanted gE or saline, Outcome 3 50 µg gE/AS01B
versus 50 µg gE/saline (unadjuvanted gE).
Review: Vaccines for preventing herpes zoster in older adults
Comparison: 8 Adjuvanted recombinant VZV subunit zoster vaccine: lower or higher quantities of adjuvants plus gE subunit VZV versus unadjuvanted gE or saline
Outcome: 3 50 g gE/AS01B versus 50 g gE/saline (unadjuvanted gE)
Study or subgroup 50 gE/AS01B 50 gE/saline Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Participants with any symptom
Chlibek 2013 130/150 32/73 1.98 [ 1.51, 2.58 ]
2 Participants with any grade 3 symptom
Chlibek 2013 14/150 2/73 3.41 [ 0.80, 14.60 ]
3 Participants with any general symptom
Chlibek 2013 95/150 24/73 1.93 [ 1.36, 2.73 ]
4 Participants with any grade 3 general symptom
Chlibek 2013 13/150 2/73 3.16 [ 0.73, 13.65 ]
5 Participants with fatigue
Chlibek 2013 72/150 16/73 2.19 [ 1.38, 3.48 ]
6 Participants with grade 3 fatigue
Chlibek 2013 9/150 2/73 2.19 [ 0.49, 9.88 ]
7 Participants with fever
Chlibek 2013 25/150 0/73 24.99 [ 1.54, 404.89 ]
8 Participants with grade 3 fever
Chlibek 2013 0/150 0/73 Not estimable
9 Participants with gastrointestinal symptom
Chlibek 2013 17/150 5/73 1.65 [ 0.64, 4.31 ]
10 Participants with grade 3 gastrointestinal symptom
Chlibek 2013 0/150 0/73 Not estimable
11 Participants with headache
Chlibek 2013 56/150 10/73 2.73 [ 1.48, 5.03 ]
12 Participants with grade 3 headache
Chlibek 2013 5/150 0/73 5.39 [ 0.30, 96.19 ]
13 Participants with myalgia
Chlibek 2013 62/150 12/73 2.51 [ 1.45, 4.36 ]
14 Participants with grade 3 myalgia
Chlibek 2013 7/150 0/73 7.35 [ 0.43, 126.98 ]
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Study or subgroup 50 gE/AS01B 50 gE/saline Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
15 Participants with any local symptom
Chlibek 2013 126/150 17/73 3.61 [ 2.36, 5.50 ]
16 Participants with any grade 3 local symptom
Chlibek 2013 8/150 0/73 8.33 [ 0.49, 142.39 ]
17 Participants with local pain
Chlibek 2013 125/150 14/73 4.35 [ 2.70, 7.00 ]
18 Participants with grade 3 local pain
Chlibek 2013 6/150 0/73 6.37 [ 0.36, 111.58 ]
19 Participants with local redness
Chlibek 2013 44/150 3/73 7.14 [ 2.29, 22.22 ]
20 Participants with grade 3 local redness
Chlibek 2013 2/150 0/73 2.45 [ 0.12, 50.39 ]
21 Participants with local swelling
Chlibek 2013 23/150 3/73 3.73 [ 1.16, 12.02 ]
22 Participants with grade 3 local swelling
Chlibek 2013 1/150 0/73 1.47 [ 0.06, 35.66 ]
23 Participants with consent withdrawal
Chlibek 2013 5/150 1/73 2.43 [ 0.29, 20.45 ]
24 Participants with lost follow-up
Chlibek 2013 1/150 0/73 1.47 [ 0.06, 35.66 ]
25 Participants with serious AE
Chlibek 2013 1/150 0/73 1.47 [ 0.06, 35.66 ]
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Analysis 8.4. Comparison 8 Adjuvanted recombinant VZV subunit zoster vaccine: lower or higher quantities
of adjuvants plus gE subunit VZV versus unadjuvanted gE or saline, Outcome 4 50 µg gE/AS01E versus saline.
Review: Vaccines for preventing herpes zoster in older adults
Comparison: 8 Adjuvanted recombinant VZV subunit zoster vaccine: lower or higher quantities of adjuvants plus gE subunit VZV versus unadjuvanted gE or saline
Outcome: 4 50 g gE/AS01E versus saline
Study or subgroup 50 gE/AS01E Saline Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Participants with any symptom
Chlibek 2013 115/149 8/38 3.67 [ 1.97, 6.83 ]
2 Participants with any grade 3 symptom
Chlibek 2013 12/149 2/38 1.53 [ 0.36, 6.55 ]
3 Participants with any general symptom
Chlibek 2013 82/149 7/38 2.99 [ 1.51, 5.92 ]
4 Participants with any grade 3 general symptom
Chlibek 2013 7/149 2/38 0.89 [ 0.19, 4.12 ]
5 Participants with fatigue
Chlibek 2013 52/149 7/38 1.89 [ 0.94, 3.83 ]
6 Participants with grade 3 fatigue
Chlibek 2013 5/149 1/38 1.28 [ 0.15, 10.59 ]
7 Participants with fever
Chlibek 2013 18/149 1/38 4.59 [ 0.63, 33.31 ]
8 Participants with grade 3 fever
Chlibek 2013 0/149 0/38 Not estimable
9 Participants with gastrointestinal symptom
Chlibek 2013 18/149 3/38 1.53 [ 0.48, 4.93 ]
10 Participants with grade 3 gastrointestinal symptom
Chlibek 2013 2/149 1/38 0.51 [ 0.05, 5.48 ]
11 Participants with headache
Chlibek 2013 37/149 4/38 2.36 [ 0.90, 6.21 ]
12 Participants with grade 3 headache
Chlibek 2013 0/149 0/38 Not estimable
13 Participants with myalgia
Chlibek 2013 49/149 2/38 6.25 [ 1.59, 24.55 ]
14 Participants with grade 3 myalgia
Chlibek 2013 2/149 1/38 0.51 [ 0.05, 5.48 ]
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Study or subgroup 50 gE/AS01E Saline Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
15 Participants with any local symptom
Chlibek 2013 106/149 3/38 9.01 [ 3.03, 26.82 ]
16 Participants with any grade 3 local symptom
Chlibek 2013 5/149 0/38 2.86 [ 0.16, 50.62 ]
17 Participants with local pain
Chlibek 2013 104/149 3/38 8.84 [ 2.97, 26.33 ]
18 Participants with grade 3 local pain
Chlibek 2013 2/149 0/38 1.30 [ 0.06, 26.53 ]
19 Participants with local redness
Chlibek 2013 26/149 0/38 13.78 [ 0.86, 221.14 ]
20 Participants with grade 3 local redness
Chlibek 2013 3/149 0/38 1.82 [ 0.10, 34.50 ]
21 Participants with local swelling
Chlibek 2013 25/149 0/38 13.26 [ 0.83, 213.01 ]
22 Participants with grade 3 local swelling
Chlibek 2013 1/149 0/38 0.78 [ 0.03, 18.78 ]
23 Participants with consent withdrawal
Chlibek 2013 2/149 0/38 1.30 [ 0.06, 26.53 ]
24 Participants with lost follow-up
Chlibek 2013 1/149 0/38 0.78 [ 0.03, 18.78 ]
25 Participants with serious AE
Chlibek 2013 1/149 0/38 0.78 [ 0.03, 18.78 ]
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Analysis 8.5. Comparison 8 Adjuvanted recombinant VZV subunit zoster vaccine: lower or higher quantities
of adjuvants plus gE subunit VZV versus unadjuvanted gE or saline, Outcome 5 50 µg gE/AS01B versus saline.
Review: Vaccines for preventing herpes zoster in older adults
Comparison: 8 Adjuvanted recombinant VZV subunit zoster vaccine: lower or higher quantities of adjuvants plus gE subunit VZV versus unadjuvanted gE or saline
Outcome: 5 50 g gE/AS01B versus saline
Study or subgroup 50 gE/AS01B Saline Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Participants with any symptom
Chlibek 2013 130/150 8/38 4.12 [ 2.22, 7.64 ]
2 Participants with any grade 3 symptom
Chlibek 2013 14/150 2/38 1.77 [ 0.42, 7.47 ]
3 Participants with any general symptom
Chlibek 2013 95/150 7/38 3.44 [ 1.74, 6.79 ]
4 Participants with any grade 3 general symptom
Chlibek 2013 13/150 2/38 1.65 [ 0.39, 6.99 ]
5 Participants with fatigue
Chlibek 2013 72/150 7/38 2.61 [ 1.31, 5.19 ]
6 Participants with grade 3 fatigue
Chlibek 2013 9/150 1/38 2.28 [ 0.30, 17.45 ]
7 Participants with fever
Chlibek 2013 25/150 1/38 6.33 [ 0.89, 45.27 ]
8 Participants with grade 3 fever
Chlibek 2013 0/150 0/38 Not estimable
9 Participants with gastrointestinal symptom
Chlibek 2013 17/150 3/38 1.44 [ 0.44, 4.65 ]
10 Participants with grade 3 gastrointestinal symptom
Chlibek 2013 0/150 1/38 0.09 [ 0.00, 2.07 ]
11 Participants with headache
Chlibek 2013 56/150 4/38 3.55 [ 1.37, 9.17 ]
12 Participants with grade 3 headache
Chlibek 2013 5/150 0/38 2.84 [ 0.16, 50.29 ]
13 Participants with myalgia
Chlibek 2013 62/150 2/38 7.85 [ 2.01, 30.67 ]
14 Participants with grade 3 myalgia
Chlibek 2013 7/150 1/38 1.77 [ 0.22, 13.98 ]
15 Participants with any local symptom
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Study or subgroup 50 gE/AS01B Saline Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Chlibek 2013 126/150 3/38 10.64 [ 3.58, 31.59 ]
16 Participants with any grade 3 local symptom
Chlibek 2013 8/150 0/38 4.39 [ 0.26, 74.43 ]
17 Participants with local pain
Chlibek 2013 125/150 3/38 10.56 [ 3.55, 31.34 ]
18 Participants with grade 3 local pain
Chlibek 2013 6/150 0/38 3.36 [ 0.19, 58.33 ]
19 Participants with local redness
Chlibek 2013 44/150 0/38 22.99 [ 1.45, 365.01 ]
20 Participants with grade 3 local redness
Chlibek 2013 2/150 0/38 1.29 [ 0.06, 26.35 ]
21 Participants with local swelling
Chlibek 2013 23/150 0/38 12.14 [ 0.75, 195.46 ]
22 Participants with grade 3 local swelling
Chlibek 2013 1/150 0/38 0.77 [ 0.03, 18.65 ]
23 Participants with consent withdrawal
Chlibek 2013 5/150 0/38 2.84 [ 0.16, 50.29 ]
24 Participants with lost follow-up
Chlibek 2013 1/150 0/38 0.77 [ 0.03, 18.65 ]
25 Participants with serious AE
Chlibek 2013 1/150 0/38 0.77 [ 0.03, 18.65 ]
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Analysis 8.6. Comparison 8 Adjuvanted recombinant VZV subunit zoster vaccine: lower or higher
quantities of adjuvants plus gE subunit VZV versus unadjuvanted gE or saline, Outcome 6 50 µg gE/Saline
(unadjuvanted) versus saline.
Review: Vaccines for preventing herpes zoster in older adults
Comparison: 8 Adjuvanted recombinant VZV subunit zoster vaccine: lower or higher quantities of adjuvants plus gE subunit VZV versus unadjuvanted gE or saline
Outcome: 6 50 g gE/Saline (unadjuvanted) versus saline
Study or subgroup 50 gE/saline Saline Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Participants with any symptom
Chlibek 2013 32/73 8/38 2.08 [ 1.07, 4.06 ]
2 Participants with any grade 3 symptom
Chlibek 2013 2/73 2/38 0.52 [ 0.08, 3.55 ]
3 Participants with any general symptom
Chlibek 2013 24/73 7/38 1.78 [ 0.85, 3.76 ]
4 Participants with any grade 3 general symptom
Chlibek 2013 2/73 2/38 0.52 [ 0.08, 3.55 ]
5 Participants with fatigue
Chlibek 2013 16/73 7/38 1.19 [ 0.54, 2.64 ]
6 Participants with grade 3 fatigue
Chlibek 2013 2/73 1/38 1.04 [ 0.10, 11.12 ]
7 Participants with fever
Chlibek 2013 0/73 1/38 0.18 [ 0.01, 4.21 ]
8 Participants with grade 3 fever
Chlibek 2013 0/73 0/38 Not estimable
9 Participants with gastrointestinal symptom
Chlibek 2013 5/73 3/38 0.87 [ 0.22, 3.44 ]
10 Participants with grade 3 gastrointestinal symptom
Chlibek 2013 0/73 1/38 0.18 [ 0.01, 4.21 ]
11 Participants with headache
Chlibek 2013 10/73 4/38 1.30 [ 0.44, 3.88 ]
12 Participants with grade 3 headache
Chlibek 2013 0/73 0/38 Not estimable
13 Participants with myalgia
Chlibek 2013 12/73 2/38 3.12 [ 0.74, 13.24 ]
14 Participants with grade 3 myalgia
Chlibek 2013 0/73 1/38 0.18 [ 0.01, 4.21 ]
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Study or subgroup 50 gE/saline Saline Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
15 Participants with any local symptom
Chlibek 2013 17/73 3/38 2.95 [ 0.92, 9.44 ]
16 Participants with any grade 3 local symptom
Chlibek 2013 0/73 0/38 Not estimable
17 Participants with local pain
Chlibek 2013 14/73 3/38 2.43 [ 0.74, 7.93 ]
18 Participants with grade 3 local pain
Chlibek 2013 0/73 0/38 Not estimable
19 Participants with local redness
Chlibek 2013 3/73 0/38 3.69 [ 0.20, 69.62 ]
20 Participants with grade 3 local redness
Chlibek 2013 0/73 0/38 Not estimable
21 Participants with local swelling
Chlibek 2013 3/73 0/38 3.69 [ 0.20, 69.62 ]
22 Participants with grade 3 local swelling
Chlibek 2013 0/73 0/38 Not estimable
23 Participants with consent withdrawal
Chlibek 2013 1/73 0/38 1.58 [ 0.07, 37.91 ]
24 Participants with lost follow-up
Chlibek 2013 0/73 0/38 Not estimable
25 Participants with serious AE
Chlibek 2013 0/73 0/38 Not estimable
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Analysis 9.1. Comparison 9 Adjuvanted recombinant VZV subunit zoster vaccine: 3 groups of VZV subunit
gE in 3 different quantities versus unadjuvanted gE or saline, Outcome 1 25 µg gE/AS01B versus 50 µg
gE/AS01B.
Review: Vaccines for preventing herpes zoster in older adults
Comparison: 9 Adjuvanted recombinant VZV subunit zoster vaccine: 3 groups of VZV subunit gE in 3 different quantities versus unadjuvanted gE or saline
Outcome: 1 25 g gE/AS01B versus 50 g gE/AS01B
Study or subgroup 25 g gE/AS01B 50 g gE/AS01B Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Participants with any fatigue
Chlibek 2014 69/164 85/166 0.82 [ 0.65, 1.04 ]
2 Participants with grade 3 fatigue
Chlibek 2014 3/164 7/166 0.43 [ 0.11, 1.65 ]
3 Participants with any fever
Chlibek 2014 19/164 18/166 1.07 [ 0.58, 1.96 ]
4 Participants with grade 3 fever
Chlibek 2014 0/164 1/166 0.34 [ 0.01, 8.22 ]
5 Participants with any headache
Chlibek 2014 47/164 59/166 0.81 [ 0.59, 1.11 ]
6 Participants with grade 3 headache
Chlibek 2014 2/164 3/166 0.67 [ 0.11, 3.99 ]
7 Participants with any myalgia
Chlibek 2014 74/164 89/166 0.84 [ 0.68, 1.05 ]
8 Participants with grade 3 myalgia
Chlibek 2014 5/164 8/166 0.63 [ 0.21, 1.89 ]
9 Participants with local pain
Chlibek 2014 115/164 121/166 0.96 [ 0.84, 1.10 ]
10 Participants with grade 3 local pain
Chlibek 2014 4/164 3/166 1.35 [ 0.31, 5.94 ]
11 Participants with local redness
Chlibek 2014 68/164 66/166 1.04 [ 0.80, 1.35 ]
12 Participants with grade 3 local redness
Chlibek 2014 2/164 5/166 0.40 [ 0.08, 2.06 ]
13 Participants with local swelling
Chlibek 2014 44/164 33/166 1.35 [ 0.91, 2.01 ]
14 Participants with grade 3 local swelling
Chlibek 2014 1/164 2/166 0.51 [ 0.05, 5.53 ]
0.01 0.1 1 10 100
25 g gE/AS01B 50 g gE/AS01B
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Study or subgroup 25 g gE/AS01B 50 g gE/AS01B Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
15 Participants with consent withdrawal
Chlibek 2014 2/164 2/166 1.01 [ 0.14, 7.10 ]
16 Participants with lost to follow-up
Chlibek 2014 2/164 0/166 5.06 [ 0.24, 104.61 ]
17 Participants with death
Chlibek 2014 1/164 4/166 0.25 [ 0.03, 2.24 ]
0.01 0.1 1 10 100
25 g gE/AS01B 50 g gE/AS01B
Analysis 9.2. Comparison 9 Adjuvanted recombinant VZV subunit zoster vaccine: 3 groups of VZV subunit
gE in 3 different quantities versus unadjuvanted gE or saline, Outcome 2 25 µg gE/AS01B versus 100 µg
gE/AS01B.
Review: Vaccines for preventing herpes zoster in older adults
Comparison: 9 Adjuvanted recombinant VZV subunit zoster vaccine: 3 groups of VZV subunit gE in 3 different quantities versus unadjuvanted gE or saline
Outcome: 2 25 g gE/AS01B versus 100 g gE/AS01B
Study or subgroup 25 g gE/AS01B 100 g gE/AS01B Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Participants with any fatigue
Chlibek 2014 69/164 73/165 0.95 [ 0.74, 1.22 ]
2 Participants with grade 3 fatigue
Chlibek 2014 3/164 6/165 0.50 [ 0.13, 1.98 ]
3 Participants with any fever
Chlibek 2014 19/164 22/165 0.87 [ 0.49, 1.54 ]
4 Participants with grade 3 fever
Chlibek 2014 0/164 0/165 Not estimable
5 Participants with any headache
Chlibek 2014 47/164 51/165 0.93 [ 0.67, 1.29 ]
0.01 0.1 1 10 100
25 g gE/AS01B 100 g gE/AS01B
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Study or subgroup 25 g gE/AS01B 100 g gE/AS01B Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
6 Participants with grade 3 headache
Chlibek 2014 2/164 4/165 0.50 [ 0.09, 2.71 ]
7 Participants with any myalgia
Chlibek 2014 74/164 70/165 1.06 [ 0.83, 1.36 ]
8 Participants with grade 3 myalgia
Chlibek 2014 5/164 6/165 0.84 [ 0.26, 2.69 ]
9 Participants with local pain
Chlibek 2014 115/164 122/165 0.95 [ 0.83, 1.09 ]
10 Participants with grade 3 local pain
Chlibek 2014 4/164 6/165 0.67 [ 0.19, 2.33 ]
11 Participants with local redness
Chlibek 2014 68/164 68/165 1.01 [ 0.78, 1.30 ]
12 Participants with grade 3 local redness
Chlibek 2014 2/164 4/165 0.50 [ 0.09, 2.71 ]
13 Participants with local swelling
Chlibek 2014 44/164 45/165 0.98 [ 0.69, 1.40 ]
14 Participants with grade 3 local swelling
Chlibek 2014 1/164 2/165 0.50 [ 0.05, 5.49 ]
15 Participants with consent withdrawal
Chlibek 2014 2/164 2/165 1.01 [ 0.14, 7.06 ]
16 Participants with lost to follow-up
Chlibek 2014 2/164 0/165 5.03 [ 0.24, 103.98 ]
17 Participants with death
Chlibek 2014 1/164 2/165 0.50 [ 0.05, 5.49 ]
0.01 0.1 1 10 100
25 g gE/AS01B 100 g gE/AS01B
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Analysis 9.3. Comparison 9 Adjuvanted recombinant VZV subunit zoster vaccine: 3 groups of VZV subunit
gE in 3 different quantities versus unadjuvanted gE or saline, Outcome 3 50 µg gE/AS01B versus 100 µg
gE/AS01B.
Review: Vaccines for preventing herpes zoster in older adults
Comparison: 9 Adjuvanted recombinant VZV subunit zoster vaccine: 3 groups of VZV subunit gE in 3 different quantities versus unadjuvanted gE or saline
Outcome: 3 50 g gE/AS01B versus 100 g gE/AS01B
Study or subgroup 50 g gE/AS01B 100 g gE/AS01B Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Participants with any fatigue
Chlibek 2014 85/166 73/165 1.16 [ 0.92, 1.45 ]
2 Participants with grade 3 fatigue
Chlibek 2014 7/166 6/165 1.16 [ 0.40, 3.38 ]
3 Participants with any fever
Chlibek 2014 18/166 22/165 0.81 [ 0.45, 1.46 ]
4 Participants with grade 3 fever
Chlibek 2014 1/166 0/165 2.98 [ 0.12, 72.67 ]
5 Participants with any headache
Chlibek 2014 59/166 51/165 1.15 [ 0.85, 1.56 ]
6 Participants with grade 3 headache
Chlibek 2014 3/166 4/165 0.75 [ 0.17, 3.28 ]
7 Participants with any myalgia
Chlibek 2014 89/166 70/165 1.26 [ 1.01, 1.59 ]
8 Participants with grade 3 myalgia
Chlibek 2014 8/166 6/165 1.33 [ 0.47, 3.74 ]
9 Participants with local swelling
Chlibek 2014 33/166 45/165 0.73 [ 0.49, 1.08 ]
10 Participants with grade 3 local pain
Chlibek 2014 3/166 6/165 0.50 [ 0.13, 1.95 ]
11 Participants with local redness
Chlibek 2014 66/166 68/165 0.96 [ 0.74, 1.25 ]
12 Participants with grade 3 local redness
Chlibek 2014 5/166 4/165 1.24 [ 0.34, 4.55 ]
13 Participants with local pain
Chlibek 2014 121/166 122/165 0.99 [ 0.87, 1.12 ]
14 Participants with grade 3 local swelling
Chlibek 2014 2/166 2/165 0.99 [ 0.14, 6.97 ]
0.01 0.1 1 10 100
50 g gE/AS01B 100 g gE/AS01B
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Study or subgroup 50 g gE/AS01B 100 g gE/AS01B Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
15 Participants with consent withdrawal
Chlibek 2014 2/166 2/165 0.99 [ 0.14, 6.97 ]
16 Participants with lost to follow-up
Chlibek 2014 0/166 0/165 Not estimable
17 Participants with death
Chlibek 2014 4/166 2/165 1.99 [ 0.37, 10.71 ]
0.01 0.1 1 10 100
50 g gE/AS01B 100 g gE/AS01B
Analysis 9.4. Comparison 9 Adjuvanted recombinant VZV subunit zoster vaccine: 3 groups of VZV subunit
gE in 3 different quantities versus unadjuvanted gE or saline, Outcome 4 25 µg gE/AS01B versus 100 µg
gE/saline (unadjuvanted gE).
Review: Vaccines for preventing herpes zoster in older adults
Comparison: 9 Adjuvanted recombinant VZV subunit zoster vaccine: 3 groups of VZV subunit gE in 3 different quantities versus unadjuvanted gE or saline
Outcome: 4 25 g gE/AS01B versus 100 g gE/saline (unadjuvanted gE)
Study or subgroup 25 g gE/AS01B 100 g gE/saline Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Participants with any fatigue
Chlibek 2014 69/164 12/54 1.89 [ 1.11, 3.22 ]
2 Participants with grade 3 fatigue
Chlibek 2014 3/164 1/54 0.99 [ 0.10, 9.30 ]
3 Participants with any fever
Chlibek 2014 19/164 0/54 13.00 [ 0.80, 211.76 ]
4 Participants with grade 3 fever
Chlibek 2014 0/164 0/54 Not estimable
5 Participants with any headache
Chlibek 2014 47/164 9/54 1.72 [ 0.90, 3.27 ]
0.01 0.1 1 10 100
25 g gE/AS01B 100 g gE/saline
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Study or subgroup 25 g gE/AS01B 100 g gE/saline Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
6 Participants with grade 3 headache
Chlibek 2014 2/164 0/54 1.67 [ 0.08, 34.19 ]
7 Participants with any myalgia
Chlibek 2014 74/164 9/54 2.71 [ 1.46, 5.03 ]
8 Participants with grade 3 myalgia
Chlibek 2014 5/164 0/54 3.67 [ 0.21, 65.25 ]
9 Participants with local pain
Chlibek 2014 115/164 9/54 4.21 [ 2.30, 7.70 ]
10 Participants with grade 3 local pain
Chlibek 2014 4/164 0/54 3.00 [ 0.16, 54.84 ]
11 Participants with local redness
Chlibek 2014 68/164 2/54 11.20 [ 2.84, 44.15 ]
12 Participants with grade 3 local redness
Chlibek 2014 2/164 0/54 1.67 [ 0.08, 34.19 ]
13 Participants with local swelling
Chlibek 2014 44/164 1/54 14.49 [ 2.04, 102.66 ]
14 Participants with grade 3 local swelling
Chlibek 2014 1/164 0/54 1.00 [ 0.04, 24.19 ]
15 Participants with consent withdrawal
Chlibek 2014 2/164 0/54 1.67 [ 0.08, 34.19 ]
16 Participants with lost to follow-up
Chlibek 2014 2/164 2/54 0.33 [ 0.05, 2.28 ]
17 Participants with death
Chlibek 2014 1/164 2/54 0.16 [ 0.02, 1.78 ]
0.01 0.1 1 10 100
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Analysis 9.5. Comparison 9 Adjuvanted recombinant VZV subunit zoster vaccine: 3 groups of VZV subunit
gE in 3 different quantities versus unadjuvanted gE or saline, Outcome 5 50 µg gE/AS01B a versus 100 µg
gE/saline (unadjuvanted gE).
Review: Vaccines for preventing herpes zoster in older adults
Comparison: 9 Adjuvanted recombinant VZV subunit zoster vaccine: 3 groups of VZV subunit gE in 3 different quantities versus unadjuvanted gE or saline
Outcome: 5 50 g gE/AS01B a versus 100 g gE/saline (unadjuvanted gE)
Study or subgroup 50 g gE/AS01B 100 g gE/saline Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Participants with any fatigue
Chlibek 2014 85/166 12/54 2.30 [ 1.37, 3.88 ]
2 Participants with grade 3 fatigue
Chlibek 2014 7/166 1/54 2.28 [ 0.29, 18.09 ]
3 Participants with any fever
Chlibek 2014 18/166 0/54 12.19 [ 0.75, 198.88 ]
4 Participants with grade 3 fever
Chlibek 2014 1/166 0/54 0.99 [ 0.04, 23.90 ]
5 Participants with any headache
Chlibek 2014 59/166 9/54 2.13 [ 1.14, 4.01 ]
6 Participants with grade 3 headache
Chlibek 2014 3/166 0/54 2.31 [ 0.12, 43.94 ]
7 Participants with any myalgia
Chlibek 2014 89/166 9/54 3.22 [ 1.74, 5.94 ]
8 Participants with grade 3 myalgia
Chlibek 2014 8/166 0/54 5.60 [ 0.33, 95.43 ]
9 Participants with local pain
Chlibek 2014 121/166 9/54 4.37 [ 2.39, 8.00 ]
10 Participants with grade 3 local pain
Chlibek 2014 3/166 0/54 2.31 [ 0.12, 43.94 ]
11 Participants with local redness
Chlibek 2014 66/166 2/54 10.73 [ 2.72, 42.37 ]
12 Participants with grade 3 local redness
Chlibek 2014 5/166 0/54 3.62 [ 0.20, 64.47 ]
13 Participants with local swelling
Chlibek 2014 33/166 1/54 10.73 [ 1.50, 76.64 ]
14 Participants with grade 3 local swelling
Chlibek 2014 2/166 0/54 1.65 [ 0.08, 33.78 ]
0.01 0.1 1 10 100
50 g gE/AS01B 100 g gE/saline
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Study or subgroup 50 g gE/AS01B 100 g gE/saline Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
15 Participants with consent withdrawal
Chlibek 2014 2/166 0/54 1.65 [ 0.08, 33.78 ]
16 Participants with lost to follow-up
Chlibek 2014 0/166 2/54 0.07 [ 0.00, 1.35 ]
17 Participants with death
Chlibek 2014 4/166 2/54 0.65 [ 0.12, 3.45 ]
0.01 0.1 1 10 100
50 g gE/AS01B 100 g gE/saline
Analysis 9.6. Comparison 9 Adjuvanted recombinant VZV subunit zoster vaccine: 3 groups of VZV subunit
gE in 3 different quantities versus unadjuvanted gE or saline, Outcome 6 100 µg gE/AS01B versus 100 µg
gE/saline (unadjuvanted gE).
Review: Vaccines for preventing herpes zoster in older adults
Comparison: 9 Adjuvanted recombinant VZV subunit zoster vaccine: 3 groups of VZV subunit gE in 3 different quantities versus unadjuvanted gE or saline
Outcome: 6 100 g gE/AS01B versus 100 g gE/saline (unadjuvanted gE)
Study or subgroup 100 g gE/AS01B 100 g gE/saline Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Participants with any fatigue
Chlibek 2014 73/165 12/54 1.99 [ 1.17, 3.37 ]
2 Participants with grade 3 fatigue
Chlibek 2014 6/165 1/54 1.96 [ 0.24, 15.95 ]
3 Participants with any fever
Chlibek 2014 22/165 0/54 14.91 [ 0.92, 241.73 ]
4 Participants with grade 3 fever
Chlibek 2014 0/165 0/54 Not estimable
5 Participants with any headache
Chlibek 2014 51/165 9/54 1.85 [ 0.98, 3.51 ]
0.01 0.1 1 10 100
100 g gE/AS01B 100 g gE/saline
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Study or subgroup 100 g gE/AS01B 100 g gE/saline Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
6 Participants with grade 3 headache
Chlibek 2014 4/165 0/54 2.98 [ 0.16, 54.51 ]
7 Participants with any myalgia
Chlibek 2014 70/165 9/54 2.55 [ 1.37, 4.74 ]
8 Participants with grade 3 myalgia
Chlibek 2014 6/165 1/54 1.96 [ 0.24, 15.95 ]
9 Participants with local pain
Chlibek 2014 122/165 9/54 4.44 [ 2.43, 8.11 ]
10 Participants with grade 3 local pain
Chlibek 2014 6/165 0/54 4.31 [ 0.25, 75.23 ]
11 Participants with local redness
Chlibek 2014 68/165 2/54 11.13 [ 2.82, 43.88 ]
12 Participants with grade 3 local redness
Chlibek 2014 4/165 0/54 2.98 [ 0.16, 54.51 ]
13 Participants with local swelling
Chlibek 2014 45/165 1/54 14.73 [ 2.08, 104.31 ]
14 Participants with grade 3 local swelling
Chlibek 2014 2/165 0/54 1.66 [ 0.08, 33.98 ]
15 Participants with consent withdrawal
Chlibek 2014 2/165 0/54 1.66 [ 0.08, 33.98 ]
16 Participants with lost to follow-up
Chlibek 2014 0/165 2/54 0.07 [ 0.00, 1.36 ]
17 Participants with death
Chlibek 2014 2/165 2/54 0.33 [ 0.05, 2.27 ]
0.01 0.1 1 10 100
100 g gE/AS01B 100 g gE/saline
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Analysis 9.7. Comparison 9 Adjuvanted recombinant VZV subunit zoster vaccine: 3 groups of VZV subunit
gE in 3 different quantities versus unadjuvanted gE or saline, Outcome 7 25 µg gE/AS01B versus saline + 100
µg gE/AS01B.
Review: Vaccines for preventing herpes zoster in older adults
Comparison: 9 Adjuvanted recombinant VZV subunit zoster vaccine: 3 groups of VZV subunit gE in 3 different quantities versus unadjuvanted gE or saline
Outcome: 7 25 g gE/AS01B versus saline + 100 g gE/AS01B
Study or subgroup 25 g gE/AS01B
Saline + 100
g
gE/AS01B Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Participants with any fatigue
Chlibek 2014 69/164 47/165 1.48 [ 1.09, 2.00 ]
2 Participants with grade 3 fatigue
Chlibek 2014 3/164 3/165 1.01 [ 0.21, 4.91 ]
3 Participants with any fever
Chlibek 2014 19/164 9/165 2.12 [ 0.99, 4.56 ]
4 Participants with grade 3 fever
Chlibek 2014 0/164 0/165 Not estimable
5 Participants with any headache
Chlibek 2014 47/164 36/165 1.31 [ 0.90, 1.91 ]
6 Participants with grade 3 headache
Chlibek 2014 2/164 0/165 5.03 [ 0.24, 103.98 ]
7 Participants with any myalgia
Chlibek 2014 74/164 49/165 1.52 [ 1.14, 2.03 ]
8 Participants with grade 3 myalgia
Chlibek 2014 5/164 3/165 1.68 [ 0.41, 6.90 ]
9 Participants with local pain
Chlibek 2014 115/164 93/165 1.24 [ 1.05, 1.47 ]
10 Participants with grade 3 local pain
Chlibek 2014 4/164 3/165 1.34 [ 0.30, 5.90 ]
11 Participants with local redness
Chlibek 2014 68/164 49/165 1.40 [ 1.04, 1.88 ]
12 Participants with grade 3 local redness
Chlibek 2014 2/164 2/165 1.01 [ 0.14, 7.06 ]
13 Participants with local swelling
Chlibek 2014 44/164 30/165 1.48 [ 0.98, 2.22 ]
14 Participants with grade 3 local swelling
0.01 0.1 1 10 100
25 g gE/AS01B saline + 100 g gE/AS01B
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Study or subgroup 25 g gE/AS01B
Saline + 100
g
gE/AS01B Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Chlibek 2014 1/164 0/165 3.02 [ 0.12, 73.55 ]
15 Participants with consent withdrawal
Chlibek 2014 2/164 1/165 2.01 [ 0.18, 21.98 ]
16 Participants with lost to follow-up
Chlibek 2014 2/164 1/165 2.01 [ 0.18, 21.98 ]
17 Participants with death
Chlibek 2014 1/164 2/165 0.50 [ 0.05, 5.49 ]
0.01 0.1 1 10 100
25 g gE/AS01B saline + 100 g gE/AS01B
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Analysis 9.8. Comparison 9 Adjuvanted recombinant VZV subunit zoster vaccine: 3 groups of VZV subunit
gE in 3 different quantities versus unadjuvanted gE or saline, Outcome 8 50 µg gE/AS01B versus saline + 100
µg gE/AS01B.
Review: Vaccines for preventing herpes zoster in older adults
Comparison: 9 Adjuvanted recombinant VZV subunit zoster vaccine: 3 groups of VZV subunit gE in 3 different quantities versus unadjuvanted gE or saline
Outcome: 8 50 g gE/AS01B versus saline + 100 g gE/AS01B
Study or subgroup 50 g gE/AS01B
Saline + 100
g
gE/AS01B Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Participants with any fatigue
Chlibek 2014 85/166 47/165 1.80 [ 1.35, 2.39 ]
2 Participants with grade 3 fatigue
Chlibek 2014 7/166 3/165 2.32 [ 0.61, 8.82 ]
3 Participants with any fever
Chlibek 2014 18/166 9/165 1.99 [ 0.92, 4.30 ]
4 Participants with grade 3 fever
Chlibek 2014 1/166 0/165 2.98 [ 0.12, 72.67 ]
5 Participants with any headache
Chlibek 2014 59/166 36/165 1.63 [ 1.14, 2.32 ]
6 Participants with grade 3 headache
Chlibek 2014 3/166 0/165 6.96 [ 0.36, 133.66 ]
7 Participants with any myalgia
Chlibek 2014 89/166 49/165 1.81 [ 1.37, 2.37 ]
8 Participants with grade 3 myalgia
Chlibek 2014 8/166 3/165 2.65 [ 0.72, 9.82 ]
9 Participants with local pain
Chlibek 2014 121/166 93/165 1.29 [ 1.10, 1.52 ]
10 Participants with grade 3 local pain
Chlibek 2014 3/166 3/165 0.99 [ 0.20, 4.85 ]
11 Participants with local redness
Chlibek 2014 66/166 49/165 1.34 [ 0.99, 1.81 ]
12 Participants with grade 3 local redness
Chlibek 2014 5/166 2/165 2.48 [ 0.49, 12.63 ]
13 Participants with local swelling
Chlibek 2014 33/166 30/165 1.09 [ 0.70, 1.71 ]
14 Participants with grade 3 local swelling
0.005 0.1 1 10 200
50 g gE/AS01B Saline + 100 g gE/AS01B
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Study or subgroup 50 g gE/AS01B
Saline + 100
g
gE/AS01B Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Chlibek 2014 2/166 0/165 4.97 [ 0.24, 102.74 ]
15 Participants with consent withdrawal
Chlibek 2014 2/166 1/165 1.99 [ 0.18, 21.71 ]
16 Participants with lost to follow-up
Chlibek 2014 0/166 1/165 0.33 [ 0.01, 8.07 ]
17 Participants with death
Chlibek 2014 4/166 2/165 1.99 [ 0.37, 10.71 ]
0.005 0.1 1 10 200
50 g gE/AS01B Saline + 100 g gE/AS01B
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Analysis 9.9. Comparison 9 Adjuvanted recombinant VZV subunit zoster vaccine: 3 groups of VZV subunit
gE in 3 different quantities versus unadjuvanted gE or saline, Outcome 9 100 µg gE/AS01B versus saline + 100
µg gE/AS01B.
Review: Vaccines for preventing herpes zoster in older adults
Comparison: 9 Adjuvanted recombinant VZV subunit zoster vaccine: 3 groups of VZV subunit gE in 3 different quantities versus unadjuvanted gE or saline
Outcome: 9 100 g gE/AS01B versus saline + 100 g gE/AS01B
Study or subgroup 100 g gE/AS01B
Saline + 100
g
gE/AS01B Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Participants with any fatigue
Chlibek 2014 73/165 47/165 1.99 [ 1.26, 3.15 ]
2 Participants with grade 3 fatigue
Chlibek 2014 6/165 3/165 2.04 [ 0.50, 8.29 ]
3 Participants with any fever
Chlibek 2014 22/165 9/165 2.67 [ 1.19, 5.98 ]
4 Participants with grade 3 fever
Chlibek 2014 0/165 0/165 Not estimable
5 Participants with any headache
Chlibek 2014 51/165 36/165 1.60 [ 0.98, 2.63 ]
6 Participants with grade 3 headache
Chlibek 2014 4/165 0/165 9.22 [ 0.49, 172.68 ]
7 Participants with any myalgia
Chlibek 2014 70/165 49/165 1.74 [ 1.11, 2.75 ]
8 Participants with grade 3 myalgia
Chlibek 2014 6/165 3/165 2.04 [ 0.50, 8.29 ]
9 Participants with local pain
Chlibek 2014 122/165 93/165 2.20 [ 1.38, 3.49 ]
10 Participants with grade 3 local pain
Chlibek 2014 6/165 3/165 2.04 [ 0.50, 8.29 ]
11 Participants with local redness
Chlibek 2014 68/165 49/165 1.66 [ 1.05, 2.62 ]
12 Participants with grade 3 local redness
Chlibek 2014 4/165 2/165 2.02 [ 0.37, 11.21 ]
13 Participants with local swelling
Chlibek 2014 45/165 30/165 1.69 [ 1.00, 2.85 ]
14 Participants with grade 3 local swelling
0.01 0.1 1 10 100
100 g gE/AS01B Saline + 100 g gE/AS01B
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Study or subgroup 100 g gE/AS01B
Saline + 100
g
gE/AS01B Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Chlibek 2014 2/165 0/165 5.06 [ 0.24, 106.23 ]
15 Participants with consent withdrawal
Chlibek 2014 2/165 1/165 2.01 [ 0.18, 22.41 ]
16 Participants with lost to follow-up
Chlibek 2014 0/165 1/165 0.33 [ 0.01, 8.19 ]
17 Participants with death
Chlibek 2014 2/165 2/165 1.00 [ 0.14, 7.18 ]
0.01 0.1 1 10 100
100 g gE/AS01B Saline + 100 g gE/AS01B
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Analysis 9.10. Comparison 9 Adjuvanted recombinant VZV subunit zoster vaccine: 3 groups of VZV subunit
gE in 3 different quantities versus unadjuvanted gE or saline, Outcome 10 Saline + 100 µg gE/AS01B versus 100
µg gE/saline (unadjuvanted gE).
Review: Vaccines for preventing herpes zoster in older adults
Comparison: 9 Adjuvanted recombinant VZV subunit zoster vaccine: 3 groups of VZV subunit gE in 3 different quantities versus unadjuvanted gE or saline
Outcome: 10 Saline + 100 g gE/AS01B versus 100 g gE/saline (unadjuvanted gE)
Study or subgroup
Saline + 100
g
gE/AS01B 100 g gE/saline Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Participants with any fatigue
Chlibek 2014 47/165 12/54 1.28 [ 0.74, 2.23 ]
2 Participants with grade 3 fatigue
Chlibek 2014 3/165 1/54 0.98 [ 0.10, 9.24 ]
3 Participants with any fever
Chlibek 2014 9/165 0/54 6.30 [ 0.37, 106.40 ]
4 Participants with grade 3 fever
Chlibek 2014 0/165 0/54 Not estimable
5 Participants with any headache
Chlibek 2014 36/165 9/54 1.31 [ 0.67, 2.54 ]
6 Participants with grade 3 headache
Chlibek 2014 0/165 0/54 Not estimable
7 Participants with any myalgia
Chlibek 2014 49/165 9/54 1.78 [ 0.94, 3.38 ]
8 Participants with grade 3 myalgia
Chlibek 2014 3/165 0/54 2.32 [ 0.12, 44.20 ]
9 Participants with local pain
Chlibek 2014 93/165 9/54 3.38 [ 1.84, 6.23 ]
10 Participants with grade 3 local pain
Chlibek 2014 3/165 0/54 2.32 [ 0.12, 44.20 ]
11 Participants with local redness
Chlibek 2014 49/165 2/54 8.02 [ 2.02, 31.88 ]
12 Participants with grade 3 local redness
Chlibek 2014 2/165 0/54 1.66 [ 0.08, 33.98 ]
13 Participants with local swelling
Chlibek 2014 30/165 1/54 9.82 [ 1.37, 70.30 ]
14 Participants with grade 3 local swelling
0.01 0.1 1 10 100
Saline + 100 g gE/AS01B 100 g gE/saline
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Study or subgroup
Saline + 100
g
gE/AS01B 100 g gE/saline Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Chlibek 2014 0/165 0/54 Not estimable
15 Participants with consent withdrawal
Chlibek 2014 1/165 0/54 0.99 [ 0.04, 24.05 ]
16 Participants with lost to follow-up
Chlibek 2014 1/165 2/54 0.16 [ 0.02, 1.77 ]
17 Participants with death
Chlibek 2014 2/165 2/54 0.33 [ 0.05, 2.27 ]
0.01 0.1 1 10 100
Saline + 100 g gE/AS01B 100 g gE/saline
Analysis 10.1. Comparison 10 Adjuvanted recombinant VZV subunit zoster vaccine (not yet available)
versus placebo, Outcome 1 Incidence of herpes zoster 3.2 years follow-up (≥ 60 yo).
Review: Vaccines for preventing herpes zoster in older adults
Comparison: 10 Adjuvanted recombinant VZV subunit zoster vaccine (not yet available) versus placebo
Outcome: 1 Incidence of herpes zoster 3.2 years follow-up (≥ 60 yo)
Study or subgroup
Not yet
available zoster
vaccine Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lal 2015 6/4053 140/4069 0.04 [ 0.02, 0.10 ]
0.01 0.1 1 10 100
Not yet available zoster vaccine Placebo
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Analysis 10.2. Comparison 10 Adjuvanted recombinant VZV subunit zoster vaccine (not yet available)
versus placebo, Outcome 2 Participants with AEs.
Review: Vaccines for preventing herpes zoster in older adults
Comparison: 10 Adjuvanted recombinant VZV subunit zoster vaccine (not yet available) versus placebo
Outcome: 2 Participants with AEs
Study or subgroup
Not yet
available zoster
vaccine Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Any symptom
Lal 2015 3765/4460 1689/4466 2.23 [ 2.15, 2.32 ]
2 Grade 3 any symptom
Lal 2015 760/4460 145/4466 5.25 [ 4.42, 6.24 ]
3 Grade 3 any symptom related to vaccination
Lal 2015 694/4460 83/4466 8.37 [ 6.69, 10.47 ]
4 Any systemic symptom
Lal 2015 2894/4375 1293/4378 2.24 [ 2.13, 2.36 ]
5 Grade 3 any systemic AEs
Lal 2015 498/4375 106/4378 4.70 [ 3.83, 5.77 ]
6 Myalgia
Lal 2015 2025/4375 530/4378 3.82 [ 3.51, 4.17 ]
7 Fatigue
Lal 2015 2008/4375 728/4378 2.76 [ 2.56, 2.97 ]
8 Headache
Lal 2015 1716/4375 700/4378 2.45 [ 2.27, 2.65 ]
9 Shivering
Lal 2015 1232/4375 259/4378 4.76 [ 4.19, 5.41 ]
10 Fever
Lal 2015 939/4375 132/4378 7.12 [ 5.96, 8.50 ]
11 Gastrointestinal symptom
Lal 2015 788/4375 387/4378 2.04 [ 1.82, 2.28 ]
12 Any local symptom
Lal 2015 3571/4382 522/4377 6.83 [ 6.30, 7.42 ]
13 Grade 3 any local symptom
Lal 2015 417/4382 16/4377 26.03 [ 15.83, 42.82 ]
14 Local pain
Lal 2015 3464/4382 490/4377 7.06 [ 6.49, 7.69 ]
0.01 0.1 1 10 100
Not yet available zoster vaccine Placebo
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Study or subgroup
Not yet
available zoster
vaccine Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
15 Local redness
Lal 2015 1664/4382 59/4377 28.17 [ 21.80, 36.40 ]
16 Local swelling
Lal 2015 1153/4382 46/4377 25.04 [ 18.70, 33.52 ]
17 Serious AEs
Lal 2015 689/7698 686/7713 1.01 [ 0.91, 1.11 ]
18 Serious AEs within 30 days after vaccination
Lal 2015 87/7698 97/7713 0.90 [ 0.67, 1.20 ]
19 Serious AEs within 30 days after vaccination related to vaccination
Lal 2015 1/7698 3/7713 0.33 [ 0.03, 3.21 ]
20 Potential immune-mediated disease
Lal 2015 78/7698 97/7713 0.81 [ 0.60, 1.08 ]
21 Deaths
Lal 2015 167/7698 174/7713 0.96 [ 0.78, 1.19 ]
22 Deaths within 30 days after vaccination
Lal 2015 8/7698 7/7713 1.15 [ 0.42, 3.16 ]
23 Unsolicited report of AEs
Lal 2015 1308/4460 1226/4466 1.07 [ 1.00, 1.14 ]
24 Grade 3 unsolicited report of AEs
Lal 2015 208/4460 151/4466 1.38 [ 1.12, 1.69 ]
0.01 0.1 1 10 100
Not yet available zoster vaccine Placebo
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Analysis 10.3. Comparison 10 Adjuvanted recombinant VZV subunit zoster vaccine (not yet available)
versus placebo, Outcome 3 Drop-outs.
Review: Vaccines for preventing herpes zoster in older adults
Comparison: 10 Adjuvanted recombinant VZV subunit zoster vaccine (not yet available) versus placebo
Outcome: 3 Drop-outs
Study or subgroup
Not yet
available zoster
vaccine Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Did not receive vaccine according to protocol
Lal 2015 4/7698 2/7713 2.00 [ 0.37, 10.94 ]
2 Received wrong vaccine
Lal 2015 9/7698 5/7713 1.80 [ 0.60, 5.38 ]
3 Had diagnosis of HZ < 30 days after dose 2
Lal 2015 4/7698 14/7713 0.29 [ 0.09, 0.87 ]
0.01 0.1 1 10 100
Not yet available zoster vaccine Placebo
A D D I T I O N A L T A B L E S
Table 1. Comprehensive risk of bias
Domain Risk of bias
Allocation (selection bias): randomisation criteria We graded 5 studies as having a low risk of bias for random sequence genera-
tion (selection bias) because they described how the randomisation was done
(Chlibek 2013; Diez-Domingo 2015; Lal 2015; Vermeulen 2012; Vesikari
2013). Chlibek 2013 stated that “Randomization was made using an algo-
rithm that stratified by country, minimized for age, and included a block
size of 11”. In Diez-Domingo 2015: “The subjects were randomised using
an electronic case report form (e-CRF)”. Lal 2015 stated that “We randomly
assigned participants in a 1:1 ratio to receive either vaccine or placebo using
an online centralized randomization system”. Vermeulen 2012 stated that
“Subjects were randomised in a 1:1 ratio to receive two doses of either zoster
vaccine or placebo, according to a computer-generated, study-centre specific
allocation schedule”. Vesikari 2013 used “blocks of randomisation, with strat-
ification by age (70-79 y and ≥ 80 y) and country”
The other 8 trials provided no details on the randomisation process and we
therefore classified them as having an unclear risk of bias for this domain
(Berger 1998; Chlibek 2014; Gilderman 2008; Levin 2000; Mills 2010;
Murray 2011; Oxman 2005; Tyring 2007).
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Table 1. Comprehensive risk of bias (Continued)
Allocation (selection bias): allocation criteria We classified Chlibek 2013, Diez-Domingo 2015, Lal 2015, Oxman 2005,
Vermeulen 2012 and Vesikari 2013 as having low risk of bias because of
adequate allocation concealment described by the trial authors as follows.
Chlibek 2013: “Treatments were allocated at each site using a central ran-
domisation system on the Internet”. Diez-Domingo 2015: “Allocation sched-
ules were generated using a 1:1 ratio with permuted blocks of 4-6”. Lal 2015:
“Participants were stratified according to region and age group (50 to 59, 60
to 69, and ≥70 years)”. Oxman 2005: “Each study site received randomly
ordered vials of zoster vaccine and placebo in separate boxes for each age stra-
tum”. Vermeulen 2012: “Allocation numbers were assigned sequentially by
the study site personnel to subjects who met the study eligibility criteria, be-
ginning with the lowest number available at the study centre, after informed
consent and medical history had been obtained. The allocation schedule was
generated by a sponsor statistician not otherwise associated with the zoster
vaccine program”. Vesikari 2013: “The allocation schedule was generated us-
ing balanced permuted blocks of randomisation”
Berger 1998, Chlibek 2014, Gilderman 2008, Levin 2000, Mills 2010,
Murray 2011 andTyring 2007 didnot report details of allocation concealment
and we therefore classified these trials as having an ’unclear’ risk of bias for
this domain
Blinding (performance bias and detection bias) 8 trials were double-blind and we considered them at low risk for this domain
(Berger 1998; Chlibek 2013; Gilderman 2008; Lal 2015; Murray 2011;
Oxman 2005; Tyring 2007; Vermeulen 2012).
The Berger 1998 trial had 4 arms: 3 received different concentrations of a live
attenuated VZV/Oka vaccine under double-blind conditions. The 4th arm
used a pneumococcal polysaccharide vaccine as a control for reactogenicity
and immune response, under single-blind conditions
Chlibek 2013 stated that “Both vaccine recipients and observers responsible
for evaluations were blinded to which formulation was administered”
Gilderman 2008 included the following comment: “Double-blind, with in-
house blinding. The vaccine and placebo were indistinguishable from each
other.”
Lal 2015 reported “Because the appearance of the reconstituted HZ/su vac-
cine differed from the placebo solution, injections were prepared and admin-
istered by study staff who did not participate in any study assessment.”
In Murray 2011, the authors reported that “The zoster vaccine and placebo
were reconstituted with sterile diluent immediately prior to administration,
and were indistinguishable from each other in appearance. Placebo was the
vaccine stabiliser of zoster vaccine with no live virus. An independent Data
Monitoring Committee was established for continuous safety oversight dur-
ing the study.”
Oxman 2005 provided the following statement: “Since the reconstituted
zoster vaccine had a different appearance from the placebo, reconstitution and
administration were performed by technicians who did not otherwise interact
with subjects, evaluate outcomes or adverse events, answer the telephone or
enter study data.”
Tyring 2007 states “Blinded subject, investigator and sponsor. The 2 potency
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Table 1. Comprehensive risk of bias (Continued)
formulations were indistinguishable in appearance”
Vermeulen 2012 declares that “The subject, investigator, clinical study site
personnel, and sponsor personnel directly involved in the study were blinded
to whether the subject received zoster vaccine or placebo. They remained
blinded until all subjects completed the study. The clinical materials were
prepared by an unblinded vaccine coordinator at each clinical site, because
of differences in the turbidity of the study vaccine and placebo. Each vial of
vaccine or placebo was labelledwith a subject-specific allocation number. The
unblinded vaccine coordinator reconstituted the study vaccine/placebo and
wrapped the syringe in an opaque label containing subject allocation number
and time of reconstitution. The unblinded vaccine coordinator did not have
any contact with the subject and did not disclose the contents of the syringe
to the person administering the study vaccine/placebo.”
We classified 3 trials as having a ’low risk of bias’ only for the domain “blinding
of participants and personnel (performance bias)” although “personnel were
not blinded” because the participants themselves were blinded and they were
the ones who described adverse events in diary cards (Chlibek 2014; Diez-
Domingo 2015; Vesikari 2013). Please see below:
Chlibek 2014 described: “solicited local reactions (pain, redness and swelling)
and general reactions (fatigue, fever, headache and myalgia) were recorded by
subjects on diary cards for seven days after each vaccination”
Diez-Domingo 2015 stated: “Between visit 1 and 2, the participants were
given a diary card to record their temperature if they were febrile (oral tem-
perature ≥38.3 C), occurrence of any solicited injection-site (erythema,
swelling and pain) adverse reactions (Days 0-4) and any unsolicited injection-
site adverse reactions, varicella, varicella-like rashes, HZ and zoster-like rashes
and other systemic adverse events (AEs) (Days 0-28). They were also asked
to report any serious AEs (SAEs) that occurred at any time during the study”
Vesikari 2013 provided the following description: “Solicited injection-site re-
actions (erythema, swelling, and pain) occurring within 4 days of vaccination
were recorded by participants in a diary card. Other injection-site reactions
and systemic AEs were recorded in the diary card for up to 28 d following
each vaccination.”
1 trial was an open study and we considered it to be at high risk of bias
for blinding (Levin 2000). We classified Mills 2010 as ’unclear risk of bias’
because the authors did not provide any information on blinding
Incomplete outcome data (attrition bias) We classified Chlibek 2013, Chlibek 2014, Diez-Domingo 2015, Gilderman
2008, Murray 2011, Oxman 2005, Tyring 2007, Vermeulen 2012 and
Vesikari 2013 as ’low risk’ in this domain because the flow of patients was
clear. Mills 2010 had no data on the first arm of the cross-over study and we
therefore classified it as ’high risk’. We also classified Lal 2015 as high risk
of bias because the patient flow is not clear. We classified Berger 1998 and
Levin 2000 as ’unclear risk’ as they did not provide any information for this
domain
Selective reporting (reporting bias) We classified the following studies as ’low risk’ in this domain. In Berger 1998,
the adverse events originally defined by the authors were presented for all
groups. Chlibek 2013 presented the adverse events originally defined by the
authors in all groups that received 2 doses of 2 different amounts of adjuvant
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Table 1. Comprehensive risk of bias (Continued)
plus gE subunit VZV, unadjuvanted gE or saline. Chlibek 2014 also presented
the adverse events associated with 2 doses of different amounts of adjuvanted
gE, unadjuvanted gE or saline. Diez-Domingo 2015 presented all adverse
events proposed in the methodology in both groups (intramuscular versus
subcutaneous zoster vaccine). Gilderman 2008 reported all adverse events
that the investigators selected, for both groups (refrigerated versus frozen
zoster vaccines). In Lal 2015, the data for efficacy and safety of the adjuvanted
recombinant zoster vaccine proposed in the methods were described in the
results.Mills 2010 described in the results all of the adverse events listed in the
methods. Murray 2011 presented in the results all the serious adverse events
that were defined in themethods section. Oxman 2005 reported in the results
all the data on effectiveness and adverse events that the authors proposed
in their methodology. Tyring 2007 provided in the results all the adverse
events defined in the methods section, for both higher-potency and lower-
potency zoster vaccines. Vermeulen 2012 described in their results all adverse
events listed by the authors in the methods for both groups and Vesikari 2013
reported all the data that had been proposed in their methodology in the
results section, for the 3 groups who received 2 doses of zoster vaccines given
at different times or a single dose
We classified Levin 2000 as having an ’unclear’ risk of bias for this domain
because it was basically a study that analysed immune response
Other potential sources of bias We did not identify any significant aspects pertaining to this domain
Table 2. Adverse events of available live attenuated VZV zoster vaccine
Comparison (studies) Results
Available live attenuated VZV zoster vaccineversus placebo
(Mills 2010; Murray 2011; Oxman 2005; Vermeulen 2012)
The risk of herpes zoster-like rash up to 42 days post-vaccination
(Oxman 2005) was lower in the vaccinated group (RR 0.47, 95%
CI 0.27 to 0.84) than the placebo group but without a significant
RD (Analysis 1.3.7).
The following systemic AEs were not significantly different be-
tween the groups receiving zoster vaccine or placebo: systemic
AEs (Mills 2010; Oxman 2005; Vermeulen 2012), systemic pru-
ritus (Vermeulen 2012), varicella-like rash not at injection site
(from day of vaccination to day 42) (Oxman 2005; Vermeulen
2012), rash unrelated to HZ (from day of vaccination to day 42)
(Oxman 2005), 1 or more SAE (including death) (Mills 2010;
Murray 2011; Oxman 2005; Vermeulen 2012), vaccine-related
SAEs (Mills 2010; Murray 2011; Oxman 2005), discontinua-
tion due to a vaccine-related AE (Mills 2010; Vermeulen 2012),
hospitalisation (Oxman 2005), and hospitalisation related to HZ
(Oxman 2005).
Specific injection site AEs were more frequent in the vaccinated
group. Specific risks for individual AEs were:
• participants with erythema: RR 5.15, 95% CI 4.51 to 5.
87; RD 0.29, 95% CI 0.27 to 0.31 and NNTH 3.4, 95% CI 3.
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Table 2. Adverse events of available live attenuated VZV zoster vaccine (Continued)
2 to 3.7 (Analysis 1.3.15) (Oxman 2005; Vermeulen 2012);
• participants with pain: RR 4.14, 95% CI 3.67 to 4.68; RD
0.26, 95% CI 0.24 to 0.28 and NNTH 3.8, 95% CI 3.6 to 4.2
(Analysis 1.3.16) (Oxman 2005; Vermeulen 2012);
• participants with pruritus, RR 6.91, 95% CI 4.87 to 9.82;
RD 0.06, 95% CI 0.05 to 0.07 and NNTH 16.7, 95% CI 14.2
to 20.0 (Analysis 1.3.17) (Oxman 2005; Vermeulen 2012);
• participants with swelling: RR 5.85, 95% CI 4.96 to 6.91;
RD 0.22, 95% CI 0.20 to 0.23 and NNTH 4.5, 95% CI 4.3 to
5.0 (Analysis 1.3.18) (Oxman 2005; Vermeulen 2012);
• participants with warmth: RR 5.15, 95% CI 2.75 to 9.66;
RD 0.01, 95% CI 0.01 to 0.02 (Analysis 1.3.19) (Oxman 2005;
Vermeulen 2012);
• participants with rash: RR 3.26, 95% CI 1.31 to 8.11 with
no significant RD (Analysis 1.3.20) (Oxman 2005);
• participants with haematoma: RR 1.13, 95% CI 0.76 to 1.
67 with no significant RD (Analysis 1.3.21) (Oxman 2005); and
• participants with mass: RR 14.67, 95% CI 3.51 to 61.33;
RD 0.01, 95% CI 0.01 to 0.01 (Analysis 1.3.22) (Oxman 2005).
Varicella-like rash at injection site (up to day 42) was also more
frequent in the vaccinated group: RR 2.86, 95% CI 1.21 to 6.76
(Analysis 1.3.23) (Oxman 2005), but without a significant RD
due to the small number of events
Duration of injection site AEs
In general, injection site AEs lasted longer in the zoster vaccine
group. There were significant differences with respect to the du-
ration of the following local AEs: erythema, with a mean differ-
ence (MD) of 2.40 days (95% CI 1.56 to 3.24) (Analysis 1.4.1)
, swelling MD 1.90 days (95% CI 1.35 to 2.45) (Analysis 1.4.2)
and pruritus MD 2.40 days (95% CI 1.32 to 3.48) (Analysis 1.4.
5).
The duration of pain and haematoma did not differ significantly
between the groups, MD 1.00 (95% CI -0.10 to 2.10) (Analysis
1.4.3) and MD -0.50 (95% CI -5.52 to 4.52) (Analysis 1.4.6)
respectively.
The duration of rash was longer in the placebo compared to the
vaccine group: RR -16.60 (95% CI -33.68 to 0.48) (Analysis 1.4.
4).
High-potency versus low-potency zoster vaccine (Tyring 2007) The comparison of high versus low-potency zoster vaccine yielded
no significant differences between groups for the following AEs:
vaccine-related AEs, systemic vaccine-related AEs and vaccine-
related serious AEs (death)
Refrigerated versus frozen zoster vaccine
(Gilderman 2008)
Compared refrigerated versus frozen zoster vaccine and reported
no significant differences between groups for the following AEs: 1
or more AEs, vaccine-related AEs, systemic AEs, systemic vaccine-
related AEs, serious AEs, vaccine-related serious AEs or death.
However, there weremore injection site AEs in the group receiving
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Table 2. Adverse events of available live attenuated VZV zoster vaccine (Continued)
frozen vaccines (RR 0.77, 95% CI 0.60 to 0.98) (Analysis 3.1.8).
Zoster vaccine versus pneumo 23
(Berger 1998)
One study compared 3different concentrations of plaque-forming
units (pfu) of live attenuated VZV and presented the following
adverse events:
3200 pfu VZV/dose versus pneumo 23
There was a lower incidence of 1 ormore injection site reactions in
the group vaccinated with the 3200 pfu/dose zoster vaccine (RR
0.61, 95% CI 0.41 to 0.91) (Analysis 5.1.1) as well as pain at the
injection site (RR 0.49, 95% CI 0.30 to 0.81) (Analysis 5.1.3).
There were no significant differences between the 3200 pfu/dose
zoster vaccine and the pneumo 23 vaccine for the following local
adverse events: induration (≥ 2 cm diameter injection site), prob-
ably vaccine-related injection site pain, redness (≥ 2 cm diameter
injection site), pruritus or vesicles (no patients had vesicles in the
3200 pfu/dose zoster vaccine nor the pneumo 23 groups)
8500 pfu VZV/dose versus pneumo 23
There was a lower incidence of 1 or more injection site reaction in
the group vaccinated with the 8500 pfu/dose zoster vaccine (RR
0.63, 95% CI 0.43 to 0.93) (Analysis 5.2.1).
There were no significant differences for the following injection
site AEs between participants who received the 8500 pfu/dose
VZV vaccine and those who received the pneumo 23 vaccine:
induration (≥ 2 cm diameter injection site), pain (injection site),
probably vaccine-related injection site pain, redness, pruritus and
vesicles
41,650 pfu VZV/dose VZV versus pneumo 23
Participants receiving the 41,650 pfu/dose zoster vaccine had sig-
nificantly lower rates of one or more injection site reaction (RR
0.41, 95% CI 0.24 to 0.68) (Analysis 5.3.1) and pain at injection
site (RR 0.43, 95% CI 0.25 to 0.74) (Analysis 5.3.3) than those
receiving the pneumo 23 vaccine.
There were no significant differences between the groups for the
following injection site AEs: induration (≥ 2 cm diameter injec-
tion site), probably vaccine-related injection site pain, redness (≥
2 cm diameter injection site), pruritus and vesicles (no patients
had vesicles in the 41,650 pfu/dose zoster vaccine nor the pneumo
23 vaccine groups)
Zoster vaccine intramuscular route versus zoster vaccine sub-
cutaneous route
(Diez-Domingo 2015)
Compared intramuscular (IM) versus subcutaneous (SC) zoster
vaccine and reported that compared to the IM group, participants
who received SC vaccines had a significantly higher incidence of
the following AEs:
• at least 1 adverse event (AE): RR 0.68 (95% CI 0.56 to 0.
82), RD -0.22 (95% CI -0.32 to -0.12) and NNTH 4.5 (95%
CI 3.1 to 8.33) (Analysis 6.1.1);
• vaccine-related AE: RR 0.58, 95% CI 0.47 to 0.72, RD -0.
28, 95% CI -0.38 to -0.18 and NNTH 3.6, 95% CI 2.6 to 5.55
(Analysis 6.1.2);
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Table 2. Adverse events of available live attenuated VZV zoster vaccine (Continued)
• solicited injection site reaction: RR 0.53, 95% CI 0.42 to
0.67, RD -0.30, 95% CI -0.40 to -0.20 and NNTH 1.8, 95%
CI 2.5 to 5 (Analysis 6.1.6);
• injection site erythema: RR 0.30, 95% CI 0.21 to 0.44,
RD -0.37, 95% CI-0.46 to -0.28 and NNTH 2.7, 95% CI 2.1
to 3.5 (Analysis 6.1.8);
• injection site pain: RR 0.65, 95% CI 0.47 to 0.88, RD -0.
14, 95% CI -0.24 to -0.04 and NNTH 7.1, 95% CI 4.2 to 25
(Analysis 6.1.10);
• injection site swelling: RR 0.37, 95% CI 0.24 to 0.56, RD
-0.24, 95% CI -0.32 to -0.15 and NNTH 4.2, 95% CI 3.1 to 6.
7 (Analysis 6.1.12);
• injection site pruritus: RR 0.27, 95% CI 0.08 to 0.97, RD
-0.05, 95% CI -0.09 to -0.00 and NNTH 20.0, 95% CI 0 to
11.0 to (Analysis 6.1.14).
There were no significant differences between groups for the fol-
lowing AEs: all systemic AEs: RR 1.03, 95% CI 0.70 to 1.51
(Analysis 6.1.3); vaccine-related systemic AE: RR 0.93, 95% CI
0.44 to 1.98 (Analysis 6.1.4); headache considered as vaccine-re-
lated by the investigator: RR 0.75, 95% CI 0.17 to 3.32 (Analysis
6.1.5); unsolicited injection site reaction: RR 0.65 95% CI 0.29
to 1.45 (Analysis 6.1.7); severe injection site erythema (> 10 cm)
: RR 0.67 95% CI 0.11 to 3.96 (Analysis 6.1.9); severe injection
site pain (inability to work or usual activity): RR 1.01, 95% CI
0.14 to 7.06 (Analysis 6.1.11); severe injection site swelling (> 10
cm): RR 0.25, 95% CI 0.03 to 2.23 (Analysis 6.1.13).
No participant withdrew from the trial because of AE (Analysis
6.1.15).
2 doses of a zoster vaccine versus a single dose and also 2 doses
given at different intervals
(Vesikari 2013)
Zoster vaccine 1-month schedule versus zoster vaccine 3-month
schedule
There was no statistical difference between participants who re-
ceived the doses of zoster vaccine 2 months apart compared to
those receiving the doses 3 months apart: AE RR 1.10, 95% CI
0.91 to 1.31 (Analysis 7.1.1), vaccine-related AE RR 1.00, 95%
CI 0.81 to 1.24 (Analysis 7.1.2); serious AE RR 0.95, 95% CI 0.
14 to 6.70 (Analysis 7.1.3); withdrawal due to AE RR 2.86, 95%
CI 0.12 to 69.80 (Analysis 7.1.5); systemic AE RR 1.34, 95% CI
0.90 to 2.00 (Analysis 7.1.8); vaccine-related systemic AE RR 1.
27, 95% CI 0.45 to 3.60 (Analysis 7.1.9); rash of interest non-
injection site rashes RR 0.95, 95%CI 0.06 to 15.14 (Analysis 7.1.
10); varicella/varicella-like rash RR 0.95, 95% CI 0.06 to 15.14
(Analysis 7.1.11); injection site reaction RR 0.99, 95% CI 0.80
to 1.23 (Analysis 7.1.13); solicited injection site reaction RR 1.
00, 95% CI 0.81 to 1.25 (Analysis 7.1.14); unsolicited injection
site reaction RR 0.41, 95%CI 0.11 to 1.56 (Analysis 7.1.15); ery-
thema injection site RR 1.01, 95% CI 0.80 to 1.27 (Analysis 7.1.
16); pain injection site RR 0.84, 95% CI 0.57 to 1.25 (Analysis
7.1.17); swelling injection site RR 1.05, 95% CI 0.75 to 1.47
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(Analysis 7.1.18).
No participants, from either group, reported the following AE:
vaccine-related serious AE (Analysis 7.1.4); vaccine-related with-
drawal due to AE (Analysis 7.1.6); non-serious vaccine-related
withdrawal due to AE (Analysis 7.1.7) and herpes zoster/zoster-
like rash (Analysis 7.1.12).
Zoster vaccine 1 month schedule versus zoster vaccine single
dose
Only participants with systemic AE: there were significant dif-
ferences in favour of the 2 doses 1 month apart, with a higher
incidence in the single dose group: RR 0.74, 95% CI 0.56 to 0.
97, RD -0.07, 95% CI -0.13 to -0.01 and NNTH 14.3, 95% CI
7.6 to 100 (Analysis 7.2.8).
For most AEs, there was no statistical difference: AE RR 0.92,
95%CI0.80 to 1.05 (Analysis 7.2.1), vaccine-relatedAERR0.91,
95% CI 0.77 to 1.08 (Analysis 7.2.2); serious AE RR 0.72, 95%
CI 0.16 to 3.30 (Analysis 7.2.3); withdrawal due to AE RR 0.36,
95% CI 0.05 to 2.82 (Analysis 7.1.5); vaccine-related withdrawal
due to AE RR 0.21, 95% CI 0.01 to 3.74 (Analysis 7.2.6); non-
serious vaccine-related withdrawal due to AE RR 0.21, 95% CI
0.01 to 3.74 (Analysis 7.2.7); vaccine-related systemic AE RR 0.
54, 95% CI 0.26 to 1.12 (Analysis 7.2.9); rash of interest non-
injection site rashes RR 1.61, 95%CI 0.15 to 17.72 (Analysis 7.2.
10); varicella/varicella-like rash RR 9.66, 95% CI 0.39 to 236.
25 (Analysis 7.2.11); herpes zoster/zoster-like rash RR 0.64, 95%
CI 0.03 to 13.36 (Analysis 7.2.12); injection site reaction RR 0.
93, 95% CI 0.78 to 1.10 (Analysis 7.2.13); solicited injection
site reaction RR 0.94, 95% CI 0.79 to 1.11 (Analysis 7.2.14);
unsolicited injection site reaction RR 0.35, 95% CI 0.11 to 1.13
(Analysis 7.2.15); injection site erythema RR 0.98, 95% CI 0.81
to 1.17 (Analysis 7.2.16); injection site pain RR 0.74, 95% CI 0.
54 to 1.01 (Analysis 7.2.17); injection site swelling RR 1.08, 95%
CI 0.82 to 1.41 (Analysis 7.2.18).
There were no participants with vaccine-related serious AE in
either group (Analysis 7.2.4).
Zoster vaccine 3 month schedule versus zoster vaccine single
dose
The participants in the group that received a single dose had a
higher incidence of the following AE in comparison to those in
the group that received 2 doses, 3 months apart: AEs RR 0.84,
95% CI 0.72 to 0.97; RD -0.09; 95% CI -0.17 to -0.02 and
NNTH 11.1, 95% CI 5.9 to 50 (Analysis 7.3.1), systemic AEs
RR 0.55, 95% CI 0.39 to 0.76, RD -0.13, 95% CI -0.18 to -0.07
andNNTH7.6, 95%CI 5.6 to 14.3 (Analysis 7.3.8) and vaccine-
related systemic AE RR 0.42, 95% CI 0.18 to 0.98), RD -0.04,
95% CI -0.06 to -0.01 and NNTH 25.0, 95% CI 16.6 to 100
(Analysis 7.3.9). There were no significant differences between
these groups in relation to the following AEs: vaccine-related AE
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RR 0.91, 95% CI 0.77 to 1.08 (Analysis 7.3.2); serious AE RR 0.
75, 95% CI 0.16 to 3.46 (Analysis 7.3.3); withdrawal due to AE
RR 0.18, 95% CI 0.01 to 3.04 (Analysis 7.3.5); vaccine-related
withdrawal due to AE RR 0.23, 95% CI 0.01 to 3.93 (Analysis
7.3.6); non-serious vaccine-related withdrawal due to AE RR 0.
23, 95% CI 0.01 to 3.93 (Analysis 7.3.7); rash of interest non-
injection site rashes RR 1.69, 95%CI 0.15 to 18.60 (Analysis 7.3.
10); varicella/varicella-like rash RR 10.14, 95% CI 0.41 to 247.
92 (Analysis 7.3.11); herpes zoster/zoster-like rash RR 0.68, 95%
CI 0.03 to 14.02 (Analysis 7.3.12); injection site reaction RR 1.
10, 95% CI 0.79 to 1.11 (Analysis 7.3.13); solicited injection
site reaction RR 0.93, 95% CI 0.78 to 1.11 (Analysis 7.3.14);
unsolicited injection site reaction RR 0.85, 95% CI 0.38 to 1.91
(Analysis 7.3.15); injection site erythema RR 0.97, 95% CI 0.80
to 1.17 (Analysis 7.3.16); injection site pain RR 0.87, 95% CI 0.
65 to 1.17 (Analysis 7.3.17); injection site swelling RR 1.03, 95%
CI 0.77 to 1.36 (Analysis 7.3.18).
There were no participants with vaccine-related serious AE in
either group (Analysis 7.3.4).
AE: adverse event
CI: confidence interval
HZ: herpes zoster
RD: risk difference
RR: risk ratio
SC: subcutaneous
VZV: varicella zoster virus
Table 3. Adverse events of adjuvanted recombinant VZV subunit zoster vaccine
Comparison (studies) Results
Adjuvanted recombinant VZV subunit zoster vaccine: lower
or higher quantities of adjuvants plus gE subunit VZV versus
unadjuvanted gE or saline
(Chlibek 2013)
Compared 4 groups that received either lower (AS01E) or higher
(AS01B ) volumes of adjuvants plus gE subunit VZ or unadju-
vanted gE or saline injections
50 ¯g gE/AS01E versus 50 ¯g gE/AS01B
There was a significantly higher incidence of AEs in the partici-
pants who received a higher quantity of adjuvant (AS01B ):
• any symptom RR 0.89, 95% CI 0.80 to 0.99; RD -0.09,
95% CI -0.18 to -0.01 and NNTH 11.1, 95% CI 5.6 to 100.0
(Analysis 8.1.1);
• fatigue RR 0.73, 95% CI 0.55 to 0.96, RD -0.13 95% CI -
0.24 to -0.02 and NNTH 7.7, 95% CI 4.2 to 50.0 (Analysis
8.1.5);
• headache RR 0.67, 95% CI 0.47 to 0.94, RD -0.13 95%
CI -0.23 to -0.02 and NNTH 7.7, 95% CI 4.3 to 50.0 (Analysis
8.1.11);
• any local symptom RR 0.85, 95% CI 0.75 to 0.96, RD -0.
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13 95% CI -0.22 to -0.04 and NNTH 7.7, 95% CI 4.5 to 25.0
(Analysis 8.1.15);
• local pain RR 0.84, 95% CI 0.74 to 0.95, RD -0.14 95%
CI -0.23 to -0.04 and NNTH 7.1, 95% CI 4.3 to 25.0 (Analysis
8.1.17);
• local redness RR 0.59, 95% CI 0.39 to 0.91, RD -0.12
95% CI -0.21 to -0.02 and NNTH 8.3, 95% CI 4.7 to 50.0
(Analysis 8.1.19).
There were no significant differences between groups for all other
AEs: any grade 3 symptom; any general symptom, any general
grade 3 symptom, grade 3 fatigue, fever, gastrointestinal symp-
toms, grade 3 gastrointestinal symptoms, grade 3 headache, myal-
gia, grade 3myalgia, any grade 3 local symptom, local grade 3pain,
local grade 3 redness, local swelling and local grade 3 swelling,
consent withdrawal, loss to follow-up and serious AE
No participants had grade 3 fever in either group.
50 ¯g gE/AS01E versus 50 ¯g gE/saline (unadjuvanted)
• any symptom RR 1.76, 95% CI 1.34 to 2.32, RD 0.33,
95% CI 0.20 to 0.47 and NNTH was 3.0, 95% CI 2.1 to 5.0
(Analysis 8.2.1);
• any general symptom RR 1.67, 95% CI 1.17 to 2.40, RD
0.22, 95% CI 0.09 to 0.36 and NNTH was 4.5, 95% CI 2.7 to
11.1 (Analysis 8.2.3);
• fever RR 18.25, 95% CI 1.12 to 298.73, RD 0.12, 95% CI
0.06 to 0.18 and NNTH was 8.3, 95% CI 5.5 to 16.6 (Analysis
8.2.7);
• myalgia RR 2.00, 95% CI 1.14 to 3.52, RD 0.16, 95% CI
0.05 to 0.28 and NNTH was 6.25, 95% CI 3.5 to 20.0
(Analysis 8.2.13);
• any local symptom RR 3.05, 95% CI 1.99 to 4.69, RD 0.
48, 95% CI 0.36 to 0.60 and NNTH was 2.0, 95% CI 1.6 to 2.
7 (Analysis 8.2.15);
• local pain RR 3.64, 95% CI 2.25 to 5.90, RD 0.51, 95%
CI 0.39 to 0.62 and NNTH was 1.9, 95% CI 1.6 to 2.5
(Analysis 8.2.17);
• local redness RR 4.25, 95% CI 1.33 to 13.57, RD 0.13,
95% CI 0.06 to 0.21 and NNTH was 7.6, 95% CI 4.7 to 16.6
(Analysis 8.2.19);
• local swelling RR 4.08, 95% CI 1.27 to 13.08, RD 0.13,
95% CI 0.05 to 0.20 and NNTH was 7.6, 95% CI 5.0 to 20
(Analysis 8.2.21).
All these AE differences were favourable to the unadjuvanted gE
group
There were no significant differences between the groups for the
following AEs: any grade 3 symptom, any general grade 3 symp-
tom, fatigue, grade 3 fatigue, gastrointestinal symptoms, grade 3
gastrointestinal symptoms, headache, grade 3 myalgia, any local
grade 3 symptom, local grade 3 pain, local grade 3 redness and
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local grade 3 swelling, consent withdrawal, loss to follow-up and
serious AE
No participants had grade 3 fever or grade 3 headache in either
group
50 ¯g gE/AS01B versus 50 ¯g gE/saline (unadjuvanted)
• any symptom RR 1.98, 95% CI 1.51 to 2.58, RD 0.43,
95% CI 0.30 to 0.55 and NNTH 2.3, 95% CI 1.8 to 3.3
(Analysis 8.3.1);
• any general symptom RR 1.93, 95% CI 1.36 to 2.73, RD
0.30, 95% CI 0.17 to 0.44 and NNTH 3.3, 95% CI 2.2 to 5.8
(Analysis 8.3.3)
• fatigue RR 2.19, 95% CI 1.38 to 3.48, RD 0.26, 95% CI
0.14 to 0.38 and NNTH 3.8, 95% CI 2.6 to 7.1 (Analysis 8.3.
5);
• fever RR 24.99, 95% CI 1.54 to 404.89, RD 0.17, 95% CI
0.10 to 0.23 and NNTH 5.8, 95% CI 4.3 to 10.0 (Analysis 8.3.
7);
• headache RR 2.73, 95% CI 1.48 to 5.03, RD 0.24, 95%
CI 0.13 to 0.35 and NNTH 4.1, 95% CI 2.8 to 7.6 (Analysis
8.3.11);
• myalgia RR 2.51, 95% CI 1.45 to 4.36, RD 0.25, 95% CI
0.13 to 0.36 and NNTH 4.0, 95% CI 2.7 to 7.6 (Analysis 8.3.
13);
• any local symptom RR 3.61, 95% CI 2.36 to 5.50, RD 0.
61, 95% CI 0.49 to 0.72 and NNTH 1.6, 95% CI 1.3 to 2.0
(Analysis 8.3.15);
• local pain RR 4.35, 95% CI 2.70 to 7.00, RD 0.64, 95%
CI 0.53 to 0.75 and NNTH 1.5, 95% CI 1.3 to 1.8 (Analysis
8.3.17);
• local redness RR 7.14, 95% CI 2.29 to 22.22, RD 0.25,
95% CI 0.17 to 0.34 and NNTH 4.0, 95% CI 2.9 to 5.8
(Analysis 8.3.19);
• local swelling RR 3.73, 95% CI 1.16 to 12.02, RD 0.11,
95% CI 0.04 to 0.19 and NNTH 9.0, 95% CI 5.2 to 25
(Analysis 8.3.21).
All these AE differences were favourable to unadjuvanted gE.
There were no significant differences between the groups for the
following AEs: any grade 3 symptom, any general grade 3 symp-
tom, grade 3 fatigue, gastrointestinal symptoms, grade 3 headache,
grade 3 myalgia, any local grade 3 symptom, local grade 3 pain,
local grade 3 redness and local grade 3 swelling, consent with-
drawal, loss to follow-up and serious AE
No participant had grade 3 fever or grade 3 gastrointestinal symp-
toms in either group
50 ¯g gE/AS01E versus saline
• any symptom RR 3.67, 95% CI 1.97 to 6.83, RD 0.56,
95% CI 0.42 to 0.71 and NNTH 1.7, 95% CI 1.4 to 2.3
(Analysis 8.4.1);
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• any general symptom RR 2.99, 95% CI 1.51 to 5.92, RD
0.37, 95% CI 0.22 to 0.51 and NNTH 9.1, 95% CI 1.9 to 4.5
(Analysis 8.4.3);
• myalgia RR 6.25, 95% CI 1.59 to 24.55, RD 0.28, 95%
CI 0.17 to 0.38 and NNTH 3.5, 95% CI 2.6 to 5.8 (Analysis
8.4.13);
• any local symptom RR 9.01, 95% CI 3.03 to 26.82, RD 0.
63, 95% CI 0.52 to 0.74 and NNTH 1.5, 95% CI 1.3 to 1.9
(Analysis 8.4.15);
• local pain RR 8.84, 95% CI 2.97 to 26.33, RD 0.62, 95%
CI 0.51, 0.73 and NNTH 1.6, 95% CI 1.3 to 1.9 (Analysis 8.4.
17).
All differences in these AEs were favourable to the saline group
There were no significant differences in the followingAEs between
the groups:any grade 3 symptom, any general grade 3 symptom,
fatigue, grade 3 fatigue, fever, gastrointestinal symptoms, grade
3 gastrointestinal symptoms, headache, grade 3 headache, grade
3 myalgia, any local grade 3 symptom, local grade 3 pain, local
redness, local grade 3 redness, local swelling and local grade 3
swelling, consent withdrawal, loss to follow-up and serious AE
No participants had grade 3 fever or grade 3 headache in either
group
50 ¯g gE/AS01B versus saline
• any symptom RR 4.12, 95% CI 2.22 to 7.64, RD 0.66,
95% CI 0.52 to 0.80 and NNTH 1.5, 95% CI 1.2 to 1.9
(Analysis 8.5.1);
• any general symptom RR 3.44, 95% CI 1.74 to 6.79, RD
0.45, 95% CI 0.30 to 0.59 and NNTH 2.2, 95% CI 1.6 to 3.3
(Analysis 8.5.3);
• fatigue RR 2.61, 95% CI 1.31 to 5.19, RD 0.30, 95% CI
0.15 to 0.44 and NNTH 1.3, 95% CI 2.2 to 6.6 (Analysis 8.5.
5);
• headache RR 3.55, 95% CI 1.37 to 9.17, RD 0.27, 95%
CI 0.14 to 0.39 and NNTH 3.7, 95% CI 2.5 to 7.1 (Analysis
8.5.11);
• myalgia RR 7.85, 95% CI 2.01 to 30.67, RD 0.36, 95%
CI 0.25 to 0.47 and NNTH 2.7, 95% CI 2.1 to 4.0 (Analysis
8.5.13);
• any local symptom RR 10.64, 95% CI 3.58 to 31.59, RD
0.76, 95% CI 0.66 to 0.86 and NNTH 1.3, 95% CI 1.1 to 1.5
(Analysis 8.5.15);
• local pain RR 10.56, 95% CI 3.55 to 31.34, RD 0.75,
95% CI 0.65 to 0.86 and NNTH 1.3, 95% CI 1.1 to 1.5
(Analysis 8.5.17);
• local redness RR 22.99, 95% CI 1.45 to 365.01, RD 0.29,
95% CI 0.21 to 0.37 and NNT 3.4, 95% CI 2.7 to 4.7
(Analysis 8.5.19).
All AE differences were favourable to saline.
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There was no significant difference in AEs between groups for the
following: any grade 3 symptom, any general grade 3 symptom,
grade 3 fatigue, fever, gastrointestinal symptoms, grade 3 gastroin-
testinal symptoms, grade 3, headache, grade 3 myalgia, any local
grade 3 symptom, local grade 3 pain, local grade 3 redness, local
swelling and local grade 3 swelling, consent withdrawal, loss to
follow-up and serious AEs
No participant had grade 3 fever in either group.
50 ¯g gE/saline (unadjuvanted) versus saline
• any symptom RR 2.08, 95% CI 1.07 to 4.06, RD 0.23,
95% CI 0.06 to 0.40 and NNTH 4.3, 95% CI 2.5 to 16.6
(Analysis 8.6.1), favourable to saline.
There were no significant differences between groups for the fol-
lowing AEs: any grade 3 symptom, any general symptom, any
general grade 3 symptom, fatigue, grade 3 fatigue, fever, gastroin-
testinal symptoms, grade 3 gastrointestinal symptoms, headache,
myalgia, grade 3 myalgia, any local symptom, local pain, local
redness and local swelling or consent withdrawal
No participant, in either group had grade 3 fever, grade 3
headache, any local grade 3 symptom, local grade 3 pain, local
grade 3 redness, local grade 3 swelling, loss to follow-up and seri-
ous AE
Adjuvanted recombinant VZV subunit zoster vaccine:
three groups of VZV subunit gE in 3 different quantities versus
unadjuvanted gE or saline
(Chlibek 2014)
3 groups of VZV plus gE were compared in 3 different quantities,
1 group that received unadjuvanted gE and 1 group that received
only saline
25 µg gE/AS01B versus 50 µg gE/AS01B
There was no difference in the incidence of the following AEs:
any fatigue, grade 3 fatigue, any fever, grade 3 fever, any headache,
grade 3 headache, any myalgia, grade 3 myalgia, local pain, local
grade 3 pain, local redness, local grade 3 redness, local swelling,
local grade 3 swelling, consent withdrawal, loss to follow-up and
serious AEs
25 µg gE/AS01B versus 100 µg gE/AS01B
There were no differences in the incidence of the following AEs:
any fatigue, grade 3 fatigue, any fever, any headache, grade 3
headache, any myalgia, grade 3 myalgia, local pain, grade 3 local
pain, local redness, local grade 3 redness, local swelling, local grade
3 swelling, consent withdrawal, loss to follow-up and serious AEs
50 µg gE/AS01B versus 100 µg gE/AS01B
• any myalgia RR 1.26, 95% CI 1.01 to 1.59, RD 0.11, 95%
CI 0.00 to 0.22 and NNTH 9.0, 95% CI 0 to 4.5 (Analysis 9.3.
7), favourable to 100 µg gE/AS01B .
There were no differences in the incidence of all the others AEs:
any fatigue, grade 3 fatigue, any fever, grade 3 fever, any headache,
grade 3 headache, grade 3 myalgia, local pain, local grade 3 pain,
local redness, local grade 3 redness, local swelling, local grade 3
swelling, consent withdrawal and serious AEs
25 µg gE/AS01B versus 100 µg gE/saline (unadjuvanted gE)
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• any fatigue RR 1.89, 95% CI 1.11 to 3.22, RD 0.20, 95%
CI 0.06 to 0.33 and NNTH 5.0, 95% CI 3.0 to 16.6 (Analysis
9.4.1);
• any myalgia RR 2.71, 95% CI 1.46 to 5.03, RD 0.28, 95%
CI 0.16 to 0.41 and NNTH 3.5, 95% C I 2.4 to 6.2 (Analysis
9.4.7);
• local pain RR 4.21, 95% CI 2.30 to 7.70, RD 0.53, 95%
CI 0.41 to 0.66 and NNTH 1.8, 95% CI 1.5 to 2.4 (Analysis
9.4.9);
• local redness RR 11.20, 95% CI 2.84 to 44.15, RD 0.38,
95% CI 0.29 to 0.47 and NNTH 2.6, 95% CI 2.1 to 3.4
(Analysis 9.4.11);
• local swelling RR 14.49, 95% CI 2.04 to 102.66, RD 0.25,
95% CI 0.17 to 0.33 and NNTH 4.0, 95% CI 3.0 to 5.8
(Analysis 9.4.13).
All these differences in AEs were favourable to unadjuvanted gE
There were no differences in the incidence of the following AEs:
grade 3 fatigue, any fever, any headache, grade 3 headache, grade
3 myalgia, local grade 3 pain, local grade 3 redness, local grade 3
swelling, consent withdrawal, loss to follow-up and serious AEs
No participant had grade 3 fever in either of the groups.
50 µg gE/AS01B versus 100 µg gE/saline (unadjuvanted gE)
• any fatigue RR 2.30, 95% CI 1.37 to 3.88, RD 0.29, 95%
CI 0.16 to 0.42 and NNTH 3.4, 95% CI 2.3 to 6.2 (Analysis
9.5.1);
• any headache RR 2.13, 95% CI 1.14 to 4.01, RD 0.19,
95% CI 0.07 to 0.31 and NNTH 5.2, 95% CI 3.2 to 14.2
(Analysis 9.5.5);
• any myalgia RR 3.22, 95% CI 1.74 to 5.94, RD 0.37, 95%
CI 0.24 to 0.49 and NNTH 2.7, 95% CI 2.0 to 4.1 (Analysis
9.5.7);
• local pain RR 4.37, 95% CI 2.39 to 8.00, RD 0.56, 95%
CI 0.44 to 0.68 and NNTH 1.7, 95% CI 1.4 to 2.2 (Analysis
9.5.9);
• local redness RR 10.73, 95% CI 2.72 to 42.37, RD 0.36,
95% CI 0.27 to 0.45 and NNTH 2.7, 95% CI 2.2 to 3.7
(Analysis 9.5.11);
• local swelling RR 10.73, 95% CI 1.50 to 76.64, RD 0.18,
95% CI 0.11 to 0.25 and NNTH 5.5, 95% CI 4.0 to 9.0
(Analysis 9.5.13).
All these differences of AEs were favourable to unadjuvanted gE
There were no differences in the incidence of the following AEs:
grade 3 fatigue, any fever, grade 3 headache, grade 3 myalgia, local
grade 3 pain, local grade 3 redness, local grade 3 swelling, consent
withdrawal, loss to follow-up and serious AEs
No participant had grade 3 fever in either of the groups
100 µg gE/AS01B versus 100 µg gE/saline (unadjuvanted gE)
• any fatigue RR 1.99, 95% CI 1.17 to 3.37, RD 0.22, 95%
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CI 0.09 to 0.35 and NNTH 4.5, 95% CI 2.8 to 11.1 (Analysis
9.6.1);
• any headache RR 1.85, 95% CI 0.98 to 3.51, RD 0.14,
95% CI 0.02 to 0.26 and NNTH 7.1, 95% CI 3.8 to 50.0
(Analysis 9.6.5);
• any myalgia RR 2.55, 95% CI 1.37 to 4.74, RD 0.26, 95%
CI 0.13 to 0.38 and NNTH 3.8, 95% CI 2.6 to 7.6 (Analysis
9.6.7);
• local pain RR 4.44, 95% CI 2.43 to 8.11, RD 0.57, 95%
CI 0.45 to 0.69 and NNTH 1.7, 95% CI 1.4 to 2.2 (Analysis
9.6.9);
• local redness RR 11.13, 95% CI 2.82 to 43.88, RD 0.38,
95% CI 0.28 to 0.47 and NNTH 2.6, 95% CI 2.1 to 3.5
(Analysis 9.6.11);
• local swelling RR 14.73, 95% CI 2.08 to 104.31, RD 0.25,
95% CI 0.18 to 0.33 and NNTH 4.0, 95% CI 3.0 to 5.5
(Analysis 9.6.13).
All these differences in AEs were favourable to unadjuvanted gE
There were no differences in the incidence of the following AEs:
grade 3 fatigue, any fever, grade 3 headache, grade 3 myalgia, local
grade 3 pain, local grade 3 redness, local grade 3 swelling, consent
withdrawal, loss to follow-up and serious AEs
No participant had grade 3 fever in either of the groups.
25 µg gE/AS01B versus saline + 100 µg gE/AS01B
• any fatigue RR 1.48, 95% CI 1.09 to 2.00, RD 0.14, 95%
CI 0.03 to 0.24 and NNTH 7.1, 95% CI 4.1 to 33.3 (Analysis
9.7.1);
• any myalgia RR 1.52, 95% CI 1.14 to 2.03, RD 0.15, 95%
CI 0.05 to 0.26 and NNTH 6.6, 95% CI 3.8 to 20 (Analysis
9.7.7);
• local pain RR 1.24, 95% CI 1.05 to 1.47, RD 0.14, 95%
CI 0.03 to 0.24 and NNTH 7.1, 95% CI 4.1 to 33.3 (Analysis
9.7.9);
• local redness RR 1.40, 95% CI 1.04 to 1.88, RD 0.12,
95% CI 0.01 to 0.22 and NNTH 8.3, 95% CI 4.5 to 100.0
(Analysis 9.7.11).
All differences in AEs were favourable to saline + 100 µg gE/
AS01B .
There were no differences in the incidence of the following AEs:,
any fatigue, grade 3 fever, any headache, grade 3 headache, grade
3 myalgia, local grade 3 pain, local grade 3 redness, local swelling,
local grade 3 swelling, consent withdrawal, loss to follow-up and
serious AEs
No participant had grade 3 fever in either of the groups.
50 µg gE/AS01B versus saline + 100 µg gE/AS01B
• any fatigue RR 1.80, 95% CI 1.35 to 2.39, RD 0.23, 95%
CI 0.12 to 0.33 and NNTH 4.3, 95% CI 3.0 to 8.3 (Analysis
9.8.1);
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• any headache RR 1.63, 95% CI 1.14 to 2.32, RD 0.14,
95% CI 0.04 to 0.23 and NNTH 7.1, 95% CI 4.3 to 25
(Analysis 9.8.5);
• any myalgia RR 1.81, 95% CI 1.37 to 2.37, RD 0.24, 95%
CI 0.14 to 0.34 and NNTH 4.1, 95% CI 2.9 to 7.1 (Analysis
9.8.7);
• local pain RR 1.29, 95% CI 1.10 to 1.52, RD 0.17, 95%
CI 0.06 to 0.27 and NNTH 5.8, 95% CI 3.7 to 16.6 (Analysis
9.8.9).
All differences in AEs were favourable to saline + 100 µg gE/
AS01B .
There were no differences in the incidence of the following AEs:
grade 3 fatigue, any fever, grade 3 fever, grade 3 headache, grade
3 myalgia, local grade 3 pain, local redness, local grade 3 redness,
local swelling, local grade 3 swelling, consent withdrawal, loss to
follow-up and serious AEs
100 µg gE/AS01B versus saline + 100 µg gE/AS01B
• any fatigue RR 1.55, 95% CI 1.15 to 2.09, RD 0.16, 95%
CI 0.06 to 0.26 and NNTH 6.2, 95% CI 3.8 to 16.6 (Analysis
9.9.1);
• any fever RR 2.44, 95% CI 1.16 to 5.15, RD 0.08, 95%
CI 0.02 to 0.14 and NNTH 12.5, 95% CI 7.1 to 50 (Analysis
9.9.3);
• any myalgia RR 1.43, 95% CI 1.06 to 1.92, RD 0.13, 95%
CI 0.02 to 0.23 and NNTH 7.6, 95% CI 4.3 to 50.0 (Analysis
9.9.7);
• local pain RR 1.31, 95% CI 1.12 to 1.54, RD 0.18, 95%
CI 0.07 to 0.28 and NNTH 5.5, 95% CI 3.5 to 14.2 (Analysis
9.9.9);
• local redness RR 1.39, 95% CI 1.03 to 1.87, RD 0.12,
95% CI 0.01 to 0.22 and NNTH 8.3, 95% CI 4.5 to 100.0
(Analysis 9.9.11).
All differences in AEs were favourable to saline + 100 µg gE/
AS01B .
There were no difference in the incidence of the following AEs:
grade 3 fatigue, headache, grade 3 headache, grade 3myalgia, local
grade 3 pain, local grade 3 redness, local swelling, local grade 3
swelling, consent withdrawal, loss to follow-up and serious AEs
No participant had grade 3 fever in either of the groups.
Saline + 100 µg gE/AS01B versus 100 µg gE/saline (unadju-
vanted gE)
• local pain RR 3.38, 95% CI 1.84 to 6.23, RD 0.40, 95%
CI 0.27 to 0.52 and NNTH 2.5, 95% CI 1.9 to 3.7 (Analysis
9.10.9);
• local redness RR 8.02, 95% CI 2.02 to 31.88, RD 0.26,
95% CI 0.17 to 0.35 and NNTH 3.8, 95% CI 2.8 to 5.8
(Analysis 9.10.11);
• local swelling RR 9.82, 95% CI 1.37 to 70.30, RD 0.16,
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Table 3. Adverse events of adjuvanted recombinant VZV subunit zoster vaccine (Continued)
95% CI 0.09 to 0.23 and NNTH 6.2, 95% CI 4.3 to 11.1
(Analysis 9.10.13).
All differences in AEs were favourable to 100 µg gE/saline.
There were no differences in the incidence of the following AEs:
any fatigue, grade 3 fatigue, any fever, any headache, any myalgia,
grade 3 myalgia, local grade 3 pain, local grade 3 redness, consent
withdrawal, loss to follow-up and serious AEs
No participant had grade 3 fever, grade 3 headache and local grade
3 swelling in either of the groups
Adjuvanted recombinant VZV subunit zoster vaccine (not yet
available) versus placebo (Lal 2015)
The AEs related the comparison between adjuvanted recombinant
VZV subunit zoster vaccine (not yet available) and placebo are
shown below:
• any symptom RR 2.23, 95% CI 2.15 to 2.32, RD 0.47,
95% CI 0.45 to 0.48 and NNTH 2.1, 95% CI 2.0 to 2.2
(Analysis 10.2.1);
• any symptom grade 3 RR 5.25, 95% CI 4.42 to 6.24, RD
0.14, 95% CI 0.13 to 0.15 and NNTH 7.1, 95% CI 6.7 to 7.7
(Analysis 10.2.2);
• any symptom grade 3 related to vaccination RR 8.37, 95%
CI 6.69 to 10.47, RD 0.14, 95% CI 0.13 to 0.15 and NNTH
7.1, 95% CI 6.7 to 7.7 (Analysis 10.2.3);
• any systemic symptom RR 2.24, 95% CI 2.13 to 2.36, RD
0.37, 95% CI 0.35 to 0.39 and NNTH 2.7, 95% CI 2.6 to 3.3 (
(Analysis 10.2.4);
• any systemic symptom grade 3 RR 4.70, 95% CI 3.83 to 5.
77, RD 0.09, 95% CI 0.08 to 0.10 and NNTH 11.1, 95% CI
10.0 to 12.5 (Analysis 10.2.5);
• myalgia RR 3.82, 95% CI 3.51 to 4.17, RD 0.34, 95% CI
0.32 to 0.36 and NNTH 2.9, 95% CI 2.8 to 3.1 (Analysis 10.2.
6);
• fatigue RR 2.76, 95% CI 2.56 to 2.97, RD 0.29, 95% CI
0.27 to 0.31 and NNTH 3.4, 95% CI 3.2 to 3.7 (Analysis 10.2.
7);
• headache RR 2.45, 95% CI 2.27 to 2.65, RD 0.23, 95%
CI 0.21 to 0.25 and NNTH 4.3, 95% CI 4.0 to 4.8 (Analysis
10.2.8);
• shivering RR 4.76, 95% CI 4.19 to 5.41, RD 0.22, 95%
CI 0.21 to 0.24 and NNTH 4.5, 95% CI 4.2 to 4.8 (Analysis
10.2.9);
• fever RR 7.12, 95% CI 5.96 to 8.50, RD 0.18, 95% CI 0.
17 to 0.20 and NNTH 5.6, 95% CI 5.0 to 5.9 (Analysis 10.2.
10);
• gastrointestinal symptom RR 2.04, 95% CI 1.82 to 2.28,
RD 0.09, 95% CI 0.08 to 0.11 and NNTH 11.1, 95% CI 9.1
to 12.5 (Analysis 10.2.11);
• any local symptom RR 6.83, 95% CI 6.30 to 7.42, RD 0.
70, 95% CI 0.68 to 0.71 and NNTH 1.4, 95% CI 1.4 to 1.5
(Analysis 10.2.12);
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Table 3. Adverse events of adjuvanted recombinant VZV subunit zoster vaccine (Continued)
• any local symptom grade 3 RR 26.03, 95% CI 15.83 to 42.
82, RD 0.09, 95% CI 0.08 to 0.10 and NNTH 11.1, 95% CI
10 to 12.5 (Analysis 10.2.13);
• local pain RR 7.06, 95% CI 6.49 to 7.69, RD 0.68, 95%
CI 0.66 to 0.69 and NNTH 1.5, 95% CI 1.4 to 1.5 (Analysis
10.2.14);
• local redness RR 28.17, 95% CI 21.80 to 36.40, RD 0.37,
95% CI 0.35 to 0.38 and NNTH 2.7, 95% CI 2.6 to 2.9
(Analysis 10.2.15);
• local swelling RR 25.04, 95% CI 18.70 to 33.52, RD 0.25,
95% CI 0.24 to 0.27 and NNTH 4.0, 95% CI 3.7 to 4.2
(Analysis 10.2.16);
• serious AEs RR 1.01, 95% CI 0.91 to 1.11 and no RD
(Analysis 10.2.17);
• with serious AEs within 30 days after vaccination RR 0.90,
95% CI 0.67 to 1.20 and no RD (Analysis 10.2.18);
• serious AEs within 30 days after vaccination related to
vaccination RR 0.33, 95% CI 0.03 to 3.21 and no RD (Analysis
10.2.19);
• potential immune-mediated disease RR 0.81, 95% CI 0.60
to 1.08 and no RD (Analysis 10.2.20);
• deaths RR 0.96, 95% CI 0.78 to 1.19 and no RD (Analysis
10.2.21);
• deaths within 30 days after vaccination RR 1.15, 95% CI
0.42 to 3.16 and no RD (Analysis 10.2.22);
• unsolicited report of AEs RR 1.07, 95% CI 1.00 to 1.14,
RD 0.02, 95% CI 0.00 to 0.04 (Analysis 10.2.23);
• unsolicited report of AEs grade 3 RR 1.38, 95% CI 1.12 to
1.69, RD 0.01, 95% CI 0.00 to 0.02 (Analysis 10.2.24).
AEs: adverse events
CI: confidence interval
HZ: herpes zoster
NNTH: number needed to treat for an additional harmful outcome
RD: risk difference
RR: risk ratio
VZV: varicella zoster virus
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Table 4. Drop-outs
Drop-outs of all included studies Available live attenuated VZV zoster vaccine versus placebo
The pooled data from the studies that compared zoster vaccine and placebo showed no differ-
ences in the reasons for drop-outs (Analysis 1.4): for any reason (RR 0.99, 95% CI 0.91 to 1.
08) (Analysis 1.4.1) (Mills 2010; Oxman 2005; Vermeulen 2012), for death (RR 1.01, 95%
CI 0.92 to 1.11) (Analysis 1.4.2) (Mills 2010; Murray 2011; Oxman 2005), for withdrawal
of consent (RR 0.87, 95% CI 0.64 to 1.19) (Analysis 1.4.3) (Murray 2011; Oxman 2005;
Vermeulen 2012), for loss to follow-up (RR 1.29, 95% CI 0.97 to 1.73) (Analysis 1.4.4) (Mills
2010;Murray 2011; Oxman 2005; Vermeulen 2012), for protocol deviation (RR 1.58, 95%CI
0.41 to 6.02) (Analysis 1.4.5) (Murray 2011; Vermeulen 2012), for clinical AE (RR 1.36, 95%
CI 0.73 to 2.54) (Analysis 1.4.6) (Murray 2011; Vermeulen 2012) and for physician decision
(RR 0.20, 95% CI 0.01 to 4.17) (Analysis 1.4.7) (Murray 2011). In Mills 2010, Oxman 2005
and Vermeulen 2012 consent was withdrawn after the intervention. In Murray 2011, some
patients apparently withdrew consent after randomisation, but the trial authors do not describe
the exact number who withdrew consent after the intervention
The pooled data from the studies that compared zoster vaccine and placebo (Mills 2010;Murray
2011; Oxman 2005) showed no differences in the reasons for participants with no follow-up
(Analysis 1.5).
High-potency versus low-potency zoster vaccine: There were no differences between the
groups (Analysis 2.6).
Refrigerated versus frozen zoster vaccine: There were no differences between the groups
(Analysis 3.2).
Zoster vaccine IM route versus zoster vaccine SC route: There were no withdrawals due to
AE in either group (Analysis 6.1.15).
2 doses of a zoster vaccine versus a single dose and also 2 doses given at different intervals:
There were no differences between the groups for participants with withdrawal due to AE
(Analysis 7.1.5; Analysis 7.2.5; Analysis 7.3.5) (Vesikari 2013).
Adjuvanted recombinant VZV subunit zoster vaccine (not yet available) - lower or higher
volumes of adjuvants plus gE subunit VZV or unadjuvanted gE or saline injections: There
were no differences between the groups for the following reasons of drop-out: participants with
consent withdrawal and participants with loss to follow-up (Chlibek 2013).
3 groups of VZV subunit gE in 3 different quantities versus unadjuvanted gE or saline:
There were no differences between groups for participants with withdrawal of consent or
participants with loss to follow-up for all comparisons provided (Chlibek 2014).
Adjuvanted recombinant VZV subunit zoster vaccine not yet available versus placebo: Lal
2015 described 3 reasons to drop-out: did not receive vaccine according to protocol (Analysis
10.3.1), received wrong vaccine (Analysis 10.3.2) and had diagnosis of HZ less than 30 days
after dose 2 (Analysis 10.3.3). For the first 2 there were no differences between the groups. The
last outcome had a RR of 0.29 (95% CI 0.09 to 0.87) but no RD and we considered it as drop-
out and not an incidence outcome since it is related to participants aged > 50 years old and not
with our age group of interest (participants 60 years old or more)
AE: adverse event
CI: confidence interval
HZ: herpes zoster
IM: intramuscular
RD: risk difference
RR: risk ratio
SC: subcutaneous
VZV: varicella zoster virus
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A P P E N D I C E S
Appendix 1. CENTRAL and MEDLINE search strategy
MEDLINE (Ovid)
1 exp Herpes Zoster/
2 Herpesvirus 3, Human/
3 shingles.tw.
4 zoster.tw.
5 (varicella adj3 virus*).tw.
6 Varicellovirus/
7 varicellovir*.tw.
8 (hhv3 or hhv-3).tw.
9 or/1-8
10 exp Vaccines/
11 exp Immunization/
12 Vaccination/
13 (vaccin* or immuni* or inocul*).tw.
14 or/10-13
15 9 and 14
16 Herpes Zoster Vaccine/
17 ((zoster or shingles) adj3 vaccin*).tw.
18 zostavax.tw,nm.
19 or/15-18
Appendix 2. EMBASE.com search strategy
#22. #18 AND #21 228
#21. #19 OR #20 856,507
#20. random*:ab,ti OR placebo*:ab,ti OR factorial*:ab,ti OR crossover*:ab,ti OR ’cross-over’:ab,ti OR ’cross over’:ab,ti OR volunteer*:
ab,ti OR assign*:ab,ti OR allocat*:ab,ti OR ((singl* OR doubl*) NEAR/1 blind*):ab,ti AND [embase]/lim 816,906
#19. ’randomized controlled trial’/exp OR ’single blind procedure’/exp OR ’double blind procedure’/exp OR ’crossover procedure’/exp
AND [embase]/lim 241,010
#18. #14 OR #15 OR #16 OR #17 3,723
#17. zostavax:ab,ti AND [embase]/lim 22
#16. ((zoster OR shingles) NEAR/3 vaccin*):ab,ti AND [embase]/lim 425
#15. ’varicella zoster vaccine’/de AND [embase]/lim 1,065
#14. #8 AND #13 3,486
#13. #9 OR #10 OR #11 OR #12 375,972
#12. vaccin*:ab,ti OR immuni*:ab,ti OR inocul*:ab,ti AND [embase]/lim 315,836
#11. ’vaccination’/de AND [embase]/lim 60,243
#10. ’immunization’/exp AND [embase]/lim 127,614
#9. ’vaccine’/exp AND [embase]/lim 146,730
#8. #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 17,850
#7. hhv3:ab,ti OR ’hhv-3’:ab,ti AND [embase]/lim 6
#6. varicellovir*:ab,ti AND [embase]/lim 31
#5. ’varicellovirus’/de AND [embase]/lim 8
#4. (varicella NEAR/3 virus*):ab,ti AND [embase]/lim 5,290
#3. shingles:ab,ti OR zoster:ab,ti AND [embase]/lim 10,726
#2. ’varicella zoster virus’/de AND [embase]/lim 8,085
#1. ’herpes zoster’/exp AND [embase]/lim 10,650
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Appendix 3. LILACS (BIREME VHL) search strategy
((MH:“herpes zoster” OR “herpes zoster” or shingles or zona or zoster OR Cobreiro OR Cobrelo OR MH:C02.256.466.423$ OR
MH:“Herpesvirus 3, Human”OR “Herpesvirus Humano 3”OR “Varicella-Zoster Virus” OR “Human herpesvirus 3” OR “Herpesvirus
varicellae”OR “Virus de laVaricella-Zoster”OR “HerpesvirusHumanoTipo 3”OR“Virus delHerpes Zoster”OR “Virus de laVaricela”
OR “Vírus da Varicela” OR varicella OR varicela OR MH:varicellovirus OR hhv3 OR “hhv-3”) AND (MH:vaccines OR vacunas
OR vacinas ORMH:D20.215.894$ ORMH:immunization OR Inmunización OR Imunização ORMH:E02.095.465.425.400$ OR
MH:E05.478.550$ OR MH:N02.421.726.758.310$ OR MH:N06.850.780.200.425$ OR MH:N06.850.780.680.320$ OR MH:
SP2.026.182.113$ ORMH:SP4.001.002.015.049$ ORMH:SP8.946.819.838$ ORMH:vaccination ORVacunación ORVacinação
OR vaccin$ OR immuni$ OR inocul$)) OR (MH:“Herpes Zoster Vaccine” OR “Vacuna contra el Herpes Zoster” OR “Vacina contra
Herpes Zoster” OR “shingles vaccine” OR “zoster vaccine” OR zostavax OR “Vacina contra Cobrelo”) > clinical˙trials
Appendix 4. CINAHL (Ebsco) search strategy
S26 S16 and S25
S25 S17 or S18 or S19 or S20 or S21 or S22 or S23 or S24
S24 (MH “Quantitative Studies”)
S23 TI placebo* or AB placebo*
S22 (MH “Placebos”)
S21 TI random* or AB random*
S20 TI (singl* blind* or doubl* blind* or tripl* blind* or trebl* blind* or singl* mask* or doubl* mask* or tripl* mask* or trebl* mask*)
or AB (singl* blind* or doubl* blind* or tripl* blind* or trebl* blind* or singl* mask* or doubl* mask* or tripl* mask* or trebl* mask*)
S19 TI clinic* trial* or AB clinic* trial*
S18 PT clinical trial
S17 (MH “Clinical Trials+”)
S16 S11 or S12 or S13 or S14 or S15
S15 TI zostavax or AB zostavax
S14 TI zoster N3 vaccin* or AB zoster N3 vaccin* Search modes -
Boolean/Phrase Interface - EBSCOhost
Search Screen - Advanced Search
Database - CINAHL 123 Edit S14
S13 TI shingles N3 vaccin* or AB shingles N3 vaccin* Search modes -
Boolean/Phrase Interface - EBSCOhost
Search Screen - Advanced Search
Database - CINAHL 52 Edit S13
S12 TI herpes zoster vaccin* or AB herpes zoster vaccin*
S11 S6 and S10
S10 S7 or S8 or S9
S9 TI (vaccin* or immuni* or inocul*) or AB (vaccin* or immuni* or inocul*)
S8 (MH “Immunization+”)
S7 (MH “Vaccines+”)
S6 S1 or S2 or S3 or S4 or S5
S5 TI (hhv3 or hhv-3) or AB (hhv3 or hhv-3)
S4 TI varicella N3 virus* or AB varicella N3 virus*
S3 TI zoster or AB zoster
S2 TI shingles or AB shingles
S1 (MH “Herpes Zoster+”)
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Appendix 5. Study selection, quality assessment and data extraction form
First author Journal/conference proceedings, etc. Year
Study eligibility
RCT/quasi-RCT Sample mean age ≥ 60 years Vaccine for herpes zoster Relevant outcomes
Yes/No/Unclear Yes/No/Unclear Yes/No/Unclear Yes/No*/Unclear
Do not proceed if any of the above answers are ’No’. If study to be included in ’Excluded studies’ section of the review, record below
the information to be inserted into ’Table of excluded studies’
Freehand space for comments on study design and treatment:
References to trial (secondary references)
Check other references identified in searches. If there are further references to this trial link the papers now and list below. All references
to a trial should be linked under one Study ID in RevMan.
Code each paper Author(s) Journal/conference proceedings etc Year
A The paper listed above
B Further papers
Participants and trial characteristics
Participant characteristics
Further details
Age (mean, median, range, etc)
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(Continued)
Sex of participants (numbers/%, etc)
Disease status/type, etc (if applicable)
Underlying disease
Setting
Other
Trial characteristics
Methodological quality
Allocation of intervention
State here method used to generate allocation and reasons for
grading
Grade (circle)
Adequate (random)
Inadequate (e.g. alternate)
Unclear
Concealment of allocation
Process used to prevent foreknowledge of group assignment in a RCT, which should be seen as distinct from blinding
State here method used to conceal allocation and reasons for grad-
ing
Grade (circle)
Adequate
Inadequate
Unclear
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Blinding
Person responsible for participants’ care Yes/No
Participant Yes/No
Outcome assessor Yes/No
Other (please specify) Yes/No
Intention-to-treat
An intention-to-treat analysis is one in which all the participants in a trial are analysed according to the intervention to which they
were allocated, whether they received it or not
All participants entering trial
15% or fewer excluded
More than 15% excluded
Not analysed as intention-to-treat
Unclear
Were withdrawals described? Yes?/No?/Not clear?
Discuss if appropriate
Data extraction
Outcomes relevant to your review
Copy and paste from ’Types of outcome measures’
Reported in paper (circle)
Primary outcomes
1) Incidence of herpes zoster at any time point Yes/No
Secondary outcomes
1) Adverse events - local, systemic or both
(e.g. pain, pruritus, swelling, headache)
Yes/No
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For continuous data
Code of paper Outcomes (re-
name)
Unit of mea-
surement
Intervention group Control group Details if outcome
only described in
text
n Mean (SD) n Mean (SD)
A etc 1) Mean dura-
tion of vaccine
protection
References to other trials
Did this report include any references to published reports of potentially eligible trials not already identified for this review?
First author Journal/conference Year of publication
Did this report include any references to unpublished data from potentially eligible trials not already identified for this review? If yes,
give list contact name and details
Trial characteristics
Further details
Single centre/multicentre
Country/countries
How was participant eligibility defined?
How many people were randomised?
Number of participants in each intervention group
Number of participants who received intended treatment
Number of participants who were analysed
Vaccine used
Dose
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(Continued)
Median (range) length of follow-up reported in this paper (state
weeks, months or years or if not stated)
Time points when measurements were taken during the study
Time points reported in the study
Time points you are using in RevMan
Trial design (e.g. parallel/cross-over*)
Other
* If cross-over design, please refer to the Cochrane Editorial Office for further advice on how to analyse these data.
WH A T ’ S N E W
Last assessed as up-to-date: 26 October 2015.
Date Event Description
26 October 2015 New citation required but conclusions have not
changed
Our conclusions remain unchanged.
26 October 2015 New search has been performed In this 2015 update we included five new trials (Chlibek
2013; Chlibek 2014; Diez-Domingo 2015; Lal 2015;
Vesikari 2013), and we excluded one new trial (Leroux-
Roels 2012).
A new vaccine that contains a varicella zoster virus gly-
coproteic fraction plus adjuvant is under study
C O N T R I B U T I O N S O F A U T H O R S
Conceived the idea for the review: Anna Gagliardi (AG), Maria Regina Torloni (MT) and Brenda Nazaré Gomes Silva (BNGS)
Co-ordinating the review: AG
Screening search results: AG, MT, BNGS
Organising retrieval of papers: AG, BS
Screening retrieved papers against inclusion criteria: AG, BS, MT
Appraising quality of papers: AG, BNGS, MT
Extracting data from papers: AG, BNGS, BS
Writing to authors of papers for additional information: AG, BNGS, MT
160Vaccines for preventing herpes zoster in older adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Providing additional data about papers: AG, BS
Obtaining and screening data on unpublished studies: AG, MT
Data management for the review: AG, BNGS, MT
Entering data into Review Manager (RevMan): AG, BNGS, MT
RevMan statistical data: AG, BNGS
Other statistical analysis not using RevMan: MT
Interpretation of data: AG, BNGS, MT, BS
Statistical inferences: AG, BNGS, MT
Writing the review: AG, BNGS, MT, BS
Guarantor for the review: AG
Responsible for reading and checking the review before submission: AG, BNGS, BS, MT
D E C L A R A T I O N S O F I N T E R E S T
Anna MZ Gagliardi: none known
Brenda NG Andriolo: none known
Maria R Torloni: none known
Bernardo GO Soares: none known
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We deleted the secondary outcome ’mean duration of vaccine protection’.
We added ’drop-outs’ as a secondary outcome as this relates to the safety of the intervention.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Herpes Zoster [∗prevention & control]; Herpes Zoster Vaccine [adverse effects; ∗therapeutic use]; Randomized Controlled Trials as
Topic; Vaccines, Attenuated [adverse effects; therapeutic use]
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Aged; Humans; Middle Aged
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